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Executive Summary
Background, Definitions and Approach
Over the last two decades the co-occurrence of addiction and mental health problems
among people seeking treatment and support has emerged as an important issue for those
who plan and fund mental health and substance abuse programs, as well as for those who
provide direct service. Concerns about concurrent disorders have been fueled by research
showing the high prevalence of such co-morbidity and its implications for the course, cost
and outcome of treatment and other support services.
The present project provides an updated synthesis of the research information and offers
specific recommendations for the screening, assessment and treatment/support of this
in-need population based on the highest quality research information that is available. The
research synthesis has been combined with the advice and input of experts and other key
stakeholders in the field, including consumers who have experienced the severe
consequences of concurrent disorders. This synthesis is best seen as complementing the
considerable amount of work that has preceded the project and the reader is encouraged to
examine the key resource material drawn upon (Appendix A).
A national inventory of specialized concurrent disorders programs, entitled “National
Program Inventory - Concurrent Mental Health and Substance Use Disorders” has also been
developed and is published separately as a companion to this document.
Intended Audience
This report is intended to be a resource to managers and staff of mental health, substance
abuse and integrated mental health/substance abuse services, as well as individual
practitioners in the community who are faced with the challenges of providing good quality
service to people presenting with concurrent mental health and substance use disorders. In
addition, the report is targeted at planners, community developers and other decision-
makers that work at a more systems level. Researchers and program evaluators will also
benefit from this synthesis.
Defining Concurrent Disorders
In general terms, the concurrent disorders population refers to those people who are
experiencing a combination of mental/emotional/psychiatric problems with the abuse of
alcohol and/or other psychoactive drugs. More technically speaking, and in diagnostic terms,
it refers to any combination of mental health and substance use disorders, as defined for
example on either Axis I or Axis II of DSM-IV.
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Substance use disorders is the diagnostic term that refers to a habitual pattern of alcohol or
illicit drug use that results in significant problems related to aspects of life such as work,
relationships, physical health, financial well-being, etc. There are two mutually exclusive
subcategories – substance abuse and substance dependence (see Appendix B). In some cases,
the use of substances per se (as distinct from abuse or dependence) negatively impacts people
with mental health problems.
To people working in the substance abuse field using the DSM-IV as the basis for the
definition of concurrent disorders may appear to be an overly medical and psychiatric
approach. This approach, however, is the most widely used in the research literature on
concurrent disorders, and it has been used in previous attempts to define best practices in
this area. This practice is continued because:
 appropriate treatment and support in the mental health field, including drug therapies,
comes after accurate assessment and diagnosis. It follows then that the same holds true for
people with concurrent mental health and substance abuse problems;
 a mental health diagnosis based on DSM can be established by some ‘non-medical’
professionals, such as registered psychologists;
 a broad psychosocial rehabilitation approach is now widely regarded as essential for
effective care and support of people with mental health problems. In the same vein, the
treatment and support of people with concurrent disorders goes well beyond strictly
medical/psychiatric interventions.
Acceptance of the medical/psychiatric framework underlying the DSM, or other mental
health classification systems, may at times be one of the challenges that substance abuse
workers and planners may need to overcome in bridging the worlds of mental health and
substance abuse. It is also recognized that this option for classification may need to be
adapted somewhat in those communities that do not have access to professionals who are
qualified to make mental health diagnoses.
Recommended Approach to Classification
Over the past two decades, the term dual diagnosis was most commonly employed for the
combination of mental health and substance use disorders. This term, however, also applies
to co-existing psychiatric disorders and developmental disabilities. Other terms and
acronyms that may be encountered will be CAMI (chemically abusing - mentally ill), or
MICA (mentally ill - chemically abusing), or SAMI (substance abusing-mentally ill). The
term concurrent disorders is preferred since it retains the emphasis on appropriate diagnosis
as a guide to planning treatment and support, and distinguishes this area from other
important work in the field of developmental disabilities and mental health. Thinking of
mental health and substance use problems as a plurality, rather than a duality, is more
consistent with the typical clinical presentation of the abuse of multiple drugs, including
alcohol, and often more than one psychiatric diagnosis.
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Clinicians and support workers need guidelines that will be helpful in dealing with specific
types of concurrent disorders. Given the early stage of research that is both substance- and
diagnosis-specific, sub-categories that make intuitive sense can be developed on the basis of
clinical experience and the most common combinations of mental health and substance use
disorders that present among the people seeking treatment and support. The following five
sub-groups within the broad group of concurrent disorders are recommended:
Group 1: Co-occurring substance use and mood and anxiety disorders;
Group 2: Co-occurring substance use and severe and persistent mental disorders;
Group 3: Co-occurring substance use and personality disorders;
Group 4: Co-occurring substance use and eating disorders;
Group 5: Other co-occurring substance use and mental health disorders.
This report focuses on the first four groups.
Defining Integrated Treatment
A distinction between “program integration” and “system integration” is proposed to reflect
innovations under way to improve care and support across treatment units or community
agencies. Program integration means:
mental health treatments and substance abuse treatments are brought together by the
same clinicians/support workers, or team of clinicians/support workers, in the same
program, to ensure that the individual receives a consistent explanation of
illness/problems and a coherent prescription for treatment rather than a
contradictory set of messages from different providers.
System integration means:
the development of enduring linkages between service providers or treatment units
within a system, or across multiple systems, to facilitate the provision of service to
individuals at the local level. Mental health treatment and substance abuse
treatment are, therefore, brought together by two or more clinicians/support workers
working for different treatment units or service providers. Various coordination and
collaborative arrangements are used to develop and implement an integrated
treatment plan.
As with program-level integration, treatment plans that cross service providers may involve
addressing the substance abuse and mental health disorders either concurrently or
sequentially, but always in the context of a consistent and coordinated approach tailored to
the unique needs and capacities of the individual.
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Need for a Broader Psychosocial Perspective
Finally, with respect to the term integrated treatment, some comments are offered about the
use of the word treatment in this context. In the mental health field, the focus on
community integration for people with severe mental illness has been a dominant force over
the past two decades. Coincident with this trend has been a shift toward a broad
psychosocial rehabilitation perspective. This broader perspective values the critical role of
acute treatment, medication management and symptom reduction in creating more long
term positive outcomes. It also advocates for supporting the person in a wide variety of areas,
including housing, employment, recreation and social networks, to name just a few. As a
result of new thinking about community integration and specific policy initiatives that have
supported the paradigm shift, a wide array of community support programs has emerged. This
includes services that are consumer-run and which bring an experiential perspective to
service delivery and support. The goals of these support services are broadly stated as helping
persons with severe mental illness become reintegrated into the community, and improving
their quality of life and that of their families.
These psychosocial support services are recommended as part of the overall package of care
and support for people with severe mental illness (e.g. schizophrenia practice guidelines).
Therefore, it must be emphasized that they also have a clear role in an integrated program or
system for people with concurrent disorders, if they are required by the person on the basis of
their needs and functional abilities. Although this is consistent with the advice of several
experts in the field, it may not be immediately obvious given the use of the term integrated
treatment. Thus, the term integrated treatment and support is preferred as it is more
consistent with this broader psychosocial rehabilitation perspective.
Rationale For Best Practice Guidelines
The rationale for developing best practice guidelines for the treatment of concurrent
disorders is grounded primarily in three areas of research and clinical experience:
 the prevalence of co-morbidity is high in the general and treatment-seeking populations
and has largely been ignored in planning, implementing and evaluating both mental health
and substance abuse services;
 substance abuse and mental health co-morbidity changes the course, cost and outcome of
care and presents significant challenges for screening, assessment, treatment/support and
outcome monitoring;
 substance abuse and mental health services in the community have typically worked in
isolation and often from competing perspectives.
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Best Practice for Concurrent Disorders at the
Service Delivery Level
There are many entry points into a community’s mental health and substance abuse systems.
While people with concurrent disorders may be more likely to show up at some entry points
than others (e.g., emergency and crisis services, homeless shelters), the research data would
suggest that the prevalence of concurrent disorders will be high across all entry points. It is
also important to note that in the mental health system, the duration of time with which a
person with a concurrent substance use disorder is being treated or supported by a particular
program is quite variable, ranging from very brief contact at a crisis service, to a few weeks or
months in an acute treatment setting, to several years of regular contact and support
through a community team, a supported housing program, a clubhouse or a consumer
survivor initiative. Similarly, across substance abuse services in the community the
opportunities for identifying someone with a mental health disorder are quite different in
different settings (e.g., brief contact at a withdrawal management centre compared to several
weeks or months of support from an outpatient or residential treatment program). In
addition, the types of professional training, experiential knowledge and perspective also
differ substantially across these settings. These factors will impact on managers, staff and
consumers when initiating various strategies that might be recommended for identification,
assessment and treatment/support. The role of the family/significant others will also be
highly variable, for example, in providing collateral reports of substance abuse, or
participating in family systems interventions. These important contextual factors
notwithstanding, there is a need for evidenced-based advice in three areas:
a) Identifying if someone has a potential substance use disorder or mental health disorder
(depending on the setting).
b) For those screened positive, conducting a comprehensive assessment that will investigate
more conclusively the nature and severity of the substance use or mental health
problem and how they are related. In areas with limited resources this step may out of
necessity also include referral to another service for support in assessing the substance
use or mental health problem, but this referral is made in the context of a coordinated
system of local services, with follow-up to ensure an integrated treatment plan is
developed.
c) For those determined to have a concurrent substance use disorder and mental health
disorder on the basis of the assessment, providing treatment/support for the immediate
problem resolution, and providing longer term monitoring, support and rehabilitation.
As above, in some communities this step may also include referral to another service for
support with the substance abuse or mental health problem but this needs to be done in
the context of an integrated treatment plan, and a coordinated system of local services.
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Screening
It is recommended that:
 all people seeking help from substance abuse services be screened for co-occurring mental
health disorders. The advice is organized around Level I and Level II approaches that are
tailored to the type of setting and time and resources available.
It is also recommended that:
 all people seeking help from mental health services be screened for co-occurring substance
use disorders. The advice is organized around Level I and Level II approaches that are
tailored to the type of setting and time and resources available.
Assessment
On the basis of a positive screen for either substance use or mental health disorders, it is
recommended that a comprehensive assessment (a) establish diagnoses (b) assess level of
psychosocial functioning and other disorder-specific factors and (c) develop a treatment and
support plan that tries to sort out the interaction between the mental health and substance
use difficulties for the individual, and work toward a positive outcome for both sets of
problems.
Treatment and support
Co-occurring substance abuse and mood and anxiety disorders:
 an integrated approach to treatment/support is recommended;
 with the exception of post-traumatic stress disorder, and in the context of an integrated
approach, a sequencing of the specific intervention (beginning with the substance abuse) is
recommended, accompanied by ongoing assessment and adjustment of the
treatment/support plan if the mood and anxiety disorder does not improve following an
improvement in the substance use disorder;
 for post-traumatic stress disorder an integrated treatment approach that deals with both
the post-traumatic stress disorder and substance abuse at the same time is recommended;
 the best current evidence for the treatment of concurrent mood and anxiety disorders,
including post-traumatic stress disorder, is cognitive behavioural treatment.
Co-occurring substance abuse and severe and persistent mental illness:
 an integrated approach to treatment/support is recommended;
 within this integrated approach, it is recommended that interventions for substance abuse
and severe mental illness be planned and implemented concurrently;
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 the best current evidence is for a range of services that includes a staged approach to
engagement and service delivery; outpatient setting; motivational interviewing and
cognitive-behavioural treatment; harm reduction and comprehensive psychosocial
rehabilitation supports, to name a few program/system components.
Co-occurring substance abuse and personality disorders:
 an integrated approach to treatment/support is recommended;
 within this integrated approach, it is recommended that interventions for substance abuse
and borderline personality disorders be planned and implemented concurrently;
 evidence on the treatment of antisocial personality disorder and substance use disorders
suggests addressing the substance use problem first;
 the best empirically supported treatment for borderline personality disorder and substance
use disorders is dialectical behaviour therapy (DBT), which includes behavioural skills
training.
Co-occurring substance abuse and eating disorders:
 an integrated approach to treatment/support is recommended;
 within this integrated approach, it is recommended that interventions for substance abuse
and the eating disorder be planned and implemented concurrently unless there are
compelling clinical reasons, such as life threatening factors, for focusing on one of the
disorders first;
 the most promising intervention is a combination of medical management, behavioural
strategies to effect change in the eating and substance abuse behaviour, and psychotherapy
to address psychological issues.
Implications of Best Practice Guidelines at the System Level
Ryglewicz and Pepper34 provide a helpful historical perspective on the increase in the
number of people in the community with concurrent disorders. They note the historical
separation of three very distinct clinical populations – mental patients, alcoholics and drug
addicts. The former were in psychiatric institutions. Alcoholism was not seen as a problem
until well along its course and, if treated at all, it was in highly specialized treatment
facilities. Drug addiction was seen as confined to a small segment of society and viewed
largely in a criminal context. These times have vanished. The shift has come primarily from
the de-institutionalization of mental health services; the corresponding movement towards
community support for people with severe mental illness73; and the increasing availability of
drugs in the community since the 1960s. So rather than the three formerly separate clinical
populations, we now have large groups of people in the community with overlapping and
interacting mental health and substance use problems. The difficulty from the service
delivery perspective is that community agencies, planners and policy makers have been stuck
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in the single-problem mode of thinking because of the long established barriers between the
treatment systems for mental health and substance abuse. The barriers came about as a
result of separate training and development in the two fields, which became entrenched in
separate funding, administrative and policy structures. An additional barrier is the perceived
complexity, uncertainty, and level of difficulty associated with a more integrated approach.
Taking an historical perspective on the emergence of the two systems helps to better
understand the problems being faced by consumers who currently need to cross over the two
systems.
A Less Prescriptive Approach at the System Level
Canada is just at the beginning stages of developing and trying out various strategies to
better integrate services at the system level. There is very little published information that
goes beyond an assessment of the many challenges and barriers to systems integration, to
actual implementation and evaluation of different concrete strategies. In general, the current
state of knowledge and practice wisdom is not sufficiently developed to offer best practice
recommendations at the system level, so the discussion is more descriptive than prescriptive.
A Shopping List of Alternatives to Support System Integration
In synthesizing the information and themes, the following list of alternative strategies may
support system-level integration:
 it is critical that people with concurrent disorders and their family members be
meaningfully involved in planning and system development activities;
 given the pace of knowledge development and the extent to which innovative solutions are
being explored there is a need for a mechanism to share information and lessons learned. A
possible vehicle to achieve this would be a Canadian-based web site and potentially a
national Concurrent Disorders Resource Centre that would support research dissemination
and knowledge transfer;
 training and education must be the centrepiece of concurrent disorders program and
system development. This includes cross-training, continuing education, formal curricula
development and credentialing;
 a healthy mix of top-down commitment from funders, senior administrators and Executive
Directors and bottom-up exploration of linkages by front- line staff based on individual
cases is suggested;
 developing a joint inter-agency planning committee is a viable option to start the local
system integration process with reasonable goals and time frames in order to maximize the
chance of success and build motivation to continue the change process. There may be
considerable value to a staged approach starting, for example, with informal coordination
activities and information sharing; to perhaps a cross-training program and then to service
agreements for assessment and treatment/support. It is important that there be a dedicated
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resource person to support the planning and development process. It is also important to
recognize that due to the complexity of integration across systems, the change process must
be seen as evolutionary, non-linear and requiring time and patience;
 there is a need for clinical case consultation, including a potential role for telepsychiatry to
support program and system integration in rural and remote areas;
 shared data systems that cross mental health and addictions should be explored and pilot
tested;
 widespread adoption of blended service delivery teams which include a substance abuse
counselor;
 formal inter-agency partnerships can be developed which go beyond joint planning
exercises to the level of service agreements or potentially merged organizations;
 central access models are often recommended in both mental health and substance abuse
reform processes. There is likely value in developing improved access models, including
basic information about services and supports that are available, and which span substance
abuse and mental health;
 policy initiatives can be undertaken at the funding level which would support integrated
services and systems and provide a mechanism for demonstration projects.
Implications for Research
 there is wide variation in the level and content of integrated treatment at the program
level. More research is needed on the effectiveness and cost-effectiveness of various
interventions for many of the sub-groups within the concurrent disorders population, as
well as fidelity measures to assess the nature and level of integration;
 there is wide variation in the level and content of integrated treatment at the system level.
More research is needed on the impact of these system-level interventions on access to
treatment and support, engagement and retention in the system, and the effectiveness and
cost-effectiveness of various interventions for each of the sub-groups within the concurrent
disorders population. Research should also investigate the value of fidelity measures to
assess the nature and level of system integration; and urban/rural differences;
 two clusters of concurrent disorders were omitted from these best practice guidelines due
to a lack of research evidence – concurrent disorders and sexual disorders, and concurrent
disorders and pathological gambling. More research is needed in these areas;
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 more research is needed on treatment/support for specific combinations of psychoactive
substance use disorders (e.g., cocaine) and specific mental health disorders (e.g.,
depression)
 more research is needed on the link between substance use disorders and anger disorders
that are independent of antisocial personality disorder;
 more research is needed on the link among dysfunctional parenting, child abuse and
co-occurring mental health and substance use disorders;
 brief, validated measures are needed that would screen for mental health disorders among
people seeking treatment for substance use disorders.
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1. Introduction
The purpose of this project is to identify best practices related to concurrent mental health
and substance use disorders. The project was initiated by Health Canada as part of a
research agenda developed by the Federal/Provincial/Territorial Committee on Alcohol and
Other Drug Issues.
The project was carried out under the direction of the Working Group on Accountability
and Evaluation Framework and Research Agenda. The working group is appointed by the
Federal/Provincial/Territorial Committee on Alcohol and Drug Issues. The mandate of the
working group is to oversee the development and implementation of research studies that
contribute to innovative substance abuse treatment and rehabilitation programs by
identifying best practices, evaluating model treatment and rehabilitation programs, and
identifying emerging issues; the knowledge is then disseminated across the country.
This project builds on a series of best practices publications including: Best Practices -
Substance Abuse Treatment and Rehabilitation (Health Canada, 1999a); Best Practices - Fetal
Alcohol Syndrome/Fetal Alcohol Effects and the Effects of Other Substance Use During Pregnancy
(Health Canada, 2001); Best Practices - Treatment and Rehabilitation for Youth with Substance
Use Problems (Health. Canada, 2001); and Best Practices - Treatment and Rehabilitation for
Women with Substance Use Problems (Health Canada, 2001).
There are four main sections to this report, in addition to this brief introduction. In the next
section (2) the considerable amount of work that has preceded this report and the key
references drawn upon are noted. Concurrent disorders and integrated treatment are
defined, and the steps followed in developing the recommendations are detailed.
In Section 3 best practice recommendations at the service delivery level are discussed. The
recommendations cover three broad areas:
 screening;
 assessment; and
 treatment and support
Further, separate recommendations for four sub-groups within the broad category of
concurrent disorders are provided:
 co-occurring substance abuse and mood and anxiety disorders;
 co-occurring substance abuse and severe and persistent mental illness;
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 co-occurring substance abuse and personality disorders; and
 co-occurring substance abuse and eating disorders.
Each section addresses prevalence and etiological issues; treatment implications and clinical
issues; and a review of the evidence and expert opinion in terms of sequencing and type of
interventions. The recommendations for best practice are drawn from this evidence and
expert opinion.
Section 4 discusses the implications of the best practice guidelines at the system level,
drawing upon focus groups held in Quebec, Ontario and British Columbia; and a key
informant survey that tapped issues related to system as well as program integration.
Mechanisms are identified for system-level integration and alternatives for improving work
at this level are discussed. Section 5 offers some additional recommendations for research.
Each of the subsections on treatment/support ends with the best practice recommendations
for that particular combination of disorders.
1.1 Project Scope
The primary focus of this project is on individuals with a co-occurring substance use and
mental health disorder. There is a small literature available on various issues related to
special sub-populations such as youth, the elderly, women, the homeless, cultural groups
including aboriginal people, and people with co-occurring physical or developmental
disabilities. While the scope of this effort has not included specific recommendations for
these special populations it is felt that the general recommendations for a more integrated
approach should apply across the board. Other more specific recommendations (e.g., specific
interventions for specific sub-populations) may emerge from other projects initiated by
Health Canada for the development of best practice advice in substance abuse treatment
that is specific to certain populations (e.g., youth, elderly).
It is also beyond the scope of the project to investigate and recommend best practices for
either the early identification or prevention of co-occurring substance use and mental health
disorders in the community at large. It is recommended that such work be considered at a
future date.
Further, there is insufficient literature on which to base best practice guidelines for the
co-occurrence of substance use and sexual disorders; substance use and attention deficit and
hyperactivity disorder (ADHD); and substance use disorders, mental health disorders and
pathological gambling. These concurrent disorders are grouped in the “other” category, not to
downplay their importance, but rather to reflect the current state of research knowledge and
practice wisdom in these areas of concurrent disorders. It is recognized that there is a
beginning literature that links substance use and abuse problems with problems of intimacy
and sexual expression, including deviant sexual expression158. These patterns include a link
between addictions (e.g., cocaine, and high sex desire and acting out; addictions and
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survivor issues159; and addictions and sex offending issues160). Integrated mental health and
substance abuse treatment is likely feasible with these groups. Recommendations for specific
interventions await further research.
The scope of this work is also limited to making recommendations for best practice either
within or across specialized substance abuse and mental health programs, while recognizing
that individuals with concurrent disorders also commonly present to more generic
community services such as primary care, community health centres, services for the
homeless, correctional services, and social welfare. Issues and strategies relevant to best
practices for screening, assessment and treatment/support of people with concurrent
disorders in such settings may be extrapolated from our recommendations for specialized
substance abuse and mental health services.
Finally, the main focus of this work is at the service delivery level, including the discussion
of specific types of interventions. It is beyond the scope of this project to evaluate the
applicability of the many hundreds of highly specific behavioural, social work and drug
therapies that have a place in the treatment of individual mental health and substance abuse
disorders (e.g., psychotherapeutic drug treatments for schizophrenia). Similarly, the specific
interactions of the many psychotherapeutic drugs for the treatment of mental health
disorders and alcohol and other psychoactive drugs have not been examined in depth. This
level of detail is best covered in best practice guidelines for individual mental health
disorders and substance use disorders. However, any promising drug therapies for specific
concurrent disorders are noted.
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2. Background, Definitions and Approach
2.1 Background to the Report
Within the last two decades the co-occurrence of addiction and mental health problems
among people seeking treatment and support has emerged as an important issue for those
who plan and fund mental health and addiction programs, as well as those people who
provide direct service. Concerns about concurrent disorders have been fueled by research
showing the high prevalence of such co-morbidity and its implications for the course, cost
and outcome of treatment and other support services.
In response to this growing concern, and the urgent need for wider use of research-based
treatment and community support strategies, Health Canada issued a Request for Proposals
(RFP) for the development of best practice guidelines for the treatment and rehabilitation of
individuals with concurrent substance use and mental health disorders. The RFP also called
for the development of a national inventory of specialized concurrent disorders programs.
This inventory, entitled “National Program Inventory - Concurrent Mental Health and
Substance Use Disorders”, is published separately as a companion to this document.
2.1.1 Concurrent Disorders are a Recognized Priority
Considerable work in Canada and elsewhere has set the stage for the development of best
practice guidelines for concurrent disorders. The general framework for community
integration for people with severe mental illness has been supported at the national level,1,2
and in several provincial initiatives. Within this general framework of community treatment
and support, most of the individual provinces and territories have sponsored work leading to
specific program and policy recommendations. For example:
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Key Points
 This report integrates and complements considerable research and
development that has been done with respect to concurrent disorders.
 Knowledge in this area is rapidly expanding.
 The report is intended primarily for managers and staff of mental health and
substance abuse programs, and individual practitioners who work with people
with concurrent disorders.
 Policy-makers, planners, researchers and program evaluators will also find it
useful.
 The “Comité permanent de lutte à la toxicomanie” of the Québec Government placed
comorbidity as a priority in its recommendations to the provincial government in both
1996 and 1997.3,4 In consultations held throughout the Province of Quebec in 1995 and
2000, concerns were expressed about concurrent disorders within all age groups;5,6
 In Ontario, individuals with concurrent disorders have been identified as a priority
population by both the addictions and mental health service delivery systems.7-9
 An Inter-ministry Task Group in British Columbia was formed to investigate how to
improve services for individuals who have a severe mental illness and substance use
disorder. The resulting report10 recommended several complementary approaches for the
development of improved services for people with concurrent disorders.
Separate national initiatives have developed best practice guidelines for mental health
services and supports,11 and substance abuse treatment.12 Practice guidelines have also been
published in the peer-reviewed literature for specific disorders, such as depression,13
schizophrenia,14-16 alcohol, cocaine and opioid use disorders17 and nicotine dependence.18,19
Guidelines have also been developed for psychiatric evaluation.20
Some of these practice guidelines, such as the Canadian guidelines for the treatment of
schizophrenia,16 and the guidelines for psychiatric evaluation,20 include recommendations for
treating and supporting people with co-occurring substance use disorders. Further, the best
practice literature for mental health disorders provides many recommendations for optimal
treatment methods, including pharmacological interventions, that will apply to people with
psychiatric problems with or without a concurrent substance use disorder. Walker et al.21
give an overview of developments in the substance abuse field concerning best practice
guidelines, including the work by:
 the American Psychiatric Association;
 the American Nurses Association;
 the National Association of Social Workers in the U.S.;
 the well-known placement criteria of the American Society of Addiction Medicine;22
 the Treatment Improvement Protocols (TIP) published by the Center for Substance Abuse
Treatment;23 and
 various international efforts.
As with similar work in the mental health field, many of these recommendations may apply
to people in substance abuse treatment with or without concurrent disorders.
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It is also important to note that planning, policy development and funding bodies in other
jurisdictions have also called for the synthesis of research and clinical opinion regarding the
development of best practice recommendations for people with concurrent disorders. For
example, the Center for Substance Abuse Treatment (CSAT) in the U.S. commissioned a
Treatment Improvement Protocol (TIP) in 1994 concerning the assessment and treatment of
people with co-existing mental illness and alcohol and other drug abuse.24 Given the
similarity in goals between the TIP project and the current project, the results from this
previous work have been valuable for this undertaking.
One important aspect of the previous work done to date has been the recognition of the
importance of system-level* factors in meeting the needs of people with concurrent
disorders.27 This includes the need for better coordination of services across networks of
mental health and substance abuse treatment providers. The importance of better
integrating mental health and substance abuse services at the systemic level has been
highlighted in several reports.28-30 Systemic issues are considered in some detail in Section 4.
2.1.2 The Rapidly Growing Literature
In summary, there is no shortage of ideas and discussion about the needs of people with
co-occurring mental health and substance use disorders, and how these needs might most
effectively be met. Relevant research also continues to be undertaken and reported at a
rapid rate. In addition to the better quality of individual research projects over the past
decade, several excellent and highly relevant books and literature reviews have been
published in the past few years.34-41 A program manual on MICA (mentally ill-chemical
abuse) by Kathleen Sciacca is available42 and there is at least one internet list serve on the
topic (http://users.erols.com/ksciacca). Recently, an issue of Clinical Psychology Review43
was dedicated to the topic of concurrent disorders, with separate articles providing a review
on concurrent substance use disorders and specific mental health disorders (e.g., personality
disorders; mood and anxiety). A new book by Mueser and colleagues44 will soon be published
and it provides the most recent summary of work on concurrent substance abuse and severe
mental illness (e.g., schizophrenia, bipolar illness). Recent work by Mueser and colleagues45
also provides an excellent review of etiologic theories about the interaction of substance
abuse and severe mental illness.
The present project provides an updated synthesis of the research information and offers
specific recommendations for the screening, assessment, and treatment/support of this
in-need population based on the highest quality research information that is available. This
research synthesis has been combined with the advice and input of experts and other key
stakeholders in the field, including consumers who have experienced the severe
consequences of concurrent disorders. This synthesis is best seen as complementing the
considerable amount of work that has proceeded the project and the reader is encouraged to
examine the key resource material drawn upon. To complement the list of references at the
end of the report, the particularly important resource material are listed in Appendix A.
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* System level, as definited by Longest25, and used by Aday et al.,26 refers to the “resources (money, people, physical
infrastructure and technology) and the organizational configurations used to transform these resources into health
care services in a given geographic area”.
2.1.3 Intended Audience
This report is intended to be a resource to managers and staff of mental health, addictions
and integrated mental health/substance abuse services, as well as individual practitioners in
the community who are faced with the challenges of providing good quality service to people
presenting with concurrent disorders. In addition, the report is targeted at planners,
community developers, and other decision-makers that work at a more systems level.
2.2 Defining Concurrent Disorders
2.2.1 The DSM Classification System
In general terms, the concurrent disorders population refers to those people who are
experiencing a combination of mental/emotional/psychiatric problems with the abuse of
alcohol and/or another psychoactive drug. Technically, it refers to any combination of
mental health and substance use disorders, as defined for example, with the classification
scheme of Diagnostic and Statistical Manual of Mental Disorders.46
DSM-IV is made up of five groups of diagnostic categories calls “axes”. Axis 1 includes the
major psychiatric disorders and diagnoses, such as the psychoses, mood disorders, etc.
Formally, Axis 1 is the group of categories for coding Clinical Disorders and Other
Conditions which may be a focus of clinical attention (e.g., family/vocational problem). Axis
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Key Points
 A large number of people live in the community with overlapping and
interacting mental health and substance use problems. Knowledge in this
area is rapidly expanding.
 In diagnostic terms, ‘concurrent disorders’ refers to any combination of
mental health and substance use disorders.
 Substance use disorders include both substance abuse and substance
dependence, and can also refer separately to many different psychoactive
drugs, including alcohol.
 People with concurrent disorders are a very diverse group reflecting many
different combinations of mental health and substance use disorders.
 Clinicians and support workers need best practice guidelines for different
sub-categories within this diverse group.
 Five sub-groups are recommended.
 These categories are subject to change as our research knowledge grows
concerning different combinations of mental health and substance-specific
disorders, (e.g., cocaine and depression, alcohol and schizophrenia).
II is for Personality Disorders and Mental Retardation exclusively; Axis III is for General
Medical Conditions. Axis IV is for Psychosocial and Environmental Problems (i.e., stressors
related to Axes I and II) and Axis V is for Global Assessment of Functioning.
Substance use disorders are part of Axis I and is the term that refers to a habitual pattern of
alcohol or illicit drug use that results in significant problems related to aspects of life, such as
work, relationships, physical health, financial well-being, etc. There are two mutually
exclusive sub-categories – substance abuse and substance dependence. In some cases,
substance use (as distinct from abuse or dependence) negatively impacts people with mental
health problems. This will be discussed further along in the document.
Based on DSM-IV classification, concurrent disorders refers to a substance use disorder in
combination with an Axis I or Axis II mental health disorder. Using a system like DSM-IV
as the basis for the definition of concurrent disorders may at times seem like an overly
medical and psychiatric approach. However, this approach for classifying concurrent
disorders is the most widely used in the research literature, and has been used in previous
attempts to define best practices in this area. This practice is continued because:
 appropriate treatment and support in the mental health field, including drug therapies,
comes after accurate assessment and diagnosis. It follows then that the same holds true for
people with concurrent mental health and substance abuse problems;
 a mental health diagnosis can be established by non-medical professionals, such as
registered psychologists;
 a broad psychosocial rehabilitation approach is now widely regarded as essential for
effective care and support of people with severe mental health illness. In the same view, the
treatment and support of people with concurrent disorders goes well beyond strictly
medical/psychiatric interventions.
Acceptance of the medical/psychiatric framework underlying the DSM, or other mental
health classification systems, may be one of the challenges that key stakeholders and
planners need to overcome in bridging the worlds of mental health and substance abuse. It is
also recognized that this option for classification may need to be adapted somewhat in those
communities that do not have access to professionals who are qualified to make diagnoses.
2.2.2 Alternative Terminology
Over the past two decades, the term dual diagnosis was most commonly employed for the
combination of mental health and substance use disorders. Other terms and acronyms that
may be encountered will be:
 CAMI (chemically abusing - mentally ill);
 MICA (mentally ill - chemically abusing);
 SAMI (substance abusing-mentally ill).
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The term concurrent disorders is preferred since it retains the emphasis on appropriate
diagnosis as a guide to planning treatment and support, and distinguishes this area from
other important work in the field of developmental disabilities and mental health. Also,
thinking of mental health and substance use problems as a plurality, rather than a duality, is
more consistent with the typical situation people present with, namely the abuse of multiple
drugs, including alcohol, and often more than one mental heath diagnosis.
The Treatment Improvement Protocol (TIP) from CSAT contains an excellent section on
concepts and definitions of the many specific mental health diagnostic categories that fall
under the general rubric of dual or concurrent disorders.24
Given the heterogeneity of the population subsumed under the general rubric of concurrent
disorders, several authors24,34,47 have argued for the definition of more homogeneous
sub-groups in order to develop concrete clinical advice and treatment evaluation criteria.
Sub-typing this population is not an easy task, as researchers and clinicians have often
grouped several diagnostically distinct categories into one group said to have concurrent
disorders.35
The problems related to psychoactive substances are themselves multidimensional48 and one
needs to consider:
 the frequency and pattern of use;
 the level of dependence;
 the consequences that result.48
Further, being high on one dimension (e.g., use) does not always mean the person is high on
the others (e.g., dependence). Complex patterns of multiple drug use44,49,50 also make it
difficult to distinguish among the literally hundreds of combinations of mental health and
substance use disorders when one goes to the level of specific substances combined with
specific mental health problems. Further, within the substance abuse field itself, there is no
working consensus on how to classify important sub-groups of people with substance-related
problems, and researchers continue to explore the relationship between alternative
classification schemes and Axis I and II co-morbidity.51 This complexity and lack of
consensus notwithstanding, there is much work to draw upon within some specific diagnostic
categories (e.g., schizophrenia, personality disorders, bipolar disorders), and which has
focused on specific patterns of substance use (e.g., cocaine and depression).
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2.2.3 Interaction Models
Within DSM- IV46 it is critical to distinguish between substance abuse and substance
dependence (see Appendix B for criteria for abuse versus dependence). This distinction is
important since the intensity and goals of required treatment are different for these
sub-groups (e.g., the appropriateness of non-abstinence goals). DSM-IV also provides a
structure to distinguish between psychiatric disorders that are substance-induced and those
which are not. Rosenthal and Westreich,39 Lehman,52 and other experts in the field, go
further and draw distinctions among several models of the interaction of the mental health
disorder and the use of psychoactive substances (e.g., psychiatric symptoms developing as a
consequence of substance use but persisting after cessation of substance use; substance abuse
and psychiatric symptomatology meaningfully linked over time). This approach, adapted
from Weiss and Collins,53 basically builds upon the DSM-IV tradition of establishing to what
extent the psychiatric symptoms are substance-induced or not. Mueser and colleagues45
provide an excellent review of four etiologic theories of the interaction of severe mental
illness and substance use disorders. The models they distinguish are:
 common factor models;
 secondary substance use disorder models;
 secondary psychiatric illness models ;
 bi-directional models.
While the evidence for and against these various models has important implications for
screening, assessment and treatment/support planning, they do not provide a typology per se
for sub-grouping consumers for the purpose of developing best practice guidelines.
Many other researchers in the field have attempted to delineate the numerous ways in which
mental health disorders can interact with co-occurring substance use disorders.45,54,55 A
distinction that is commonly made is that of the primary/secondary disorder. This distinction
attempts to ascertain (where possible) which problem is designated as primary (i.e. the
underlying or pre-existing problem), and which is secondary (i.e., the disorder that
developed later temporally, or potentially developed as a consequence of the presence of the
first one).56-58 For people with severe and persistent mental illness this approach is no longer
recommended, given the highly variable course of symptom development.44 However, the
approach may be of value for other types of concurrent disorders such as concurrent mood
and anxiety disorders (see Section 3.3.1).
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2.2.4 Stage of Treatment/Motivation
Approaches to understanding and categorizing the person’s “stage of treatment” or
“motivation for change”49-62 provide important insights for assessment and planning a course
of treatment and support. Thus, one might consider these stages as appropriate for broader
classification purposes. However, the categories generalize across virtually all the various
concurrent disorders and do not serve as an appropriate foundation for best practice
guidelines. The Prochaska and DiClemente model, while applying to addictions, also
presents a problem with some concurrent disorders as motivation will vary with the pattern
of the disorder. For example, in the manic phase, a person may be very enthusiastic about
treatment and express much confidence in motivation for change. However, symptoms of a
less manic phase may make it difficult to act on the expressed motivation.
Clinicians and support workers need guidelines that will be helpful in dealing with specific
types of concurrent disorders. Given the early stage of research that is both substance- and
diagnosis-specific, sub-categories that make intuitive sense can be developed on the basis of
clinical experience and the most common combinations of mental health and substance use
disorders that present among the people seeking treatment and support. Along this vein,
there are two approaches that have been followed to develop sub-groupings.
2.2.5 Classifying on the Basis of Severity
An approach outlined by Ryglewicz and Pepper34 considers the mix of substance abuse and
mental health disorders in the categorization scheme, using categories that reflect the
relative severity of each set of problems, as well as psychosocial functioning, motivation, and
vulnerability to even small amounts of alcohol and other drugs. For example, their first of
four sub-groups includes those with a major mental illness and a major problem with alcohol
and/or drug abuse, dependence, or addiction. Their second group includes those with a major
mental illness and a special vulnerability to the effects of alcohol and other drugs. This approach is
very similar to the schema presented by Rosenthal and Westreich,39 and adapted from Weiss
et al.47 whereby four categories are used which correspond to the cells of a two-by-two table
(high – low psychiatric severity and high – low substance abuse severity). A Case Manager
Rating Form which assesses severity of psychiatric symptoms, substance abuse severity,
functional disability and treatment noncompliance63 is cited by Rosenthal and Westreich39 as
being helpful in placing the individual into the proper category.
2.2.6 Approach Based on DSM
The second approach is to form sub-categories based on a broad DSM-IV classification of
mental health disorders, and which reflect the most frequent disorders presenting with
substance use disorders in the population seeking treatment and support (e.g., mood and
anxiety disorders; personality disorders; severe and persistent mental illness). This approach
does not seek to sub-type further on the basis of pattern or severity of the concomitant
substance abuse problems.
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Both the severity approach and the DSM diagnostic strategies have merit and there is not a
consensus among the experts as to the preferred method; although all agree some
sub-categorization is necessary. For this project, the diagnostic approach, compared to the
classification method adopted by Ryglewicz and Pepper (see Appendix C)34 and Rosenthal
and Westreich,39 is favoured since it:
 is more directly linked to a preferred course of treatment and support, including
pharmacological symptom management which is highly disorder-specific;
 still recognizes the need for comprehensive and ongoing assessment to sort out the
interaction of the substance use and symptoms within each of the broad categories;52
 still retains considerable flexibility within the categories to discuss common patterns of
presentation, for example, the high percentage of consumers presenting to methadone
programs who are dependent on opiates, and who have a personality disorder; and the high
prevalence of schizophrenia and alcohol abuse among clients of psychiatric units,
community mental health centres and programs for the homeless.
It is acknowledged that one’s preferred approach to sub-grouping people with concurrent
disorders may depend on your location in the community service network; which doorway to
the treatment and support system the person has entered (i.e., a mental health or substance
abuse treatment entry point); and whether the program/system has access to a
physician/psychiatrist. In this report, however, we go to some length to recommend a more
seamless, holistic approach so that the person with concurrent disorders might expect a
similar approach and quality of service regardless of the entry point to the system.
The following categories are based on the more common presenting groupings of concurrent
mental health disorders, recognizing the wide variation that will exist within each category
in terms of use, abuse and potential dependence on one or more psychoactive substances. It
is recommended that these five sub-categories within the broad group of concurrent
disorders be used as a schema for developing, and subsequently refining, implementing and
evaluating the best practice guidelines.
The five groupings are:
Group 1: Co-occurring substance use and mood and anxiety disorders;*
Group 2: Co-occurring substance use and severe and persistent mental disorders;
Group 3: Co-occurring substance use and personality disorders;**
Group 4: Co-occurring substance use and eating disorders;
Group 5: Other co-occurring substance use and mental health disorders.***
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* While technically speaking bipolar affective disorders fall within the broad DSM-IV mood and anxiety category,
they are typically considered as ‘severe and persistent’ mental illness and are included in our second group.
** It has been the experience of the writers that the majority of people with co-occurring substance use disorders and
problems related to anger, impulsivity and/or aggression will also fall into this category.
*** Including but not limited to sexual disorders and pathological gambling.
This report focuses on the first four groups. There is a need to keep a developmental
perspective in mind that would:
 recognize the many age-dependent associations within and across mental health and
substance use disorders;
 emphasize that an aspect of understanding the phenomenon of concurrent disorders is to
understand the pathway leading up to this situation for the individual; and
 highlight the importance of early detection and intervention.
It is beyond the scope of this project to focus on these developmental issues in depth.
2.2.7 Current Limitations of the Data Regarding Substance Use
These five categories are based primarily on the clustering of different types of mental health
disorders within the broad grouping of substance use disorders. This categorization scheme
belies the tremendous complexity and heterogeneity within substance use disorders
themselves. In the substance abuse field one can think in terms of the level of risk associated
with the amount and pattern of use. This substance use may or may not result in particular
consequences that would support a formal diagnosis of substance abuse. Further, the
presence of these negative consequences is important but not a necessary or sufficient
criterion for a diagnosis of substance dependence. This three part conceptualization – use,
abuse and dependence – is further complicated by at least 10 different classes of
psychoactive substances (e.g., alcohol, opiates, stimulants, inhalants), and the many specific
types of drugs within these drug classes (e.g., cannabis, cocaine, heroin, glue). Complex
categorization schemes that might more adequately convey the heterogeneity within the
substance use disorders themselves were considered.* After careful consideration, however, it
was felt that the research literature and practice wisdom, were not yet strong enough at this
level of detail on which to base best practice guidelines. It is recommended, however, that
the five-category scheme be seen as a classification model that is open to change on the basis
of further diagnosis-specific and substance-specific research on concurrent disorders.
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* For example, a four dimensional model based on (a) mental health disorder; (b) substance; (c) high risk
use/abuse/dependence and (d) level of functioning.
2.3 Defining Integrated Treatment
Integrated treatment for people with concurrent disorders arose in the early 1980’s as a
solution to the difficulties and poor outcomes associated with treatment and support being
provided across the two separate systems of mental health and substance abuse services.
Given the pivotal role that this term plays in the research literature, and our subsequent best
practice recommendations, it is important that it be defined early in this report.
Drake et al.64 succinctly describe the developmental history of integrated treatment in a
recent review. Most of the other major reviews of treatment models for concurrent disorders
also include a definition and description of integrated treatment, typically in contrast to
sequential* or parallel treatment.24,34,37,39,65,66
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Key Points
 The terms “integrated”, “sequential” and “parallel” treatment have been used
in previous attempts to define best practice in this area.
 An important distinction must be made between program-level and
system-level integration.
 Integration at either or both the program or systemic levels is to be
encouraged on the basis of research.
 Critical features of program- or system-level integration include that there be
an agreed upon and well communicated treatment plan and a consistent and
well coordinated implementation of that plan.
 Clinicians/support workers in an integrated program or system should provide
specific services concurrently or sequentially, depending on the particular
combination of concurrent disorders and other individual factors.
 The wide variation in expression, risk and need associated with concurrent
disorders typically converge in significant problems in social functioning.
 Both program- or system-level integration exist in degrees and it is important
that it be monitored to be sure the key principles are in place and sustainable.
 Integrated treatment and support for people with concurrent disorders,
particularly those with severe and persistent mental illness includes the
provision of a broad range of both counselling-therapy strategies and
psychosocial rehabilitative supports.
* Serial treatment is a term often used synonymously with sequential treatment.
2.3.1 Integrated vs. Sequential vs. Parallel Treatment
Reviews commissioned in the U.S., in the mid-1980’s by the National Institute of Mental
Health (NIMH), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and
the National Institute on Drug Abuse (NIDA), identified the problems encountered by
people with concurrent disorders with treatment being provided across the two systems of
care.67,68 Recommendations called for better integration of mental health and substance
abuse treatment. This was followed up with a demonstration program which developed and
evaluated various interventions within the context of integrated models. While there are
several different ways in which treatment integration can be operationalized the following
definition will be used:
mental health treatments and substance abuse treatments are brought together by the
same clinicians/support workers, or team of clinicians/support workers, in the same
program, to ensure that the individual receives a consistent explanation of
illness/problems and a coherent prescription for treatment rather than a
contradictory set of messages from different providers (adapted from Drake and
Mueser.)64
The more comprehensive integrated program models include common mental health
interventions, such as medication management and support services, as well as assertive
outreach, intensive case management, individual, group and family counseling and, on
occasion, intensive day or residential components. Some of these features such as assertive
outreach and intensive case management are critical features of Assertive Community
Treatment (ACT) teams which can include substance abuse counselors. As the models for
integrated treatment evolved, they incorporated interventions tailored to the person’s stage
of recovery,61 motivational interviewing and a range of other service activities (see Drake
and Mueser64 for an overview, and Mueser et al.,44 for a detailed outline of specific
interventions within their integrated treatment model).
In contrast to integrated treatment, sequential treatment was a term that referred to one
treatment (either mental health or substance abuse) followed by the other treatment, but
through referral to another agency, or specialized unit within the same treatment
organization.65 An example would be a person receiving counseling for panic attacks at a
community mental health center and who is referred to a local substance abuse treatment
service to deal with frequent binge drinking. The terms sequential or serial treatment were
meant to imply that first the person would deal with one set of problems and then the other,
but through two agencies or treatment units working largely independent of each other.
A parallel model of treatment referred to the simultaneous, concurrent treatment of both
the psychiatric disorder(s) and substance use disorder(s) by two separate agencies, or two
specialized units within the same treatment facility.65 As with the definition of sequential
treatment, the term parallel treatment was meant to imply that clinicians in the two agencies
or treatment units were working largely independent of each other.
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Hence, the primary distinction between sequential, parallel and integrated treatment has
been the implication that the latter involves concurrent treatment in terms of concepts,
personnel, program and facility.24
2.3.2 The Need for New Systems Terminology
While the three terms reflected very distinct approaches when they were first proposed, their
definitions have become somewhat dated and blurred with the advent of a more systems
approach to treatment,69 and the exploration of various strategies to improve the
coordination of services spread along a continuum of care that spans treatment units or
agencies in the community.31,32,33,45,70-72 Specific examples of system coordination strategies
are discussed in more detail in Section 4.4.2. In short, there are many ways to better
integrate an individual’s treatment and support across units within the same facility or across
community agencies. This increasing collaboration blurs the distinction between the old
terms of integrated treatment and sequential or parallel treatment.
In this report, a distinction between “program integration” (as per the original integrated
model), and “systems integration” to reflect innovations underway to improve care and
support across treatment units or community agencies is proposed. The earlier definition of
integrated treatment is used as the definition of program-level integration. However, even in
the context of an integrated program (i.e. one treatment/support plan with the same clinician(s)
and support worker(s) in the same program) specific interventions for substance use and mental
health disorders may be delivered either concurrently or sequentially depending on the
particular combination of disorders, and the urgency that may arise within the individual
circumstance (e.g., life threatening issues that must be given priority). Concurrent or
sequential interventions in an integrated program model will be delivered in the context of
an agreed upon treatment and support plan, and a consistent and co-ordinated team
approach tailored to the unique needs and capacities of the individual.
System integration means:
the development of enduring linkages between service providers or treatment units
within a system, or across multiple systems, to facilitate the provision of services to
individuals at the local level. Mental health treatment and substance abuse
treatment are, therefore, brought together by two or more clinicians/support workers
working for different treatment units or service providers. Various coordination and
collaborative arrangements are used to develop and implement an integrated
treatment plan.*
As with program-level integration, this treatment plan may involve addressing the substance
use and mental health disorders either concurrently or sequentially, but always in the
context of a consistent and coordinated approach tailored to the unique needs and
capacities of the individual.
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* This definition is adapted from the definition of systems integration employed in the ACCESS project for the
homeless in the U.S. 71]
Integration at the program level has been the subject of considerable research.35,44,64 Models
for system integration, however, have been much less frequently evaluated. This situation is
likely to change over the next several years as accountability demands increase to show that
models to improve service coordination ultimately translate into improved consumer
outcomes and cost-effectiveness. This variation in research evidence, notwithstanding, there
is no compelling evidence at present to recommend program-level integration over
system-level integration, or vice versa. Subsequent recommendations about the importance
of integrated treatment are meant to encourage integration from both program-specific and
systemic perspectives.
2.3.3 The Need to Monitor Integration Activities
Organizational and larger systemic changes often require culture shifts and time to evolve. For
example, what may begin as a collaborative initiative to cross-train staff may evolve into
supplementary program components (e.g., a mental health agency may begin offering an
substance abuse support group). It may then evolve further into a more fully integrated
service (e.g., all consumers entering a mental health/agency are screened for substance
abuse, and if needed, their individualized treatment and support plan covers both the mental
health and substance use disorder).
Since efforts toward system integration may evolve over time, including the drift away from
initial intentions, the development and widespread application of monitoring measures is
recommended to assess the degree and type of system integration that has been achieved
within any one organization that spans both addictions and mental health, or within a larger
network of programs in the community. Integration should not be permitted to devolve into
treatment that places responsibility for integration solely on individual therapists who may,
for example, be more comfortable dealing with mental health issues to the exclusion of the
substance use problems or vise versa.
2.3.4 The Need for Psychosocial Supports
In the mental health field, the focus on community integration for people with severe mental
illness has been a dominant force over the past two decades.73 Coincident with this trend has
been a shift toward a broad psychosocial rehabilitation perspective. This broader perspective
values the critical role of acute treatment, medication management and symptom reduction
in facilitating more long-term positive outcomes. However, it also advocates for supporting
the person in a wide variety of areas, including housing, employment, recreation, and social
networks. As a result of new thinking about community integration, and specific policy
initiatives that have supported the paradigm shift, a wide array of community support
programs has emerged. This includes services that are consumer-run, and which bring an
experiential perspective to service delivery and support.74 The goals of these psychosocial
support services are helping persons with severe mental illness become reintegrated into the
community, and improving their quality of life and that of their families.
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The psychosocial support services are recommended as part of the overall package of care
and support for people with severe mental illness (see for example, the schizophrenia
practice guidelines).15 Therefore, we would like to emphasize that they also have a clear role
in an integrated program or system for people with concurrent disorders, if they are required
by the person on the basis of their needs and functional abilities. Although this is consistent
with the advice of several experts in the field,44 it may not be immediately obvious given the
widespread use of the term integrated treatment. Thus, we prefer the term integrated
treatment and support as it is more consistent with this broader psychosocial rehabilitation
perspective.
2.4 Rationale for Best Practice Guidelines
2.4.1 Prevalence Rates
Among consumers in substance abuse treatment and mental health settings, and among
members of the general population who need treatment and support but who have yet to
seek help, the prevalence of co-occurring mental health and substance use disorders
problems is very high. Despite the high prevalence, there is a reported lack of knowledge and
training as to how best to identify and address needs.
a) Prevalence among the general population
Much of the literature on rates of comorbidity in the general population has been
contributed by studies conducted in the United States. The report from the
well-known Epidemiology Catchment Area (ECA) study75 is frequently cited as one
of the first demonstrations of the high rates of co-morbidity in the general population.
They found that the prevalence of substance use disorders among people with a
concurrent mental disorder was 29% compared to 16% in the general population. A
more recent report by Kessler et al.76 using data from the 1990-1992 National
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Key Points
 The prevalence of co-morbidity is high in the general and treatment-seeking
populations and has largely been ignored in planning, implementing and
evaluating both mental health and addiction services. Knowledge in this area
is rapidly expanding.
 The high variability in prevalence rates across studies results from studying
different sub-groups of people in different settings with different methods.
 Co-morbidity changes the course, cost and outcome of care and presents
significant challenges for screening, assessment, treatment/support and
outcome monitoring.
 Substance abuse and mental health services in the community have typically
worked in isolation, and often from competing perspective.
Comorbidity Study, found a total of 28.8% of the general population aged 15-54 had
a concurrent (i.e., in the last year) alcohol and/or drug and mental disorder diagnosis.
For those people with any current substance use disorder 42.7% showed a concurrent
mental health problem; while 14.7% of those presenting with a psychiatric disorder
showed a concurrent substance use disorder. This pattern of increased probability of
mental health problems among people with substance use disorders, and vise versa, is
mirrored in studies emanating from many developed countries.77-79
In Canada, and using methods and definitions which paralleled the U.S. National
Comorbidity Study but with an age range that was 10-years wider (15-64), 18.6% of
respondents from the 1990 Ontario Mental Health Supplement presented with one or
more current alcohol, drug or mental health problems.80 A more recent report on
co-morbidity of alcohol use and mental health disorders in the Ontario sample81
found that 55% of those with a lifetime alcohol diagnosis also qualified for a lifetime
mental health diagnosis.
Epidemiological surveys suggest that while only a minority of individuals with alcohol
or other substance abuse problems in the community enter treatment,82 the most
severe cases with multiple concurrent mental disorders are the most likely to be
treated.78,83,84 Kessler et al.76 have also shown that those in the general population
with concurrent disorders present the highest probability of seeking treatment. This is
corroborated by data from the 1992 National Longitudinal Alcohol Epidemiologic
Survey which showed that respondents with past-year alcohol use disorders were
twice as likely to seek help for their alcohol problems if they had a concurrent drug
use disorder or major depression; and they were five times more likely to seek help
when both these concurrent conditions were present.85 An unpublished secondary
analysis of the Quebec Health Survey of 1987 provided data consistent with these
findings in the U.S.86 Such findings are congruent with the recognition that those
who seek help are the most severe cases in the general population.83
b) Prevalence among people seeking help
Clients of substance abuse treatment services who are diagnosed with a psychiatric
disorder also use more health services generally,87 and are more often readmitted to
treatment.88,89 The frequent use of expensive hospital and emergency services, and
the persistence of both mental health and substance use disorders over time,
contributes significantly to the extremely high economic cost associated with
treatment and ongoing support for these individuals.90,91
Several studies have assessed the prevalence of concurrent substance use and mental
health disorders among those people seeking help from either mental health or
substance abuse treatment settings. Recent summaries of this literature,40,66 clearly
show that the rates of alcohol and other drug problems are consistently higher among
people seeking help from mental health services than the general population.
Compared to the general population, the lifetime risk for developing alcohol
dependence is 21 times more likely among individuals with an antisocial personality;
six times more likely among those suffering from mania; four times more likely in
people with schizophrenia; and twice the risk among those suffering from panic
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disorder, obsessive-compulsive disorder, dysthymia, major depression or somatization
disorder.92 Weisner and Schmidt93 found that 38% of clients of mental health services
in a California county reported one or more alcohol dependence symptoms in the
previous year, compared to 27% in the general adult population and 65% in the
criminal justice system. In the same study, 21% of mental health clients reported the
use of three or more types of illicit drugs compared to 1% in the general population,
and 12% of people arrested for a criminal offence.
Similarly, clients in substance abuse treatment have higher rates of mental health
problems than are found in the community at large. Since those who suffer from
concurrent disorders have a higher probability of seeking treatment than their
counterparts in the general population,76 the vast majority of individuals admitted to
treatment exhibit one or more clinical symptom.94-96 Studies have reported that close
to 77% of those treated for alcohol-related disorders have experienced at least one
other psychiatric disorder during their lifetime.97 Most clients suffer from at least one
disorder of mood or anxiety;95,98-100 and the rates for personality disorder range from
53% to 100%.101-106 Ross et al.105 found that 68% of clients attending an outpatient
treatment facility in Toronto qualified for a concurrent psychiatric diagnosis; the
most common being antisocial personality, phobia, anxiety, and depression.
c) Summary
There is wide variability in the prevalence estimates derived from both community
samples and from treatment populations. The variability comes from such factors as:
 the assessment method and criteria employed to establish diagnoses;
 the treatment/support setting;
 the demographic characteristics of the community or service recipients.44
2.4.2 Relationship to Treatment Outcome and Other Clinical Issues
It is very difficult to disentangle the relationship between a substance use disorder and a
mental health disorder from the perspective of “what caused what”. This makes it difficult to
draw firm conclusions about the causal role of either substance use or mental health disorders
in determining the course of either single or concurrent disorders, and the influence of
various factors on long-term recovery.
Given the difficulty in establishing antecedents and consequences in much of the research, it
is safer to speak of issues of association rather than causality. As noted by Drake and
colleagues in a recent review,35 it was two decades ago when the high rate of substance abuse
among young people with schizophrenia began to be seen as a factor complicating
community adjustment.107-109 Since then, research has shown that concurrent disorders are
associated with:
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 the risk of relapse and re-hospitalization;109
 depression and risk of suicide;109
 incarceration;109
 homelessness;110,111
 family problems;109,112
 an increased risk of child abuse and neglect;113,114
 domestic violence;115
 increased risk of violence;116
 HIV infection;117-118
 the increased risk of victimization;119-121
 the special needs of women in treatment;122,123 and
 functional difficulties such as unemployment or work instability109,124,125 and chronic
interpersonal conflicts.109
Outcomes associated with mental health treatment and ongoing community support seem to
be negatively affected by co-occurring substance abuse.126 In particular, there is a strong
association between poor outcomes for schizophrenic patients and the combined influence of
medication compliance/non-compliance, current substance abuse and lack of outpatient
contact.127 The converse also appears to be the case with the outcome of substance abuse
treatment which is significantly and negatively associated with psychiatric impairment (or at
least generalized psychological distress).128 This seems to be particularly the case among
opiate, alcohol and cocaine abuse populations.129-131 Co-existing mental disorders increase
the probability of abandoning treatment prematurely;130,132-136 which in turn negatively
influences treatment outcome.137,138 Early dropout from treatment can be explained by the
fact that many of these clients encounter difficulties in engaging in treatment and
establishing a therapeutic alliance.139-145 Treatment engagement and therapeutic alliance are
interconnected since the beneficial effects of treatment are positively correlated with
continuation in treatment.146-154 If they do remain in treatment, the amount of attention and
the length of treatment required by these individuals often exceeds the services normally
planned by the program.132 Given the higher risks of relapse, higher likelihood of re-entering
more expensive services, and the high likelihood of leaving needed services prematurely,
effective assessment and treatment of people with concurrent disorders could help reduce
health, social and correctional service costs.
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2.4.3 Service Integration, Coordination and Planning
There is widespread agreement that individuals who have co-occurring mental health and
substance use disorders have typically had to seek treatment and ongoing support from two
very separate service delivery systems (see for example, Ridgely et al.27 and the TIP
concurrent disorders protocol).24 This is particularly true for people with concurrent
substance abuse and severe and persistent mental illness (Group 2) and many people with
concurrent personality disorders (Group 3). Whether the issues are discussed from a U.S.
perspective and some of the nuances of their health care system, or from the perspective of
more universal access to Canadian health care, the same basic theme emerges about the
historical separation of the two systems of care. Furthermore, most analysts agree that these
historical barriers are at the heart of many of today’s problems experienced by consumers
with concurrent disorders who are trying to access help in the two systems.
Many factors account for the historical separation of the two systems. History,
notwithstanding, it is generally agreed that having two systems of care for people with such
an overlap in their constellation of needs has had more negative than positive effects on
continuity of care and consumer outcomes.
Having two separate systems of care has usually meant parallel or sequential services being
delivered across the two systems with little or no coordination and less than optimal
outcomes. Poorer outcomes are thought to result from various systematic factors, including:
 compounded feelings of stigma;155
 competing perspectives on the primary problem; and
 the additional burden on the consumer to retell their story, deal with additional
transportation issues and, in general, follow through on two separate treatments which may
offer conflicting therapeutic advice plans.156
Examples of conflicting approaches to treatment are abstinence versus harm reduction goals,
and philosophical differences in the use of confrontational techniques (abstinence goals and
confrontation being more common in some substance abuse treatment settings). The
acceptability of psychoactive medication that helps manage the symptoms of mental illness
also remains controversial in some substance abuse treatment settings.
In the worst case scenarios, the delivery of services across the two separate systems of care
and support has meant the individual, and often the person with the most severe
constellation of problems, has simply been referred across to the ‘other side’. Such referral
has also typically meant little or no case management, to ensure contact has been made, and
that the person has been successfully engaged in the system. Dropout rates from concurrent
treatment programs that are not well coordinated can run as high as 60%.157 Thus, high
attrition from programs can be seen from the perspective of the low accessibility and
acceptability of the services being offered. These concerns about poor coordination are
echoed in research studies that have examined the coordination of services across mental
health and substance abuse services and potential solutions.155 These issues are also quite
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salient in testimonials and personal stories of consumers participating in community
system-level planning exercise,31 including the focus groups held for the current project
(see Section 4.2.1).
2.4.4 Summary
In summary, there is a very strong rationale for the development of the best practice
guidelines:
 there are many people with concurrent disorders in the general population and already in
contact with the health care system;
 outcomes are poorer and the costs of care from the consumer, family and service delivery
perspectives are very high;
 there is a long history of poor coordination and often competing perspectives across the
mental health and substance abuse treatment systems.
2.5 The Approach to Defining Best Practice for this Project
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Key Points
 The current high interest in best practice guidelines is related to larger trends
in health care to improve consumer outcomes and reduce variation in care
and associated costs.
 Best practices are usually developed at the service delivery level (e.g. clinical
guidelines) but can also be developed at the system level.
 Given the current state of knowledge in the area of concurrent disorders the
focus in this report is at the service delivery level; implications and
alternatives are identified for implementing best practices within service
delivery systems.
 Best practices can be defined on the basis of scientific evidence and/or expert
consensus; some combination of these methods is usually employed.
 The approach used in developing this report has been a detailed review and
synthesis of the research literature, expert and key stakeholder opinion,
including consumers.
 More research is needed about the impact of best practice guidelines on the
attitudes and behaviour of health care policy makers, planners, and
providers, and on consumer health outcomes.
Defining best practice guidelines is a burgeoning area within health care. Best practices have
been defined as “systematically developed statements to assist practitioner and patient
decisions about appropriate care for specific clinical circumstances”.161 These guidelines are
typically directed at the service delivery level; that is they offer guidance to clinicians,
therapists, social workers, etc. on the most effective, or cost-effective, services that can be
delivered directly to health care consumers. There are, however, some examples of guideline
development that explicitly aim for recommendations of best practice for health service
organizations (e.g., performance measurement mechanisms and processes), and systems of care
(e.g., policy development, planning and funding mechanisms and processes).162
2.5.1 Evidence-Based Versus Expert Consensus
There are two main models for developing best practices163, 164 – the scientific evidence-based
model and the expert consensus model. In the scientific evidence-based model, best practice
guidelines are extrapolated from a comprehensive literature review.
Several concerns have been raised about this strictly research-based approach.165,166 These
include:
 reliance on a body of literature that is subject to pervasive publication bias;
 lack of attention to multicultural issues;
 limitation on generalizability; and
 over reliance on the “gold-standard” research design, the randomized control experiment.
The expert-consensus model is typically conceived of as an adjunct to the scientific
evidence-based model whereby the opinions of experts are used to fill the gaps in the
scientific literature. The four main methods of consensus formation are:
 informal processes;
 formal consensus development conferences;
 nominal groups;
 Delphi methods.163,164,167
Criticisms of this approach often centre on the fact that the process of selecting experts is
often a reflection of professional hierarchies which may result in no more than a group
guess.168
It is often necessary to develop treatment recommendations on the basis of less than
conclusive research literature, and to use expert opinion to advantage. Thus, a mixed
methodology is often used that takes the best information from published research studies
and combines some form of expert review and consensus development.165 The specific
features of the combined methodology is often driven by the available budget.
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2.5.2 Approach
The guidelines developed in the present project are based on:
 an extensive review of relevant literature;
 a synthesis of this literature according to the professional judgment and experience of the
study team, including what the literature does not tell us, and a summary of other issues
that must be taken into account in extrapolating from the published studies;
 review and advice of an expert panel concerning our general approach and results of our
knowledge synthesis;
 a review of preliminary recommendations by key stakeholders in the mental health and
substance abuse systems as obtained by a key informant survey;
 focus groups with consumers who have experienced concurrent disorders in order to
validate our synthesis of research and expert opinion with their needs and lived
experience;
 further synthesis of the above by the research team and additional review and input from
the expert panel;
 in addition to ongoing process management the draft report was reviewed by Health
Canada to ensure consistency with the study objectives and obtain additional input from
the various provincial and territorial representatives on the Health Canada Working
Group; and
 preparation of final recommendations.
It is important to be clear that the guidelines emanating from this project are not based on:
 a formal rating of the strength of the research evidence (however, highest priority was given
to research from experimental or quasi-experimental studies). Based on this research
evidence we also distinguish, where possible, between the ‘best’ and the ‘most promising’
interventions for a given combination of concurrent disorders; or
 a consensus among the members of the expert panel (however, areas of strong agreement as
well as dissenting opinion have been noted in an anonymous fashion).
These methodological decisions are based largely on budgetary constraints as well as the
current state of the literature in the area of concurrent disorders. Future attempts to update
these best practice guidelines may have a larger literature to draw upon in some areas, and
therefore will be more suited to these methodological improvements over our work.
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3.0 Best Practice for Concurrent Disorders
at the Service Delivery Level
Appendix D provides an overview of both the mental health and substance abuse service
delivery systems in Canada. This section summarizes the main points from this overview and
the implications for best practice guidelines at the service delivery level.
Mental Health Services:
 mental health reform has given high priority in policy and program development to a wide
range of community mental health services and some developing social supports that are
designed to maintain people with severe mental illness outside of institutions or inpatient
care;
 there has been steady progress in involving consumers and families in the design and
delivery of services and supports;
 general practitioners and many other health care specialists provide the largest proportion
of primary mental health care in Canada;
 mental health reform has also involved closures and/or reductions in the size of the large
provincial psychiatric hospitals, and a corresponding increase in the role of general hospital
psychiatric units in providing acute care and crisis response;
 the prevalence of mental health disorders and concurrent disorders is very high in
correctional systems across Canada and there is a close and complex relationship between
the mental health system and the criminal justice system;
 there are also several population sub-groups with particularly high needs for mental health
services and which must be carefully considered when planning and delivering services for
people with concurrent disorders (e.g., the homeless; aboriginal people; perpetrators and
victims of family violence and child abuse).
Substance Abuse Services:
 the alcohol and drug treatment system in Canada has evolved through several stages, and
is currently grounded in a broad biopsychosocial perspective;
 medical and psychiatric professionals play an important, but increasingly less dominant,
role in assessment and treatment for substance abuse compared to other mental health and
substance abuse counseling professionals, such as psychologists, social workers and certified
substance abuse counselors;
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 reform of substance abuse services has given high priority to developing a wide range of
community-based services typically defined along a ‘continuum of care’ – withdrawal
management, comprehensive assessment, brief intervention, more intensive outpatient or
day treatment, short or longer term residential treatment and continuing care;
 related to the continuum of care approach is a stepped-care model, whereby clients are first
engaged in the least intrusive level of care and then “stepped-up” or “stepped-down” on
the basis of results from ongoing outcome monitoring;
 there is more emphasis on prevention and early identification than is evident in the mental
health sector. Many services adopt a harm reduction approach; others adhere to
abstinence as the primary goal of treatment. There is considerable variation in this regard
across the provinces and territories;
 self-help groups (e.g. Alcoholics Anonymous) play an important role in local treatment
systems across the country;
 the prevalence of substance use disorders is very high in correctional systems across
Canada, and there is a close but complex relationship between the substance abuse
treatment system and the criminal justice system;
 as with mental health, there are also several population sub-groups with particularly high
needs for substance abuse treatment services and which must be carefully considered when
planning and delivering services for people with concurrent disorders (e.g., youth, the
homeless, Aboriginal people).
In summary, there are many entry points into a community’s mental health and substance
abuse systems. While people with concurrent disorders may be more likely to show up at
some entry points than others (e.g., emergency and crisis services; homeless shelters), the
research data would suggest that the prevalence of concurrent disorders will be high across
all entry points. It is also important to note that in the mental health system, the duration of
time with which a person with a concurrent substance use disorder is being treated or
supported by a particular program is quite variable. This can range from very brief contact at
a crisis service, to a few weeks or months in an acute treatment setting, to several years of
regular contact and support through a community team, a supported housing program, a
clubhouse or a consumer survivor initiative. Similarly, across substance abuse services in the
community the prospects for identifying someone with a mental health disorder are quite
different in different settings (e.g., brief contact at a withdrawal management centre
compared to several weeks or months of support from an outpatient or residential treatment
program). In addition, the types of professional training, experiential knowledge and
perspective also differ substantially across these settings. These factors will impact on the
ability and interest among managers, staff and consumers in initiating various strategies that
might be recommended for identification, assessment, and treatment/support. The role of
the family/significant others will also be highly variable, for example, in providing collateral
reports of substance abuse, or participating in family systems interventions. These important
contextual factors notwithstanding, there is a need for evidenced-based advice in three
areas:
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1. identifying if someone has a potential substance use disorder or mental health disorder;
2. for those screened positive, conducting a comprehensive assessment that will investigate
more conclusively the nature and severity of the addiction or mental health problem
and how they are related. In areas with limited resources, this step may out of necessity
also include referral to another service for support in assessing the substance use or
mental health problem, but this referral is made in the context of a coordinated system
of local services, with follow-up to ensure an integrated treatment plan is developed;*
3. for those determined to have a concurrent substance use disorder and mental health
disorder on the basis of the assessment, providing treatment/support for the immediate
problem resolution, and to provide longer term monitoring, support and rehabilitation.
As above, in some communities this step may also include referral to another service for
support with the substance use or mental health problem, but this needs to be done in
the context of an integrated treatment plan and a coordinated system of local services.
This section is organized into three sub-sections corresponding to screening (Section 3.1);
assessment (Section 3.2); and treatment and ongoing support (Section 3.3) of people with
concurrent disorders. Each sub-section, in turn, recognizes that the person may initially
enter either a mental health service, a substance abuse service, or an integrated program and
that regardless of the entry point the consumer with a concurrent disorder should expect the
same general approach and quality of care.
3.1 Best Practice in Screening for
Substance Use and Mental Health Disorders
3.1.1 General Issues in Screening
Attempts to treat substance abuse among people with mental health disorders, and vice
versa, must begin with recognition.169,41 The purpose of screening is not to determine the
complete profile of psychosocial functioning and needs, or to make a diagnosis; but rather to
identify whether the individual may have a mental health or substance abuse problem that
warrants more comprehensive assessment.
In general, the goal is to have screening instruments that are brief; do not identify a high
proportion of false positives; and have good reliability and validity (see Appendix E for
definitions of these and other terms related to screening instruments). As noted above the
needs and opportunities for identification vary considerably across different types of mental
health and substance abuse treatment settings. It is not possible to recommend one approach
or screening tool. Therefore, the recommendations are organized into two levels of effort;
with the second level requiring more time and expertise than the first, but yielding
potentially greater benefits in terms of reliability and validity. Further, this is an area of
research that is expanding rapidly and several new screening instruments are available or on
the horizon, but which have yet to be validated in either the substance abuse or mental
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* As discussed earlier high quality integrated treatment and support can be achieved through systems as well as
program integration.
health population. Where appropriate new instruments that are being developed or tested,
and which may be appropriate for people with concurrent disorders in either or both
populations are mentioned.
In this review the work of Dr. Kate Carey and colleagues40,170,178 has been drawn on for
screening. The seminal work of Drs. Robert Drake, Kim Mueser and colleagues has also been
valuable.156 The reader is encouraged to review the reports and literature reviews published
by these research teams. Several of their reports are listed in Appendix A, and in the
References.
The following points concern terminology and some other general issues:
 while it is important to have screening tools that have excellent psychometric properties, a
distinction can be made between what is needed for clinical decision-making, compared to
what might be needed for a highly controlled research study. In other words, even though
there may be no proven screening tool available at present which will work in all settings,
there is still value in asking a few simple questions, or otherwise having a high index of
suspicion using readily available information. We include these approaches under Level I
screening strategies;
 in an integrated system it will be critical to have the linkage between services for screening
and assessment well-established and monitored in order to reduce the burden on the
consumer to “retell their story”. This was an important theme identified in the consumer
focus groups;
 research generally supports the value of getting information about alcohol and drug use
from different sources to corroborate information obtained solely from the self-report of the
consumer. Although self-reported information about alcohol and drug use can be
considered reliable and valid in some contexts, self-reports are not as trustworthy in other
contexts (see Carey170 and Carey & Correia41). For example, concerns about self-report
may be particularly important when working with a person to be admitted to a psychiatric
service and for whom admission of substance abuse has potential negative consequences in
terms of ongoing treatment and support (e.g., loss of housing). It is generally acknowledged
that laboratory tests which screen for substance use disorders on the basis of biochemical
markers are much less sensitive and useful with people with concurrent disorders than are
collateral reports from family, friends or past records;41
 there is a preference for screening tools and procedures in the public domain; that is they
are available at no cost to the service provider;
 services which are providing support to a consumer for an extended period of time, such as
an intensive case management program or a clubhouse for people with severe mental
illness, will be able to monitor the situation over a longer period of time. Thus, screening
need not only occur at intake into the service. The judgment of the case worker can have a
high predictive value as the consumer becomes better known and trust is established;171
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 in the mental health field there is an important distinction between diagnostic screening
instruments and those based on psychological distress/functioning. Similarly, for substance
use disorders, there are diagnostic screening instruments and there are those based on
consequences or pattern of substance use. Both methods among the Level II screening
approaches are considered;
 most screening tools for substance use disorders are focused on either alcohol or other
drugs but not both. Given the common pattern of multiple substance use, one can miss
important substance-related problems if one screens only for alcohol problems or only for
drug problems. Few instruments are available which screen for both alcohol and other drug
problems. CAGE-AID172 and the Dartmouth Assessment of Lifestyle Instrument
(DALI: Rosenberg et al.173) are notable exceptions;
 there are important developmental issues to consider when selecting a screening tool or
procedure for consumers of different ages. Some instruments are designed specifically for
adolescents;174,175
 finally, there are critical issues related to the use of different screening instruments within
different cultural sub-groups without first having tested their psychometric properties and
appropriateness in the particular sub-group of interest. Other practical and methodological
issues concern the literacy level of the consumer; the extent to which they need support in
answering screening questions; and the influence of lending support to the person in
completing the questions on the reliability and validity of the answers (e.g., impact of
wanting to answer in a socially desirable way41).
3.1.2 Screening for Substance Use Disorders
a) Level I Screening Procedures
Within this level four alternatives are described. These alternatives require very little
time and effort on the part of clinicians/support workers during the initial contact
with the consumer, or within the context of an official intake process. Sensitivity and
specificity values derived with a group of people with concurrent disorders are not
available for all the alternatives listed. However, such measures and approaches may
still have value as part of a clinical decision-making process, especially in settings
where more psychometrically sophisticated approaches may not be appropriate during
the early period of contact or intake to the program (e.g., acute crisis settings). It is
better to cast a wide net in the screening process and subsequently rule out a
substance use disorder on the basis of further assessment.
 Index of suspicion: If other methods are not feasible or appropriate, it is possible
to use a simple checklist of behavioural, clinical and/or social indicators that
together can raise the suspicion that the person has a substance use disorder. The
following have been considered as common consequences of substance abuse in
people with severe mental illness (Group 2). Examples are given in Appendix F.
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 housing instability;
 difficulty budgeting funds;
 symptom relapses apparently unrelated to life stressors;
 treatment non-compliance;
 prostitution, other sexual acting out or sexual deviance;
 social isolation;
 violent behaviour or threats of violence;
 pervasive, repeated social difficulties;
 sudden unexplained mood shifts;
 employment difficulties;
 suicidal ideation or attempts;
 hygiene and health problems;
 cognitive impairments;
 legal problems.
On the basis of current practice wisdom the following should be added to this list:
 avoidance of disclosure (of likely concurrent disorders) for fear of being
admitted to inpatient psychiatry;
 repeated self-harm in the absence of clear situationally relevant stressors;
 a cyclic history of substitute or replacement addictions.
 Asking a few questions: Some research has shown that the response to a
straightforward question about previous problems related to alcohol is highly
correlated with the results of more detailed screening instruments.176 The evidence
on the value of this approach with people with concurrent disorders is mixed. The
reluctance of people to be completely forthright in such self-diagnosis has been
noted, and this may be particularly true upon first presentation to some mental
health settings where no trusting relationship has yet been established between the
consumer and the provider. Indeed, this was identified as a theme in the consumer
focus groups. Drake et al.156 warn of the difficulty people with severe mental illness
may have in perceiving the relationships between substance use and psychosocial
difficulties, and of the tendency to provide socially desirable answers. On the other
hand, Barry et al.171 compared consumer self-report and case manager ratings. They
found the consumer ratings on some of the questions to be more predictive of a
substance use disorder as determined by DSM-III-R criteria. The best predictor of a
substance use problem by the consumer was their perception that others were
concerned about their substance use (70% sensitivity: 88% specificity; 76% positive
predictive value; and 84% negative predictive value). It is cautiously recommended
that the three following questions be used as potential Level I screening questions
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for substance use disorders in mental health settings when other approaches are
considered inappropriate. A positive response to any one question should indicate
the need for further investigation.
Have you ever had any problems related to your use of alcohol or
other drugs? (yes/no)
Has a relative, friend, doctor or other health worker been
concerned about your drinking or other drug use or suggested
cutting down? (yes/no)
Have you ever said to another person “No, I don’t have [an
alcohol or drug] problem, when around the same time, you
questioned yourself and FELT, “Maybe I do have a problem?”
(yes/no)
 A brief screening instrument: The third approach for Level I screening is based
on the CAGE questionnaire,177 and a modification known as CAGE-AID that
incorporates both alcohol and other drugs.172 They are considered Level I measures
because of their brevity; being comprised of four items which can be routinely
incorporated into a formal intake process or a discussion with a consumer seeking
help. The CAGE has been validated with a sample of people with severe mental
illness and has reasonably high sensitivity and specificity.156,178 Wolford et al.,179
however, compared several screening measures for substance use disorders for
people with severe mental illness and, while the CAGE performed better than
other approaches such as clinical variables, laboratory tests and collateral reports,
it still yielded only modest sensitivity (60.9%) and specificity (69.5%).* The CAGE
and CAGE-AID collect information related to lifetime rather than current
substance use problems and some may also find this to be a limiting factor.
 Case manager judgment: In mental health settings which maintain contact with
the consumer for several weeks, months or even years, case managers can ask
themselves a few questions to screen for a substance use disorder.171 In the study by
Barry et al.171 the best predictor of a consumer’s meeting the DSM-III-R criteria for
a substance use disorder was the one question: “Do you think the client has ever
had a drinking or other drug problem? Would you say definitely, probably or not at
all?”
A relatively new brief screening tool for alcohol use disorders may hold promise for
identifying people with concurrent disorders in mental health settings on the basis
of further research. This instrument, known as RAPS4, has been developed as a
brief screening tool for problematic drinking in emergency room settings.181 It is
comprised of four questions related to: Remorse, Amnesia, Performance and
Starter (i.e., morning drinking). In emergency settings, a positive response to any
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* On some criteria, the TWEAK screening instrument for alcohol problems180 performed better than the CAGE.
However, the CAGE has been better researched with people with concurrent disorders and has been adapted to
relate to both alcohol and drug problems.
one item has been found to have high sensitivity (93%) and specificity (87%). The
instrument has also performed well across gender and ethnic sub-groups. Although
promising it needs to be validated in mental health settings.
b) Level II Screening Procedures
Within this level there are four alternative instruments.* They require somewhat
more time and effort to incorporate into routine practice than the Level I alternatives
(e.g., there are too many items to commit to memory with a simple mnemonic device
such as with the four CAGE questions). However, all measures are still quite brief
and easy to administer by interview or self-completion. Also, all the instruments
noted below have been validated with people with mental health disorders and they
are all in the public domain.
 Dartmouth Assessment of Lifestyle Instrument (DALI):173 This instrument is
the only screening instrument for substance use disorders that has been developed
specifically for use with people with severe mental illness. It consists of 18 items
that come from various existing screening tools. It was developed to be interviewer
assisted. Eight items predict drug use disorders, nine predict alcohol use disorders.
Two items overlap alcohol and drug use disorders. Results suggest it is reliable over
time and across interviewers, and that it is more sensitive and specific than several
measures including the MAST, TWEAK, CAGE or DAST.173
 Michigan Alcoholism Screening Test (MAST):182 Teitelbaum and Carey178
provide a comprehensive review of substance abuse assessment and screening
measures applicable for people with severe mental illness. Their review includes
many studies including the MAST,182 and its shorter version (SMAST):183 (see
also184). The MAST was also one of several screening measures evaluated by
Wolford et al.179 While the instrument has been used extensively with people with
severe mental illness, it is limited in comparison to the DALI since a separate
screening tool will need to be used for drugs other than alcohol** (e.g., the Drug
Abuse Screening Test (DAST).185 It also gathers lifetime versus current
information. A score of five or more indicates alcoholism; a score of four is
suggestive and a score of less than four indicates non-problematic drinking. The
SMAST is recommended over the full MAST due to its brevity (12 items). In the
recent study by Wolford et al.179 the much shorter self-report scales such as the
CAGE or the TWEAK performed equally well as the MAST, if not better.
However, all the brief self-report screening tools missed 25% to 40% of the people
with alcohol disorders. While the results obtained in other studies with the MAST
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* The project team is aware of the common use of the Substance Abuse Subtle Screening inventory (SASSI) as a
screening and assessment tool used by many addictions programs in Canada. The limited validation data for the
SASSI generally, and for application with people with concurrent disorders specifically, preclude our recommending
it in the present context.
** As with the CAGE instrument a SMAST-AID (i.e. And Including Drugs) has been developed. However, it has not
been tested with a sample of people with mental health disorders. Given the potential for confusion in the use of the
term “drug use” the measure can not be recommended for use with this population at this time.
have been better than found in this recent study (e.g., 86.8% sensitivity noted by
Drake et al.156) the MAST or the SMAST need to be complemented by other
information such as collateral reports and behavioural observation.
 Drug Abuse Screening Test (DAST):185 The DAST is similar to the MAST in
that it is based on consumer’s self-report and is not diagnostic; being based more
on the consequences related to drug use than drug dependence per se. The items
can be either interviewer or self-administered. In contrast to the MAST, the
DAST items refer to the past 12-months rather than lifetime. Recent research on
the DAST with psychiatric outpatient populations has confirmed the internal scale
properties with this group and established acceptable test-retest reliability,
criterion-related validity, sensitivity and specificity.186,187 In these studies the
briefest version of the DAST (10 items) also performed adequately as a screening
instrument. The authors of these recent studies recommend a cut-off point of
between 2-4 positive items on the DAST-10 as warranting further substance abuse
assessment. However, they also point out that different cut-off points can be used
depending on the clinician’s interest in maximizing sensitivity or specificity. The
cut-off point of 2 positive items was reported as achieving a good balance. Maisto
et al.187 also point out that the positive predictive value of the DAST-10 was low
compared to that reported for the DALI by Rosenberg and colleagues.173 This was
attributed to the comparatively low base rate of current drug use disorders in their
sample. This underscores the importance of considering the underlying prevalence
of substance use disorders in the mental health setting when evaluating the
appropriateness of a screening tool. For example, lower prevalence rates will lead
to lower predictive value. A tool with low predictive value in a given setting can
still be useful if a goal is to limit the number of individuals for whom more
extensive, and more costly, assessments of substance use problems would be
conducted. The appropriateness of this strategy versus the one of maximizing the
number of people screened positive, including false positives, will need to be
determined within individual settings and treatment systems.
 The Alcohol Use Disorders Identification Test (AUDIT):188 The AUDIT is a
well-known, 10-item self-report screening instrument designed to identify people
for whom the use of alcohol puts them at risk for negative alcohol-related
consequences, or who are experiencing such consequences. Its performance has
recently been evaluated with people with severe mental illness.187 The time
reference for the AUDIT items is the past year, although a few items have no
specific time referent. It can be interviewer or self-administered. Maisto and
colleagues187 confirmed the value of the AUDIT in identifying people with alcohol
use disorder, or expressing symptoms of that disorder, in the past year. Estimates of
sensitivity ranged from .95 to .85 depending on the cut-point used. Specificity
ranged from .65 to .77. Consistent with the use of the AUDIT in other settings189
a cut-point of 7 or 8 struck a good balance between sensitivity and specificity when
using the diagnostic criteria of DSM-IV as the standard for comparison.
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Level II Screening Measures for Substance Abuse
All of the above screening tools are based primarily on consequences related to
alcohol or drug use and the item responses do not map onto DSM-IV criteria. One
brief tool that is available does provide this mapping and it also covers both alcohol
and other drugs with the same set of items. The measure, however, has not yet been
extensively evaluated, in particular with people with concurrent disorders. This set of
16 items (Substance Abuse and Dependence Scale: SADS) is a scale within the
Global Appraisal of Individual Needs (GAIN:190). The SADS provides a useful screen
for dependence (tolerance, withdrawal, inability to control use) and abuse
(consequences of use) based on DSM-IV criteria. It also produces a symptom count
score which can be used to monitor change over time.
In addition, the Psychiatric Screener described in the next section for screening for
mental health disorders, also provides a list of items that map onto the DSM-IV
criteria for substance abuse and dependence.
c) Summary:
There are many alternatives for screening for substance abuse among people
presenting to mental health services. The specific strategy selected may depend on
the time and resources available. Asking a few simple questions or using a basic index
of suspicion will be better than not giving any attention at all to substance abuse
issues. It is also recommended that the results of brief screening tools (e.g.,
CAGE-AID) be complemented by corroborating information from different sources.
Case manager ratings may be particularly helpful in those services with ongoing
contact with the consumer. The DALI is the preferred tool for screening for
substance abuse among people with severe mental illness.
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Best Practice Recommendation
 It is recommended that all people seeking help from mental health
treatment services be screened for co-occurring substance use disorders.
This advice is organized around Level 1 and Level II approaches that can
be tailored to the type of setting and the time and resources available.
 Level I approaches include:
– using an index of suspicion
– asking a few questions
– using a brief screening instrument
– using case manager judgment
 Level II approaches include the:
– Dartmouth Assessment of Lifestyle Instrument (DALI)
– Short Michigan Alcoholism Screening Test (SMAST)
– Drug Abuse Screening Test (DAST)
– Alcohol Use Disorders Identification Test (AUDIT)
3.1.3 Screening for Mental Health Disorders
a) Level I Screening Procedures
Within this level, there are two alternatives that require very little time and effort on
the part of clinicians/therapists during the initial contact with the consumer, or
within the context of an official intake process. As with the Level I procedures for
screening for substance abuse in mental health settings, reliability, validity, sensitivity
and specificity values are not available for these procedures. However, suggestions are
based on current practice wisdom and may still have value as part of a clinical
decision-making process, especially in settings where more psychometrically
sophisticated approaches may not be appropriate during the early period of contact or
intake to the program (e.g., withdrawal management settings).
 Index of suspicion: If other methods are not feasible or appropriate, it is possible
to use a simple checklist of behavioral, clinical and/or social indicators that
together can raise the suspicion that the person has a mental health disorder and
for whom a subsequent mental health assessment is needed. Consistent with the
TIP concurrent disorders protocol,24 the following ABC checklist for a mental
health status exam is recommended.
 Appearance, alertness, affect, and anxiety:
Appearance: General appearance, hygiene, and dress.
Alertness: What is the level of consciousness?
Affect: Elation or depression: gestures, facial expression, and speech.
Anxiety: Is the individual nervous, phobic, or panicky?
 Behavior:
Movements: Rate (hyperactive, hypoactive, abrupt, or constant?).
Organization: Coherent and goal-oriented?
Purpose: Bizarre, stereotypical, dangerous, or impulsive?
Speech: Rate, organization, coherence, and content.
 Cognition:
Orientation: Person, place, time, and condition.
Calculation: Memory and simple tasks.
Reasoning: Insight, judgment, problem solving.
Coherence: Incoherent ideas, delusions, and hallucinations?
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 Asking a few questions: It is cautiously recommended that the three following
questions be asked if other approaches are considered inappropriate in a particular
setting:
Have you ever been given a mental health diagnosis by a qualified
mental health professional? (yes/no)
Have you ever been hospitalized for a mental health-related
illness? (yes/no)
Have you ever harmed yourself or thought about harming yourself
but not as direct result of alcohol/drug use? (yes/no)
If answered forthrightly by the consumer these three questions will still no doubt
miss many people with concurrent disorders, especially those with less severe mental
illness. However, the questions are better than not asking any questions at all, in
those settings where the application of a longer psychometrically validated screening
tool may not be appropriate.
b) Level II Screening Procedures
There is a real need for a brief, validated screening instrument for mental health
disorders that would be suitable for use in a wide cross-section of substance abuse
treatment services. As noted earlier there is also an important distinction to be made
between screening instruments that are based on measures/indicators of general
psychological distress compared to those with questions that are intended to map
directly onto DSM diagnostic criteria. Each approach has advantages and
disadvantages. It is also important to keep in mind that the goal of the screening is to
identify people who should receive a full mental health assessment at which time
diagnosis would be confirmed.
One of the difficulties encountered in identifying potential screening instruments for
mental health problems is that the best researched instruments tend not to be in the
public domain and therefore require a fee for their use. A good example is the Brief
Symptom Inventory which is a 53-item self-report short form of the SCL-90-R.191 It
has been used extensively in substance abuse treatment research as a reliable and
valid general screen for psychopathology. Another example is the General Health
Questionnaire192 and its shorter versions (GHQ-28);193 which has also been widely
used in the substance abuse field. There are also brief screening tools specific to some
mental health disorders, for example the Centre for Epidemiologic Studies Depression
Scale (CES-D):194 and these are cited in the later sections on specific sub-groups of
people with concurrent disorders.
 Psychiatric Sub-scale of the Addiction Severity Index (ASI):195 The best
practice recommendation from among current alternatives in the public domain is
the psychiatric sub-scale of the Addiction Severity Index. The scale is comprised of
11 items that tap into previous treatment for psychological or emotional problems;
disability pension; use of medication; and experiencing various symptoms (e.g.,
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depression, serious anxiety, hallucinations, cognition difficulties, suicide ideation)
but which are not a direct result of drug/alcohol use. In addition to these 11 items,
both the client and the therapist provide various ratings of problem severity.
Through communication with the developers of the ASI, the following four
questions can supplement the ASI Psychiatric Sub-scale in its published form.
Have you had a significant period of time (that was not a direct result of
alcohol/drug use) in which you have (0=no; 1=yes):
1. Experienced significant problems with controlling your eating (e.g.
binging, purging, unable to eat)
Past 30 days? _______________ Lifetime? _________________
2. Experienced significant problems with your sleep? (e.g. falling/staying
asleep, sleeping too much)
Past 30 days? _________________Lifetime? _________________
3. Experienced panic attacks or extreme anxiety out of the blue?
Past 30 days? _________________Lifetime? _________________
4. Experienced a trauma that comes back in unwanted flashbacks?
Past 30 days? ________________Lifetime? _________________
Level II Screening Measures for Mental Health
There are three promising screening tools under development:*
 A mental health screening tool known as the Psychiatric Screener197 is being developed
by the Centre for Addiction and Mental Health** in Toronto. The preliminary
reliability and validity testing of the Psychiatric Screener is currently under
investigation and the results to date have been very encouraging.
The Psychiatric Screener assesses 12 dimensions of psychopathology across Axis I of
the DSM. Each dimension results in a 0 to 1 scoring system, and is not continuous in
terms of degree of severity. Individuals receive a gross categorization of either having
the disorder or not having the disorder (to be followed by a full mental health
assessment). In addition, for those who have a positive score for having the disorder,
the screening instrument scores the person in terms of the disorder being current or in
the past (i.e., occurred sometime before the month in which testing took place).
The Psychiatric Screener also assesses symptoms associated with dependence or abuse
of each of several classes of psychoactive substances; the items reflecting the criteria in
DSM-IV.
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* Another measure known as PRIME-MD screens for psychiatric disorders but has been developed spcecifically for
physicians.196 While it may have some potential value in treatment settings with a staff physician it would require
some modification to be more widely applicable. Further the tool has not been tested and validated with people with
concurrent disorders.
** The contact person for information about this screening tool is Mr. Wayne Skinner (1-416-525-8501, Ext. 6387)
 In addition to the Psychiatric Screener which is diagnosis-based, another important
option for screening for mental health problems based on psychological
distress/functioning is on the horizon. In the GAIN assessment package mentioned
earlier in the context of screening for substance use disorders,190 there is a 21-item
General Mental Distress Index (GMDI) that screens for depression, anxiety and suicide
ideation. It also has additional screening items for traumatic distress and external
distress (e.g. ADHD, conduct disorder).198 The measure, however, has not yet been
extensively validated, in particular with people with concurrent disorders.
 Another brief mental health screening tool based on psychological distress/functioning
is also in the early stages of development by Ron Kessler.199
c) Summary:
There are alternatives available for screening for mental health disorders among
people presenting to substance abuse services. The specific strategy selected may
depend on the time and resources available. Asking a few questions or using a
checklist for mental health status will be better than not giving any attention at all to
mental health issues. The psychiatric subscale of the Addiction Severity Index is
recommended and should be supplemented by a small number of additional items.
Promising new screening tools for mental health disorders are currently under
development.
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Best Practice Recommendation
 It is recommended that all people seeking help from substance abuse
treatment services be screened for co-occurring mental health disorders.
The advice is organized around Level I and Level II approaches that are
tailored to the type of setting and the time and resources available.
 Level I includes:
– using an index of suspicion
– asking a few questions
 Level II includes:
– psychiatric sub-scale of the Addiction Severity Index (ASI)
device
3.2 Best Practice in the Assessment of
People with Concurrent Disorders
3.2.1 General Issues in Assessment
The importance of conducting a comprehensive assessment of the potential substance use or
mental health problem identified in the screening process has been underscored in recent
years by several experts in the field of concurrent disorders.40,41,52,170,178,200 All agree on the
critical need for a comprehensive assessment for consumers of mental health services
thought to have a substance use disorder, and vise versa for those attending substance abuse
services. Assessment is seen as intimately linked to treatment planning and the delivery of
quality services.52,178 Assessment data also serve another important function as baseline
information for the determination of outcome.41 However, the additional and often complex
task at hand, is to investigate the inter-relationship of the mental health disorder(s) and the
substance use disorder(s) in terms of their interaction and etiology. As discussed in an earlier
section there are many ways in which alcohol and other drug use (AOD) can interact with
severe mental health problems.24,41,156,178 Mueser et al.45 provide the most inclusive discussion
to date of etiological theories.
There is cause for concern about the reliability of information from substance abuse or
mental health assessments conducted with people with concurrent disorders (see Del Boca
& Noll,201 for a recent review). There is evidence of lower reliability of self-reported past or
current psychiatric disorders among drug abusing versus non-drug-abusing individuals.202,203
There is also lower reliability of self-reported alcohol and drug use and consequences among
people with severe mental illness, this being exacerbated by fluctuations in acute
symptomatology, cognitive impairment and mental status.178
Suggestions from Carey & colleagues178,213,218 for improving the accuracy and reliability of
self-reported substance use and related problems by people with concurrent disorders
include:
 use multiple assessment methods;
 conduct multiple assessments over time (e.g. after 2 to 3 weeks of decrease in
consumption);
 be sensitive to consumers’ concerns;
 conduct the assessment when he/she is sober, drug-free and reasonably stable emotionally;
 provide assurance of confidentiality;
 establish a good rapport before asking for a lot of details;
 use simple direct questions with clearly defined time frames;
 do not aim for levels of specificity that exceed assessment goals;
40
 frame questions to normalize different substance use patterns (e.g., many people have
experimented with drugs? Have you ever had any experiences with……?); and
 verify the information as much as possible with other sources to converge on a consistent
set of conclusions.
One of the strongest recommendations made by experts in the field is for assessment to be
conducted over more than one interview and to include multiple sources of information.
Assessment should be seen as an ongoing process, that extends over a period of time,
including a period of abstinence or significant reduction in use.41 This integrative,
longitudinal approach is described, for example, by Drake et al.156 and Kranzler et al.204
Kranzler et al.204 have formalized this integrative approach into the Longitudinal Expert All
Data Procedure (LEAD). This integrates all information and observations about the
consumer that is available from multiple clinicians and support workers, and over repeated
assessments. Carey and Correia41 note that this approach was found to be less effective for
concurrent mood and anxiety disorders compared to other comorbidities. The longitudinal
approach, however, is critical to sorting out the “chicken and egg” problem. As noted by
Carey and Correia,41 if psychiatric symptoms continue during periods of abstinence this helps
establish the DSM-IV criterion of “not due to substance use”. Alternatively, the resolution
of some or all of the psychiatric symptoms during periods of little or no use is consistent with
a substance-induced disorder.
3.2.2 Alternative Approaches and Measures
A primary goal of a comprehensive assessment of substance use or severe mental illness is to
confirm diagnoses.41 For substance use disorders this involves making the important
distinction between substance abuse or dependence using the criteria of the DSM-IV. This
can be done with the substance abuse module of a full diagnostic interview such as the
Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-IV).205 For mental health
evaluation, a full structured or semi-structured mental health interview is required by a
professionally qualified mental health
professional.20
The Alcohol Use Scale (AUS) and the Drug Use Scale (DUS)206 are two five point
clinician-rating scales that have been developed to classify people with severe mental illness
into categories that correspond to the level of severity of substance use. The results also map
onto DSM-IV criteria. The clinician makes the ratings using all available information that
has been accumulated over a six-month period. Results show the scales can be completed
reliably and that the results correspond well with other methods of screening and
assessment.
Dennis207 provides a recent overview of measures to consider for a comprehensive substance
abuse assessment. For example, it is recommended that a substance abuse assessment
include:
 a detailed behavioural component that examines the frequency and pattern of alcohol and
drug use;208-210 and
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 factors predictive of relapse such as the confidence the person has that they can avoid
drinking or drug use in high risk situations.211,212
Few assessment measures, however, have been assessed for their reliability and validity with
people with concurrent mental health disorders. Carey170 has assessed the reliability and
validity of the Time-Line Follow-Back interview among psychiatric outpatients and
concluded that it can appropriately be used with this population. Teitelbaum and Carey178
and others35,44 note that the focus on the actual amount and pattern of alcohol and drug use
is critical since moderate use of these substances which would not normally be considered
“abuse” can still influence the course of severe mental illness and treatment outcome.
Indeed, Drake’s research with people with schizophrenia suggests that full-blown alcohol
dependence is the exception rather than the rule.
The Addiction Severity Index (ASI)195 is one of the most commonly used standardized
assessment instruments in the field of substance use disorders and there is an increasing
amount of research on its applicability for people with co-occurring mental health disorders.
The general conclusion drawn from most individual studies,213 and research summaries,213 is
that many of the sub-scales do not perform as well as to be expected with people who have
severe mental illness. In addition to poorer reliability than found with other populations, the
ASI has been found to be relatively insensitive to the consequences of lower amounts of
substance use; a particular difficulty for people with severe mental illness.44
The ASI has a high acceptance in the field and has been successfully employed in treatment
planning, research and program development in addiction treatment centres that have
special programs for concurrent disorders, or admit clients with concurrent disorders.214
There is also an adolescent version of the ASI that is available in both French and
English.215 After much discussion of the available research on the ASI, it is recommended
that the ASI be used cautiously in the assessment of people with concurrent disorders, and
particularly with people with severe mental illness. For this particular sub-group (Group 2),
the ASI should be supplemented with other information, such as the Time-Line Follow-Back
interview,216 clinician ratings,206 or other methods.
3.2.3 Assessing Stage of Change and Treatment Motivation
A third consistent recommendation for the assessment of people with concurrent disorders is
to evaluate their motivation for change, including the stage of change61,217,218 and/or the
person’s stage in the treatment process.62,218 The “Stages of Change” model is well-known in
the substance abuse field. There are five stages in the change/recovery process:
 pre-contemplation is the stage at which there is no intention to change behavior in the
foreseeable future;
 contemplation is the stage in which people are aware that a problem exists and are seriously
thinking about overcoming it but have not yet made the commitment to take action;
 preparation combines the intention to take action within the next month with lack of
success in taking action during the past year;
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 action is the stage in which individuals modify their behavior, experiences, or environment
in order to overcome their problems;
 in maintenance, people work to prevent relapse and consolidate the gains attained during
the action phase.
The measure of the “stage in treatment motivation” is conceptually related to the stage of
change model but developed specifically for people with concurrent disorders (Group 2).
The measure is known as the Substance Abuse Treatment Scale (SATS) and complements
clinician ratings of alcohol and drug use. The scale places the individual along stages of
engagement, persuasion, active treatment and relapse prevention.
To these recommendations of assessing “stage of change” and/or “stage of treatment
motivation”, is added the importance of assessing both these intrinsic motivational factors,
and the more extrinsic pressures to seek help (e.g., coercion from the legal system).219,220
Tailoring the treatment plan for people with concurrent disorders based on client stage and
motivation, is one of the key principles of an integrated treatment plan as defined by
Mueser,45 and Drake and colleagues,64 and is a good example of how the assessment
information must be linked to the treatment plan.
Further, there may be many shifts and regression in motivation for change based on:
 the dynamics and expression of particular mental disorders (e.g., people in a manic phase
may have high confidence and focused energy);
 the presence of substance abuse relapse risk factors (e.g., increased party activity while in a
manic phase); and
 the interaction between the substance use risks and the mental health risks (e.g.,
overconfidence in manic phase in the ability to self-control one additional drink).
The issue is that evaluation of motivation may be quite unstable.
3.2.4 Assessing Psychosocial Functioning
Finally, both mental health and substance use assessment must look at the broader
psychosocial functioning of the person including such basic needs as housing, access to food,
social supports, work, education and training.64 This would also include an assessment of
high-risk behaviour for HIV and Hepatitis C (e.g., needle sharing), violence and
victimization. The most comprehensive protocol for the assessment and classification of
social functioning is the Person-in-Environment System (PIE).221,222 This assessment tool has
been developed by the social work profession and is consistent with the broad
bio-psychosocial perspective of addictions and mental health. It complements the
diagnostic-based assessment process underlying DSM-IV and its predecessors* by focusing
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* While DSM accommodates psychosocial stressors and functioning on separate Axes (IV and V) the assessment is
limited to two summary ratings of severity and contributes little information to an individual’s treatment and support
plan.
separately on factors related to social functioning (e.g., family, friendships, community) and
environmental problems (e.g., access to food, housing, employment) and subsequently
incorporating mental and physical health diagnosis. Clinician ratings of severity, duration
and coping are included in the system.
While there are few published accounts of the application of the PIE assessment process for
people with concurrent disorders223 the approach has a high degree of face validity given the
important role that psychosocial functioning plays in determining the course and outcomes
of concurrent disorders (see subsections below). The length of the PIE assessment process
(on average 90 minutes) may limit its application in some settings. However, a computerized
version is pending and this should considerably reduce time for administration and scoring.
The short version of PIE [mini-PIE] may be scored by the mental health/substance abuse
counselor in less than 15 minutes. There is reliability and validity data for the use of PIE in
various human services contexts.
Another alternative for assessment of functioning is the Global Assessment of Functioning
Scale (GAF).224 The GAF asks a clinician familiar with an individual to rate that person’s
overall level of psychological, social and occupational functioning on a scale ranging from 1
to 100. Clear and concise anchors are provided for each 10-point range on the scale. The
GAF can be completed with reference to varying time periods (e.g., currently, highest level
of past year) and it constitutes the operationalization of Axis V of the DSM-IV mutiaxial
assessment.46 It is a slightly modified form of the Global Assessment Scale and it can be used
with a high level of reliability.224
3.3 Best Practice for the Treatment/Support of
People with Concurrent Disorders
This section outlines the best practice guidelines for treatment/support within four
sub-groupings of people with concurrent disorders:
 co-occurring substance abuse and mood and anxiety disorders;
 co-occurring substance abuse and severe and persistent mental illness;
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Best Practice Recommendation
On the basis of a positive screen for either substance use or mental
health disorders, a comprehensive assessment is recommended to (a)
establish diagnoses (b) assess the level of psychosocial functioning and
other disorder- specific factors; and (c) develop a treatment and support
plan that seeks to sort out the interaction between the mental health
and substance use difficulties for the individual, and work toward a
positive outcome for both sets of problems as well as any related
problems.
 co-occurring substance abuse and personality disorders;
 co-occurring substance abuse and eating disorders.
Before dealing with each sub-group separately, some of the common elements of an effective
approach to treatment and support are highlighted:
 both substance abuse and mental health problems can be chronic, recurring health
problems which usually require some immediate interventions as well as ongoing
monitoring and support. Mental health symptoms may have an independent trajectory that
may nevertheless be exacerbated by substance use. This is sometimes akin to ‘kindling’
effect whereby the use of substances exacerbate mental health problems, which in turn
exacerbate housing difficulties, problems with the law, etc. Alternatively, the mental
health symptoms may be a clear consequence of chronic and heavy use of psychoactive
substances (e.g., chronic depression). One purpose of ongoing monitoring and support is to
help sort out the interaction between the substance use/abuse and the mental health
problems and symptoms;
 consistent with our earlier definitions of program- and system-level integration some
specific interventions for some sub-groups may best be delivered sequentially, while others
are best delivered at the same time. Integration is about communication, consistency, and
coordination of all the various clinicians and support workers and not whether one set of
problems (mental health or substance abuse) is addressed before the other;
 treatment and ongoing support for all sub-groups of people with concurrent disorders
should also include attention to the person’s basic needs for housing, access to food, social
support and other aspects of psychosocial circumstance and social functioning;64,225
 the research evidence suggests there is considerable value in tailoring the intervention for
people with concurrent disorders to the motivational level or ‘stage’ that the consumer is
at, at that particular point in time.62,218 Thus, for all sub-groups there may be value to
assessing motivational stage and utilizing motivational interviewing techniques,226
recognizing that with some disorders clinicians may expect expressed or felt motivation to
be unstable;
 there is little evidence in support of residential treatment over intensive outpatient care;35
 self-help groups such as AA and other 12 Step programs226,227,228 and consumer/survivor
initiatives in the mental health field74 play a critical role in community mental health and
addiction systems.
3.3.1 Co-Occurring Substance Abuse and Mood and Anxiety Disorders
a) Prevalence and Etiological Issues
Several reviews in recent years have demonstrated marked comorbidity between
substance use and mood and anxiety disorders.54,229-231 Elevated associations between
unipolar depression have also been consistently observed 231 These reviews summarize
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a substantial body of evidence pointing to the high prevalence of mood and anxiety
disorders among people in treatment for substance use disorders as well as elevated
rates of substance abuse among individuals in mental health settings.229,232-235
Significant rates of comorbidity between substance use disorders and mood and
anxiety problems have also been found in large multi-site community studies 75 This
suggests that the positive association between these problems in clinical groups is not
an artifact of self-selection into treatment. For example, the ECA study75 found
anxiety disorders to represent the most prevalent non-substance use diagnoses (19%)
among people with alcohol use disorders. Those with any anxiety disorder had a 50%
increase in the odds of being diagnosed with an alcohol use disorder. A similarly
elevated risk was found in The National Comorbidity Survey.76
These patterns can also be found in the community studies of mood disorder and
substance abuse where lifetime prevalence of major depression among substance users
was much higher (24.3%) than the rate in the general population (5.8%).75
Furthermore, rates of substance abuse disorders among those with depression (27.2%)
and bipolar disorder (60.7%) were also quite high.
The strength of the association between specific anxiety-related diagnoses and
substance use disorders varies considerably. Phobic anxiety disorders and, in
particular, panic disorder with agoraphobia and social phobia, appear to be most
highly associated with alcohol use disorders. In addition, the overlap between
post-traumatic stress syndrome (PTSD)* and substance use disorders is extremely
high with estimates of co-occurrence ranging from 12%-59%.237 The prevalence of
post- traumatic stress syndrome amongst people with substance use disorders is higher
for women than men and estimated to range from 30-59%.236
The growing awareness of substance-induced mood and anxiety disorders46 suggests
that for many people the effective treatment of their substance abuse would alleviate
the symptoms of the mood and anxiety disorders.
b) Implications for Screening and Assessment
Screening for an alcohol or drug problem among people with anxiety disorders can be
accomplished with one or more of the screening tools identified in Section 3.1.2 (e.g.,
the Alcohol Use Disorder Identification Test;188 Drug Abuse Screening Test.)185
Levels of severity can be rapidly determined using the Alcohol Dependence Scale237
and a more detailed picture of alcohol or drug use can be obtained with the Timeline
Follow-back method.208,216 The Beck Anxiety Inventory,238 or the Brief Symptom
Checklist191are useful screening instruments for mood and anxiety disorders.
Specialized instruments are available to assess trauma symptoms and dissociation.
One such instrument is the Trauma Symptom Checklist-33 that measures long term
sequelae of sexual abuse.239 Psychiatric diagnosis of the anxiety or alcohol use
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* Post-traumatic stress disorder is an anxiety disorder which involves a cluster of symptoms characterized by a strong
tendency to avoid emotion. Post-traumatic stress syndrome may occur as a consequence of experiencing a severe
and stressful life event. Simple post-traumatic stress syndrome may result following a single traumatic event whereas
complex post-traumatic stress syndrome arises from repeated incidents of trauma and is associated with a broader
range of symptoms.
disorder should be carried out by a psychiatrist, registered psychologist (in some
jurisdictions also registered clinical social workers) using a structured and validated
interview such as the SCID for the DSM-IV.205
A greater challenge is encountered in assessing the relationship between an alcohol
and a mood and anxiety disorder. Such an assessment should include several sources
of data including:
 family history of both disorders;
 natural history of both disorders (i.e., onset, course, fluctuations, remissions);
 the effect of improvements of one disorder on the course of the other;
 childhood variables (e.g., trauma, neglect, abuse); and
 patterns and severity of alcohol consumption (e.g., episodic vs. daily).
Assessment does not occur only at intake; re-assessment over the course of care and
support is critical to sorting out whether the mood and anxiety problems are
substance-induced. In the case of mood and substance abuse, Brown et al.235 and
Schuckit & Monteiro96 have suggested waiting several weeks prior to making a
definitive diagnosis.
c) Clinical Issues and Treatment Implications
One of the more salient issues facing treatment of individuals with anxiety or mood
disorders is the difficulty in accurately diagnosing the nature of the relationship
between these disorders and concurrent substance abuse. The observation that
psychoactive substances can produce signs and symptoms strongly resembling anxiety
or mood disorders creates the dilemma of not knowing whether such disorders should
be treated directly or if they would resolve following reduction in substance use. Also,
withdrawal from many substances may also produce signs and symptoms that
resemble mood or anxiety disorders which can hamper treatment. This diagnostic
confusion can lead to inappropriate or delayed treatment.
Additional issues relevant to concurrent dependence on substances and
mood/anxiety disorders include the increased danger of suicide, especially in the case
of mood disorders. There may also be increased ambivalence evident in the
motivation to address the substance problems since in many cases the abused
substance may be perceived as temporarily improving the distressing mental health
symptoms. It is thus very important to regularly monitor and strengthen motivational
status. Furthermore, concurrent mood/anxiety disorders and substance use appear to
be associated with poorer response to both psychological and pharmacological
treatments;240-241 poorer prognosis (i.e., higher relapse rates, residual dysfunction),
and higher rates of medication use;242 and greater probability of requiring additional
treatment.235
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The co-occurrence of post-traumatic stress syndrome and substance abuse is
associated with poorer treatment outcomes.243-246 People with substance use disorders
and post-traumatic stress syndrome are:
 more likely to abuse harsher classes of psychoactive substances, such as heroin or
cocaine;
 have high rates of substance abuse; and
 are more vulnerable to re-traumatization.247
Studies comparing individuals with post-traumatic stress syndrome and substance
abuse disorders compared to those with substance use disorders alone have found that
the former have a more impaired clinical profile. Problems include higher rates of
unemployment, greater social and family dysfunction, poorer medical and
psychological status, including more co-morbid Axis I disorders.243,246
d) Review of the Evidence
This section summarizes the evidence relevant to two questions:
 Is there evidence for or against a particular sequencing of interventions?
 Is there evidence that points to one or more specific treatment approaches or
interventions as being particularly effective?
i) Sequencing: With respect to the first question, there are several compelling
reasons why a sequenced approach, specifically dealing with the substance
related problems first, may be more appropriate than a concurrent approach for
the majority of consumers with co-occurring mood and anxiety and substance
use disorders. This sequenced approach would still be undertaken within an
integrated program and/or system whereby the various clinicians and support
workers would have agreed to work together on this general treatment plan.
Some of the reasons for the sequenced approach include:
 the mood and anxiety syndromes that are observed in people who are alcohol
dependent are often organic consequences of chronic alcohol use and can improve
significantly with a reduction in use; 248
 psychoactive substances negatively impact on many areas of the individuals’ life
such as work, health, interpersonal relationships, finances and cognitive
functioning. Reducing substance use will lessen the strain on these areas. For
example, most of the incidents of suicide in a study by Murphy249 were committed
under acute intoxication.159,250 As long as psychoactive substances are still being
used, the person may experience many of the consequences that are generally
associated with mood/anxiety disorders.
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The suggestion to start with the substance abuse for most people with
concurrent mood and anxiety and substance use disorders is strongly supported
by a recent study by Verheul et al.145 Their results show that people who were
recovering from an alcohol use disorder were 16.7 times more likely to recover
from their mood/anxiety disorder than people who did not recover from their
alcohol use disorder. Those recovering from an opioid use disorder, were 4.3
times more likely to recover from their mood/anxiety disorder than those who
did not. This increased probability was not observed among those recovering
from cocaine use disorder in comparison to those who did not.
While a general rule of thumb may be to begin with the substance use problem
this is not likely to be successful in all cases, and an ongoing assessment will be
required to adjust the treatment plan if the mood and anxiety symptoms are not
alleviated through a reduction in substance use. Symptoms of anxiety and
depression may not only interfere with optimum outcomes from substance abuse
treatment, but are frequently reported as triggers for relapse.251-256 If the client
succeeds at significantly reducing their alcohol and/or drug consumption, and
continues to experience anxiety symptoms, then there is a high likelihood that
they also suffer from an independent mood or anxiety disorder and treatment
should proceed to deal specifically with that disorder. Thus, comprehensive and
repeated assessment is critical when a sequenced approach is followed. For other
people, mood and anxiety disorders can precede and be functionally related to
the substance use problem.54 Such situations may require explicit treatment of
the mood and anxiety disorder from the outset, keeping in mind that the
symptoms which may be self-medicated by the substances are still exacerbated by
substance misuse.
There is one major exception to the general rule of thumb to start first with the
substance use disorder for concurrent substance use and anxiety related
disorders. This exception concerns co-occurring post-traumatic stress syndrome,
whereby prevailing clinical wisdom would recommend concurrent treatment
interventions within a fully integrated model.159 For example, Najavits et al.257
argue that specific treatments known to be effective for post-traumatic stress
syndrome may not be helpful on their own for individuals with concurrent
substance abuse and post-traumatic stress syndrome . An example would be
exposure procedures that can increase emotional intensity, which in turn may
trigger a relapse to substance use. Similarly, 12- step programs often include a
focus on the present rather than the past (e.g., public disclosure and
surrendering to a higher power) and can be experienced as re-traumatizing to the
client with post-traumatic stress syndrome.257 A concurrent integrated approach
is also favored by clients.258 Although there is limited empirical evidence on
concurrent versus sequenced approaches to substance use and mood and anxiety
disorders, the evidence and the reasoning is strong enough to suggest such an
approach be followed for post-traumatic stress syndrome.
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ii) Interventions: Whether the interventions are delivered in sequence or
concurrently, what are the treatment approaches and interventions for
concurrent mood and anxiety disorders and substance abuse that are the most
highly supported by research? Recent reviews, summarizing a large number of
well-controlled treatment studies have found overwhelming evidence for the
efficacy of cognitive-behavioural therapy (CBT) for alcohol use disorders.12,259
This includes several key components such as:
 ensuring client choice;
 treating the context of substance misuse;
 tailoring to the person’s stage and motivation for change;
 practical problem-solving;
 emphasis on action;
 reliance on social supports;
 resolving ambivalence about change;
 identifying and managing cues to misuse.
Concurrent anxiety disorders: CBT is by far the most effective treatment for
anxiety disorders,260-262 and is consistent with the CBT approaches found to be
effective for alcohol use disorders. An individual whose substance use is a means
of controlling their anxiety symptoms will require a strategic and effective
intervention for these symptoms during the window of opportunity afforded by a
reduction in drinking or drug use. Otherwise the risk of relapse and dropout may
be high.253 Thus, the clinician should be able to effectively administer CBT
treatments for the phobic disorders which are characterized primarily by
behavioral avoidance (i.e., social phobia, agoraphobia, specific phobia), and the
anxiety states which are characterized primarily by somatic activation and
cognitive symptoms (e.g., panic disorder, generalized anxiety disorder, acute
stress disorder). For each of these disorders there are well-established and
empirically supported treatment protocols which guide the clinician in case
conceptualization and treatment, including pharmacological approaches.* 260
Psychological treatment typically stresses:
 problem definition;
 functional analysis of the symptoms;
 identification of cognitive distortions and schemas;
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* Benzodiazepines for anxiety disorders can be contraindicated with substance dependent individuals because these
drugs are especially susceptible to being abused and have a synergistic interaction with alcohol.
 exposure to the phobic stimulus;
 arousal management; and
 other strategies.
CBT for alcohol dependence may need to take into consideration the impact of
the concurrent anxiety by negotiating treatment goals; identifying the types of
high-risk situations; the role of cognitive distortions; the kinds of environmental
and social support and resources available; the rate of change, etc.
Concurrent mood disorders: Similarly, with respect to mood disorders an
analysis of the depressive symptoms will identify the specific cognitions,
behavioral pattern and coping skills that may be maintaining the depressed mood
and associated symptoms. Well-described and detailed protocols exist outlining
the specific techniques that can modify depressed mood and behavior, including
pharmacological treatment.263,264 For concurrent depression and alcohol use
disorders the evidence also points to CBT as an effective approach. For example,
Brown et al.265,269 treated depression and alcoholism with eight sessions of either
CBT or relaxation therapy and found superior effects for the CBT treatment on
mood and anxiety symptoms and percentage days abstinent. Results were even
more pronounced at the 6-month follow-up.
Despite addressing the alcohol and mood/anxiety symptoms, some individuals
may require ongoing relapse prevention, case management and booster sessions.
These would include the clients who have difficulty coping with chronic stress or
negative life events; occasionally succumb to drinking cues; display less than
effective interpersonal behavior. For this population, treatment may often be an
ongoing process and require the use of a wide variety of modalities and services
(e.g., family therapy, vocational counseling, stress management, lifestyle
re-education), in addition to direct treatment of their alcohol abuse and
mood/anxiety symptoms. Individuals with concurrent personality disorders often
fall into this category.
For individuals who demonstrate serious impairment in several areas, such as
work or school, family relations, judgment, thinking or mood, a close and
ongoing monitoring of functioning is required as the recovery from substance use
disorder may not eliminate the serious impairment in functioning. These
individuals remain particularly vulnerable to problematic life events due to their
poor coping skills. Suggesting and enabling them to come for additional support
when they experience significant stress will probably be a useful preventive
strategy. With those individuals who have significant impairments in
functioning, considerable vigilance should be exercised for those whose
substance abuse is not improving. For them, the various risks associated with
mood/anxiety disorders remain. For example, as noted earlier, the risk of suicide
under acute intoxication is high.249,250 There is also an increased risk of domestic
violence,115 child neglect,113 child abuse, etc.114
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Concurrent post-traumatic stress syndrome: The limited scientific literature
on the treatment of co-occurring post-traumatic stress syndrome and substance
abuse does not allow for an empirically validated recommendation on the best
standard of care beyond the recommendation noted earlier for a concurrent
integrated model. Until recently there were no programs designed to treat
post-traumatic stress syndrome and substance abuse. Recently, there have been
developments in the area of integrated approaches. These researchers agree on
the need for an initial phase that helps the person stabilize and improve
functioning.266 It is also recommended that treatment help the individual learn
about both disorders, including their inter-relationship and symptoms.
Najavits et al.246 and Najavits267 were the first to develop and evaluate a
cognitive-behavioral approach within a concurrent, integrated model.
Participation in their program, known as “Seeking Safety”, was associated with
high retention rates, and reduced substance use as well as post-traumatic stress
syndrome symptoms.236 This treatment program is probably the most widely
studied for this population and is currently being evaluated in eight different
subgroups for concurrent post-traumatic stress syndrome and substance use
disorder. The “Seeking Safety” treatment is designed for clients in the first stage
of recovery in which the goal is to reduce substance use and post-traumatic
stress syndrome symptomatology. The treatment seeks to:
 increase clients’ knowledge of both disorders;
 enhance life structure and increase coping skills in the management of painful
affect; and
 enhance self-care and interpersonal relationships.
Evans and Sullivan159 offer another dynamic approach to addressing post-
traumatic stress syndrome patterns and substance abuse.
Drug Therapies: There is a small literature on pharmacologic treatment tailored
specifically to people with concurrent mood/anxiety and substance use disorders.
While some alternatives are beginning to show promise there is insufficient
evidence at present for a best practice recommendation. Fluoxetine has been
shown to possess relaxing effects in people with substance use disorders that
were also diagnosed with social phobia and panic.268,269 Tollefson,
Montague-Clouse & Tollefson270 found that buspirone reduced alcohol use
among people with concurrent anxiety disorders. Kranzler et al.204 found similar
results. The use of benzodiazepines is generally cautioned against due to the risk
of cross-addiction20 unless the individual has been abstinent for a stable period.
While traditional tricyclic anti-depressants effectively treat the depression, they
do not impact on alcohol consumption.271,272 Fluoxetine (a selective serotonin
re-uptake inhibitor) reduced mood symptoms and alcohol consumption in people
with alcohol dependence who were clinically depressed.273 Kranzler et al.274
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found similar results for fluoxetine and naltrexone. There is some evidence for
the use of naltrexone in the management of alcohol abuse275-278 for people with
concurrent mood/anxiety disorders.
In the past decade there has also been some evidence that pharmacotherapeutic
interventions can be effective in reducing symptoms associated with
post-traumatic stress syndrome and substance use disorders. Trotter et al.279
observed positive results in a 12- week trial of sertraline in an alcohol dependent
sample of individuals (two-thirds female) with co-occurring post-traumatic stress
syndrome. The results indicated significant reductions in post-traumatic stress
syndrome symptomatology, substance abuse and symptoms of depression.
3.3.2 Co-occurring Severe and Persistent Mental Disorders
a) Prevalence and Etiological Issues
While many specific psychiatric disorders fall under the general rubric of “severe and
persistent mental illness”, the most common diagnostic categories are schizophrenia
and bipolar illness. The literature on the prevalence of concurrent substance use and
severe mental illness disorders is most recently summarized by Rosenthal and
Westreich,39 Drake and Muesser64 and Mueser and colleagues.44 The general
conclusion from these reviews and others4,40 is that between 40-60% of individuals
with severe mental illness will develop a substance use disorder at some point during
their lives, and about half currently meet criteria for substance abuse or
dependence.75,101 These rates are clearly higher than the prevalence of substance use
disorders among people in the general population without concomitant psychiatric
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Best Practice Recommendations
 An integrated approach to treatment/support(see Section 2.3 for
discussion of program and system integration) is recommended.
 With the exception of post-traumatic stress syndrome (PTSD), and in the
context of this integrated approach, a sequencing of the specific
intervention (beginning with the substance abuse) is recommended,
accompanied by ongoing assessment and adjustment of the
treatment/support plan if the mood and anxiety disorder does not
improve following an improvement in the substance use disorder.
 For post-traumatic stress syndrome an integrated treatment approach
that deals with both the post-traumatic stress syndrome and substance
abuse at the same time is recommended.
 The best current evidence for the treatment of concurrent substance use
and mood and anxiety disorders, including post-traumatic stress
syndrome, is cognitive-behavioural treatment.
disorders. Diagnostic sub-groups within the general category of “severe and persistent
mental illness” do not show a high preference for one type of substance over another.
Alcohol is the most frequently abused followed by cannabis and cocaine.44 Drug use
preferences basically follow those in the general population.
Schizophrenia: For schizophrenia specifically, population surveys have consistently
shown elevated rates of alcohol use disorders (about three times the risk), and drug
use disorders (about five times the risk).75,76 Several studies reviewed by Mueser et
al.44 have also shown the high rates of substance use disorders among people with
schizophrenia who are in treatment for the illness. Cuffel101 suggests that about half
the youth at the first episode of schizophrenia present with or will develop a
substance use disorder. Among people in treatment for alcohol abuse, the lifetime
prevalence of schizophrenia is in the order of 4.5% to 6%, and among those in
treatment with drug use disorders, 28%.
Bipolar disorders: With respect to bipolar disorder, it is widely acknowledged to be
the most common Axis I disorder to co-occur with substance use disorders. For
example, in the classic ECA study by Regier et al.75 the lifetime prevalence of any
substance abuse or dependence among persons with any bipolar disorder was 56.1%.
Further, the rates of substance abuse among those with bipolar disorder were several
times higher than among those with unipolar depression. The high rate of
co-morbidity has also been demonstrated among people in treatment for bipolar
affective disorder, and among people seeking treatment for substance use disorders
(see, for example, Weiss et al. 280 and Rosenthal and Westreich39 for an overview of
key studies and reviews).
As with all the concurrent disorders, co-occurring substance abuse/dependence and
severe mental illness can interact in several complex ways that have important
implications for screening, assessment and the planning of treatment and support. A
detailed discussion of interaction issues specific to bipolar and substance use disorders
and schizophrenia and substance use disorders is provided by Strakowski and
Debbello281 and Blanchard et al.282 respectively. For severe mental illness generally,
Mueser et al.45 review the various etiological and interaction models and find
considerable support for a super-sensitivity model whereby people with severe mental
illness are more sensitive to the effects of alcohol and other drugs due to increased
biological vulnerability and, therefore, experience more negative consequences from
relatively small amounts of alcohol or other drugs.
While more research is needed, experts generally agree that multiple factors are likely
to be important for different groups of people, and even within the same person. It is
generally understood, however, that severe and persistent mental disorders such as
schizophrenia and bipolar disorder follow their course with or without significant
improvement or recovery from the substance use disorder.
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b) Screening and Assessment Issues
Screening for an alcohol or drug problem among people with concurrent severe and
persistent mental illness can be accomplished with one or more of the screening tools
identified in section 3.1.2. Indeed, it is this subgroup of people with whom most of
the research on screening tools and assessment issues has been conducted. Specific
examples for screening procedures and tools include the index of suspicion provided
by Mueser and colleagues;44 the DALI;173 and the AUDIT.187 Case manager ratings
may also be particularly effective given the length of time that many people with
severe mental illness may be involved with a case management program. The
following assessment instruments have also been developed or tested specifically for
this sub-group:
 the Alcohol Use Scale;206
 the Drug Use Scale;206
 the Substance Abuse Treatment Scale;62
 Readiness-to-change.218
An important implication of the super-sensitivity model discussed above45 is that only
a minority of people with concurrent substance abuse and severe persistent mental
illness may be able to sustain controlled substance use. This is because moderate use
may result in negative consequences or dramatically increase the risk of more severe
substance use. It is critical to educate consumers about their biological sensitivity to
the effects of alcohol and drugs. This process can begin during the assessment phase.
Assessing motivation and the stage of treatment is particularly critical as the findings
are directly related to treatment planning.62,218 Similarly, with respect to the
assessment of medical and psychosocial needs (e.g., housing, food, health care).
Mueser and colleagues44 provide an up-to-date treatment of these, and many other
assessment related issues and challenges with people with co-occurring substance
abuse and severe and persistent mental illness. For this new sub-group it is
recommended that the reader consult this new resource book from Mueser and
colleagues.44 See Appendix G for a list of common obstacles to assessment with this
sub-group and potential solutions.
c) Treatment Implications and Clinical Issues:
Clients with combined severe mental illness and substance use disorders encounter
serious cognitive and affective problems in addition to interpersonal difficulties. For
instance, people in treatment for schizophrenia may experience hallucinations, have
reduced emotional responses, and may at times be thought-disordered or express
delusions. There is little harmony between cognition, emotional experiences and
their expression. Since many of these individuals often have difficulty engaging in
relationships with people in general, such may also be the case with a therapist. The
decision-making process that is required to overcome inappropriate consumption
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patterns is affected by the ambivalence that characterizes these clients. Therapists
that are working towards a remission of substance-related disorders may find it
difficult to identify a real sense of motivation in their clients. Moreover, the misuse of
substances will affect the pharmacodynamics of the medication taken for the primary
disorder, exacerbating all the symptoms. Finally, the lack of social supports, adequate
housing, meaningful daytime activity, as well as the functional impairment require a
multifaceted approach to treatment and support.
d) Review of the Evidence
This section summarizes the evidence relevant to two questions:
 Is there evidence for or against a particular sequencing of interventions?
 Is there evidence that points to one or more specific treatment approaches or
interventions as being particularly effective?
i) Sequencing: There is a broad consensus, supported by research and current
practice wisdom35,44 that people with concurrent substance abuse and severe and
persistent mental illness are best treated in an integrated program or system of
services that deal concurrently with both the mental health and substance use
problems.
ii) Intervention: In addition to studies which have examined outcomes associated
with the degree or types of program integrations35 there have been a small
number of studies of specific interventions for this sub-group. Jerrell and
Ridgely283 conducted a partial experimental study (about 50 % of people were
randomly assigned) to treatment conditions comparing a 12-step program,
behavioral skills training and intensive assertive case management. Each of the
latter two interventions was more effective than the 12-step condition on mental
health outcomes and global life satisfaction. However, the effects on substance
use were quite modest.
The effectiveness of the intensive case management and assertive outreach using
Program for Assertive Community Treatment (PACT) model was examined in
several of the studies reviewed by Drake et al.35 This outpatient model involves a
multidisciplinary team of specialized substance abuse and mental health
professionals serving as the core resource and support team for a small number of
consumers. It retains several features of the basic ACT model284-286 including 24
hour, seven day a week coverage, assertive outreach, counseling and
psychosocial supports complemented with specific substance abuse interventions
tailored to the persons stage of change/stage of treatment motivation. In one of
the better controlled studies,206 consumers in the PACT conditions showed more
progress toward substance use recovery and decreased substance use severity.
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Currently, the recommended compilations of empirically supported treatment
and practice wisdom for this sub-group of people with concurrent disorders are
the new resource book by Mueser and colleagues44 and the recent review by
Drake and Mueser,64 Mueser and colleagues44 first recommend the critical (i.e.
minimal) components of a solid foundation of mental health services which must
then be complemented by specialized concurrent disorders services.
The foundation of mental health services includes:
 medical management (including psychopharmacology);
 family support and education;
 supported employment;
 training in psychiatric self-management;
 crisis response services;
 housing;
 and, when needed, inpatient psychiatric hospital services.
The core components of specialized concurrent disorders treatment and support
include:
 concurrent disorders assessment;
 clinical case management based on stages of treatment;
 motivational interviewing;
 a harm reduction approach (e.g. flexible goals);
 cognitive-behavioral substance abuse counseling;
 concurrent disorders group interventions, including social skills training groups;
 self-help liaison (e.g. Double Trouble; AA);
 work with families including behavioral family therapy and psychoeducation; and
 residential options, including housing.
Most consumers with co-occurring substance use disorders and severe and
persistent mental illness will demonstrate serious impairment in several areas,
such as work or school, family relations, judgment, thinking, or mood.225 As
clinicians and support workers assisting this population know, these functional
limitations will probably not disappear. The clients require detailed functional
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assessment, long term support, and an ongoing monitoring of functioning as part
of the integrated treatment program.35 In contrast with the heavy and regular
use of substances by consumers with co-occurring mood/anxiety disorders, the
consumption patterns of many of these consumers may have features more
consistent with alcohol or drug abuse than severe dependence per se. This
occurs, for example, when periods of heavy consumption are mediated by
experiences of high stress.
While a high level of social-emotional support is likely to be needed to help the
person with a severe mental illness remain in the community and remain at least
minimally functional, the person’s problems, risks and needs are greatly
exacerbated by co-occurring substance use problems. Symptoms and related
patterns of social functioning will normally be more negatively impacted by the
interaction of two disorders. The fear experienced by many, especially after the
first psychotic episode is quite overwhelming - sometimes characterized as “I
thought I had lost control of myself and I would never come back.” Social
support often brings with it more stability and sufficiently adequate social
functioning to remain in the community while taking part in an active and
hopefully integrated treatment enterprise. With people with schizophrenia, for
example, treatment and support, and the language of treatment and support,
must be concrete, socially engaging and stabilizing. While self-help groups
provide some support, people with severe mental illness must often rely on
professional services for both therapy and social support. Active advanced case
management that is able to integrate social support and some therapy holds
promise.
As described above, a wide range of social supports may increase the likelihood
of psychosocial stability, with sufficient integration and stability of the self to
enable the person to actively participate in the ongoing assessment and
treatment enterprise. These engagements are not likely to be consistent over
time and mental health and substance abuse professionals must be prepared for
instability of gains and regressions without blaming the client for being resistant
to treatment, or consciously choosing relapse.
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3.3.3 Co-occurring Substance Abuse and Personality Disorders
a) Prevalence and Etiological Issues
The results of a number of studies show that the overlap in personality disorders and
substance use disorders is very high among people seeking help at substance abuse
services.104 Using DSM-III diagnostic criteria, the proportion of individuals attending
substance abuse treatment that are found to have at least one personality disorder
varies from 53 % to 100 %102-104,295. The WHO classification system (ICD), which is
stricter than the DSM criteria, yields more conservative estimates of the prevalence
of personality disorders.287,296 Individuals entering mental health services for the
treatment of personality disorders also have high rates of concurrent substance use
disorders.288
Substance use behaviour can lead to criminal activity, aggressiveness, disinhibition,
chaotic lifestyle and therefore resemble personality disorder diagnostic criteria.
Although overlap in the diagnostic criteria is apparent, studies that have examined
this problem and adjusted for symptom overlap have still found substantial
comorbidity.288,289
Antisocial Personality Disorder: While all types of personality disorders are found
within individuals in substance abuse treatment, most research on the rates of
co-occurrence concentrate on the cluster B disorders (e.g. antisocial, borderline,
narcissistic). Antisocial personality disorder (ASPD) has received considerable
attention because it presents the highest association with substance use disorders.
Antisocial personality disorder is also the only Axis II personality disorder that can be
assessed by lay interviewers using the Diagnostic Interview Schedule or DIS.301,290 It is,
therefore, the most commonly measured. The prevalence rates of antisocial
personality disorder using DSM-III-R criteria in samples of people being treated for
alcohol use disorder, vary from 10% to 53%.92,97,291,292,302. In the Epidemiological
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Best Practice Recommendations
 An integrated approach to treatment/support (see Section 2.3 for
discussion of program and system integration) is recommended.
 Within this integrated approach, it is recommended that interventions
for substance abuse and severe mental illness be planned and
implemented concurrently.
 The best current evidence is for a range of services, including a staged
approach to engagement and service delivery; outpatient setting;
motivational interviewing and cognitive behavioural treatment; harm
reduction and comprehensive psychosocial rehabilitation supports, to
name a few program/system components.
Catchment Area Study303 the probability of presenting with a diagnosis of antisocial
personality disorder was multiplied by four for men and by 12 for women, when an
alcohol use disorder was present.92
Antisocial personality disorder, closely related to substance use disorders and conduct
disorder, the childhood precursor to antisocial personality disorder, is a common
antecedent problem among persons who subsequently develop mental illness.
Further, antisocial personality disorder is more common among clients with severe
mental illness than in the general population45 Thus, the evidence is reasonably
strong that antisocial personality disorder is a common etiological factor that may
account for at least some of the higher rates of concurrent substance abuse among
clients with severe mental illness.
Borderline Personality Disorder: With the exception of individuals diagnosed as
antisocial, those diagnosed with a borderline personality disorder (BPD) are more likely,
compared to other subgroups of people receiving psychiatric services, to meet the
criteria for a substance use disorder.288,293-295 Studies on the co-morbidity of borderline
personality disorder and substance use disorders report an overlap ranging from 15% -
66%.296-299 In studies of individuals attending alcohol treatment centres, reports of the
prevalence of borderline personality disorder range from 13%-65%.296,299,300 Kosten et
al.134 observed a rate of 12% of co-occurring borderline disorder in a sample of 150
people in treatment for opiate dependence. Epidemiological studies of individuals in
the mental health system indicate even higher rates of co-occurrence between
borderline personality and substance use disorders. In a study of 50 psychiatric
outpatients who met criteria for borderline personality disorder, 84% had met criteria
for a substance use disorder sometime in their life.295 In a Canadian study of people
with borderline personality disorder, 23% met lifetime criteria for a substance use
disorder.301 A large study with a sample size of 2,463 examined the overlap between
borderline personality disorder and substance use disorders among people admitted to
a psychiatric hospital and found a prevalence rate of 21%.293
A number of issues should be kept in mind when interpreting these findings. These
studies were almost exclusively carried out with individuals in treatment settings and,
therefore, may be biased towards the detection of people experiencing greater
dysfunction.
b) Screening and Assessment Issues
The validity of a diagnosis of personality disorder has long been a controversial
subject.302 Its onset in adolescence or early adulthood is a necessary condition for
diagnosis. However, the reliable assessment of personality disorders, especially in
individuals with substance use problems, poses significant challenges. Since the
assessment of a personality disorder can be contaminated by the effects of the
substance use, it can be difficult to separate out the effects of the drug use from
behaviour that constitutes a true personality characteristic. This phenomena has
been described as the trait-state artefact. Substances can increase mood instability,
impulsivity, and interpersonal problems, which are features of personality disorders.
Structured classification instruments and clinical interviewing are recommended to
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improve the reliability of diagnoses. A number of simple screening tools can be used
to detect features of personality disorders. Self-reports such as the Personality
Interview Questionnaire II303 or the Personality Diagnostic Questionnaire –4th
Edition304 provide a basic screen of Axis II symptoms. The Borderline Personality
Disorder Scale305 is a useful approach to screen for symptoms associated with
borderline personality disorder. The weakness with these self-administered
questionnaires is that they have yielded high rates of false positives. These
instruments should be utilized as a first step in a more comprehensive assessment.
Diagnosis of personality disorders should be conducted in a clinical interview with a
qualified mental health practitioner (e.g., psychologist, psychiatrist, registered social
worker). Structured interviews are recommended to facilitate more reliable diagnosis.
The best and most widely known interview is the Structured Clinical Interview for
the DSM-IV Axis II Personality disorders.306 Another well established interview is the
International Personality Disorder Exam (IPDE)307 used by the World Health
Organization. This instrument may not be as useful for clinicians since it is long and
requires more training than the SCID. Both of these structured interviews for
diagnosing personality disorders require clinical expertise in noticing clinically
relevant criteria. In addition to assessing for the presence of a personality disorder, as
with all individuals with concurrent disorders, an assessment of functioning is
necessary. Those individuals with lower levels of functioning have a poorer treatment
prognosis and will require more ongoing support.
It is important to assess the relationship between anger management difficulties and
anti-social personality disorder. Many but not all people with an anger disorder will
also have an anti-social personality disorder. Timing issues are important to
investigate since resumption of substance abuse is a key predictor of relapse into an
anger-aggression cycle.
c) Treatment Implications and Clinical Issues
The clinical implications of concurrent personality and substance use disorders have
been described in a number of studies. Generally, individuals with both disorders
experience greater dysfunction than their substance abuse counterparts without a
personality disorder.297 Studies suggest that individuals with personality disorders not
only have higher rates of substance use generally but are more likely to be polydrug
users.134 Further, a consistent finding is a higher comorbidity of personality disorders
in drug users than alcohol users.308 People with a substance use and borderline
personality disorder compared to substance abusers without borderline personality
disorder are more likely to have a history of self harm behavior including suicide
attempts; comorbidity for depressive disorders; and poor impulse control.134,296,297
Many individuals with concurrent personality and substance use problems have high
rates of chronic unemployment and lack social supports. These factors make it
difficult for treatment to be effective since therapists cannot rely on a stable and
constructive environment to support change.309,310
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Treatment of substance users who have a concurrent personality disorder poses a
number of special challenges to clinicians. The clinical literature on individuals
diagnosed with both disorders describes treatment as notoriously difficult.
Interpersonally, these individuals are more rigid which contributes to greater
difficulties in interpersonal relationships in the work place, with relatives and friends,
as well as with therapists and treatment centres. These individuals often have greater
difficulty with trust and intimacy. People with borderline personality who abuse
alcohol and other drugs have been observed to be ambivalent about therapy and only
moderately compliant.311 These individuals are typically more avoidant, especially of
cues associated with negative affect, and this is associated with impulsive behaviour
via rapid acting, mood-altering substances.312 For individuals with concurrent
antisocial personality disorder, the ideas and behaviors that are at the core of the
problem may be experienced as quite “natural”. In addition, these individuals often
have difficulty understanding the impact of their behavior on others. These features
of the disorder increase the challenge for the therapist. Working with these
individuals often leaves treatment providers feeling stressed. Consequently, it can be
more difficult for clinicians to establish a working alliance, and retention in
treatment is lower.313
d) Review of the Evidence
This section summarizes the evidence relevant to two questions:
 Is there evidence for or against a particular sequencing of interventions?
 Is there evidence that points to one or more specific treatment approaches or
interventions as being particularly effective?
i) Sequencing: At this point much is unknown about what is the best approach to
treating individuals with a concurrent personality and substance use disorder.
The bulk of the literature to guide recommendations on treatment is primarily
based on the results of research on the treatment of one disorder while tracking
the impact on the other disorder. The results of these studies have conflicting
implications for whether or not to utilize a concurrent treatment approach with
this combination of disorders.
There is some literature, such as the recent study by Verheul et al.145 to suggest
that the best predictor of remission of the personality disorders is a recovery of
the substance use. In other studies the components of 12-step programs within
substance abuse programs have been observed to have an effect on personality
structure.314 Another study conducted a one-year follow-up of people attending a
6-8 week alcohol treatment program and found that people with concurrent
borderline personality disorder showed significant improvements in leisure time
satisfaction, decreased hospitalizations and stronger family relationships.315 The
implications of these research findings is that the focus of treatment should be
the recovery of the substance use disorder, this being the key to the remission
and/or improvement of the Axis II disorders.
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In contrast to the above-mentioned studies, many other studies have found that
the presence of a co-occurring personality and substance use disorder negatively
affects the outcome of the index disorder. Kosten et al.134 in a study of 150
opiate users observed that 2 ½ years following substance abuse treatment,
individuals diagnosed with personality disorders had a poorer outcome. In other
studies, the presence of antisocial personality disorder was associated with poorer
social functioning, higher levels of substance use and worse response to
traditional substance abuse treatment programs.131 The presence of antisocial
personality disorder features has been linked to higher dropout rates from
substance abuse treatment.316 These findings suggest that the presence of the
two disorders is associated with poorer treatment prognosis, and that the
concurrent treatment of both disorders is critical. Many clinicians conceptualize
the Axis II disorder as independent from the substance use disorder and that
improvements in the area of substance use may be difficult to accomplish
without simultaneously addressing the disturbances in character.
Studies of integrated models for treating co-occurring personality disorder and
substance use disorders are scant. There is some recent evidence to suggest that
treatment of borderline personality disorder and substance use disorders at the
same time can be effective.317 Further, prevailing clinical wisdom is that
concurrent treatment is likely more sensitive to addressing the issues associated
with borderline personality disorders and substance use disorders. In contrast to
the treatment of clients with borderline personality disorder, most clinicians
generally recommend routing clients with antisocial personality disorder and
substance use disorders into substance abuse treatment. This trend likely reflects
the lack of empirically supported treatments for antisocial personality disorder
itself.
ii) Interventions: Though evidence for the specificity of psychosocial treatments
has not been established, there is increasing interest and promise in cognitive
behavioral approaches. Dialectical behavior therapy (DBT), developed by
Linehan,318,319 has recently gained considerable notice in the literature because
of its empirical support. DBT is based on a biosocial theory that views the
dysfunctional behavior as a problem-solving behaviour, which functions to
soothe painful emotions.318 From this perspective, while substance abuse
behaviour is considered to be a maladaptive response, it is hard to change
because it helps in the short run to modulate overwhelming, uncontrollable, and
intensely negative emotions.312
Linehan and Dimeff312 have developed a treatment manual that articulates an
extension of standard DBT to fit the needs of borderline individuals with
concurrent substance abuse disorders (DBT-S). The treatment emphasizes
attachment strategies to increase retention, strategies to address urges and
tendencies to use drugs, ad lib case management to provide coaching to address
concrete needs, and pharmacotherapy where indicated with specific subtypes of
substance users (e.g., methadone for opiate dependent individuals).
63
In a recent study, Linehan et al.,317 randomly assigned 28 women to DBT or a
treatment-as-usual condition of community-based care. The women who were
diagnosed as having borderline personality disorder, were dependent on alcohol
or other drugs and tended to have other psychiatric diagnoses. The women
received one-year of treatment, including individual therapy and group skills
training. Results indicated that those receiving DBT compared to the control
group had significantly greater reductions in their substance use. The women in
DBT were also more effectively retained in treatment; 64% compared to 27%.
As well, those in DBT had better social and global adjustment after one-year of
treatment, and at 16-month follow-up. A replication of this study is currently
underway,320 and further studies with larger sample sizes are needed.
Regardless of the specific treatment approach, the degree of overall impairment
should be used to guide treatment interventions. Some people with co-occurring
personality and substance use disorders may not present with significant
functioning difficulties. These individuals have the best prognosis. Others may
present with moderate social and occupational impairment and lack coping
skills. While one may expect an amelioration with a significant improvement or
recovery from the substance use disorder, the prognosis is not as good as with
higher functioning individuals. A frequent problem for individuals with
co-occurring personality and substance use disorders is their serious impairment
in several areas of functioning. Many of these individuals lack money, work, food
and/or shelter. They may have been evicted from housing situations; be on no
admit lists to housing resources; be living in abusive relationships; be engaged in
very disturbed family relations; and may have trouble with the law. Assistance
and ongoing support is needed for these problems. This can be achieved through
intensive case management and ongoing monitoring of functioning. Assertive
outreach may be necessary to reduce the likelihood of premature termination
from treatment.312
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Best Practice Recommendations
 An integrated approach to treatment/support (see Section 2.3 for
discussion of program and system integration) is recommended.
 Within this integrated approach, it is recommended that interventions
for substance abuse and borderline personality disorders be planned and
implemented concurrently.
 Evidence on the treatment of antisocial personality and substance use
disorders suggests addressing the substance use problem first.
 The best empirically supported treatment for borderline personality and
substance use disorders is dialectical behaviour therapy (DBT), which
includes behavioural skills training.
3.3.4 Co-occurring Substance Abuse and Eating Disorders
a) Prevalence and Etiological Issues
With increased concern about concurrent disorders in the past two decades, there
has been more attention to the combination of substance use and eating disorders.
Common types of eating disorders are anorexia nervosa, bulimia nervosa and binge
eating. Most of the data on the co-occurrence of substance abuse and eating disorders
is based on samples of people with the latter. While the association between eating
and substance use disorders is higher than expected it also varies significantly across
studies (3% to 49%).
Substance abuse is clearly higher among individuals with bulimia than those with
restricting anorexia.321-323 The reported rates of co-occurrence with anorexia nervosa
are estimated to range from 6.7% to 23%.324,325 In contrast, estimates of the
prevalence of co-morbid bulimia nervosa and substance abuse problems range from
9% - 55%.326-331 From the reverse perspective, studies of the prevalence rates of eating
disorders within the substance abuse treatment population also yield highly variable
estimates, ranging from 1% to 32%.248,332-334 In one study of people with alcohol
dependence, 10% had a lifetime history of anorexia nervosa and 20% had a lifetime
history of bulimia.335 In another study of individuals presenting to an alcohol
treatment centre for the first time, 7% met current criteria for anorexia and 7% met
criteria for bulimia.336 In a study of people abusing cocaine, 32% met DSM- III
criteria for anorexia nervosa, bulimia or both, less than 1% of men and 4% of women
met criteria for anorexia whereas 20% of men and 23% of women met criteria for
bulimia.348
Divergent theories have been put forth to explain the association between eating
disorders and addiction problems. These theories emphasize the biological,
psychological and behavioral mechanisms that link them. One prevalent view is that
both disorders reflect addictive disorders.337-339 There is a growing opinion that eating
disorders are different from other addictive behaviors. One theory is that the eating
and substance use disorders are linked by underlying difficulties in the regulation of
affect. From this perspective, the problematic behavior functions to regulate painful
affect.340,341
b) Screening and Assessment Issues:
Given the higher than expected prevalence of eating disorders in individuals with
substance abuse problems, it is important for people to be routinely screened for the
presence of an eating disorder when presenting to substance abuse treatment services.
The importance of this initial screening must be underscored with clinicians working
within the substance abuse treatment system who may be more inclined to overlook
emaciation and poor appearance as a secondary effect of substance use. Inquiry
should not be limited to individuals who appear underweight since there are higher
rates of bulimia amongst individuals who abuse psychoactive substances. Individuals
with bulimia may frequently appear of normal weight and, therefore, their symptoms
may not be readily apparent.
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Individuals with eating problems often do not volunteer information about their
bulimia and compulsive eating without direct questioning about their symptoms and
the problems may go undetected. A variety of assessment measures are available but
tend to be lengthy or incomplete in their focus. The Psychiatric Screener discussed in
the previous section on generic mental health screening is one tool that can be used
to screen for an eating disorder.
More attention also needs to be directed at the detection of eating disorders in men.
A growing number of studies342,343 have observed high rates of eating disorders
amongst men with substance use disorders. Since eating disorders are generally
viewed as a disorder linked to women they are more likely to be overlooked in men.
For example, clinicians have been observed to make more inquiries into eating
disorder symptoms with thin women than with thin men.
For those people suspected as having an eating disorder on the basis of the initial
screening, they should then be assessed using standardized diagnostic criteria (e.g.,
DSM-lV) to ensure reliable measurement. Assessment should focus on both current
and past symptoms since clinicians caution that eating disorder symptoms often
resurface as the substance use problems improve. Assessment of the eating disorder
should also be repeated to determine its course in relation to possible improvement or
worsening of the substance use disorder.
c) Treatment Implications and Clinical Issues
There are a range of physiological, physical, psychological and social consequences
associated with the co-occurrence of eating disorders and substance use problems.
Depending on the severity and chronicity of these disorders, their impact can range
from mild to life threatening. Problems stemming from weight loss include fatigue,
anxiety, sluggishness, amenorrhea and depression.344 Some individuals report using
drugs, such as cocaine or methamphetamines which are anorectic agents, in the
pursuit of low body weight. Others may rely upon substances to interrupt binges,
elevate mood or to cope with the numbness. There is some evidence to indicate that
eating and substance use disorders are associated with greater dysfunction, in
particular problems with impulsivity, affective instability and instability. One study
showed that individuals with concurrent anorexia nervosa and alcohol abuse had
higher levels of theft, binge eating and purging.321 Individuals with both disorders
often have greater difficulty achieving abstinence and are more likely to relapse.342
Other research indicates that substance using individuals with a concurrent eating
disorder compared to those with only an addiction problem have:
 more severe substance problems (with the exception of heroin and tobacco);
 poorer health, more disturbed cognitive functioning (e.g., memory problems,
confusion);
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 greater affective instability;
 interpersonal problems; and
 poorer global functioning.343
The treatment of individuals with both disorders can be especially challenging to
health professionals because few have the familiarity or expertise in the treatment of
both disorders. The consequence of this is that clinicians often tend to focus on the
treatment of the disorder with which they are most familiar. While expertise in both
disorders is recommended, if this is not possible, consulting with other professionals
who possess the requisite knowledge is necessary.
d) Review of the Evidence
This section summarizes the evidence relevant to two questions:
 Is there evidence for or against a particularly sequencing of interventions?
 Is there evidence that points to one or more specific treatment approaches or
interventions as being particularly effective?
i) Sequencing: The dearth of research literature on the treatment of both of these
disorders limits the conclusions that can be drawn about the most effective
treatment. There do not appear to be any controlled trials to evaluate the
effectiveness of treating individuals with co-occurring eating and substance use
disorders. This is largely due to the fact that until recently there have been no
integrated treatment programs for people with concurrent substance use and
eating disorders. Indeed, the presence of eating disorders in substance users has
typically been ignored.
There are conflicting data on the effects of treating one disorder and tracking
the other. A few studies have observed that the treatment of individuals with
bulimia nervosa is not impacted by a prior history of psychoactive substance
use.345,346 On the other hand, other research shows that the treatment of one
disorder without attention to the other can reduce the overall effectiveness of
treatment.336,347,348 Some clinicians speculate that as the substance use problems
improve, the eating disorder may worsen due to symptom substitution. It may be
difficult to break patterns of problematic eating and substance use without
education and the development of effective coping strategies.
The prevailing clinical wisdom on the treatment of individuals with both
disorders calls for interventions to be planned and implemented concurrently.349
Notwithstanding this view, there are compelling clinical reasons to suggest that
if either of the disorders is so severe that it compromises the individuals’ life, or
critical aspects of functioning, treatment should first be targeted to that disorder.
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Once the more serious disorder is stabilized the two disorders can be treated
simultaneously. If neither of the disorders could be considered severe, or both
are equally severe, they should be targeted simultaneously.
ii) Intervention: Regardless of theoretical orientation, the majority of writers on
this topic recommend a combination of:
 medical management to stabilize the individual;
 behavioral strategies to effect change in the eating and substance use behavior;
and
 psychotherapy to address psychological issues.
A few integrated approaches to the treatment of these disorders have been
described in the literature but are lacking empirical evaluation. A 12-step
approach which integrates principles from Alcoholics Anonymous and
Overeaters Anonymous has been described.361 Within this model, both disorders
are seen as being linked by an underlying addictive process. A few descriptions of
inpatient programs for women with concurrent eating and substance use
disorders are also described in the literature.350,351 These programs integrate a
variety of treatment strategies with common elements that include:
 a thorough psychosocial and medical assessment;
 monitoring of weight and food intake;
 nutritional assessment;
 dietary plans and supervision;
 behavioral modification to increase awareness of eating behaviors and stabilize
aberrant behavior;
 education to address the denial associated with both disorders;
 psychopharmacology for severe symptomatology;
 individual and group therapy; and
 after-care.
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At the Centre for Addiction and Mental Health, in Toronto, an integrated
program for individuals with co-occurring eating disorders and addiction
problems was recently established. The program provides outpatient treatment,
based on a modified version of Linehan’s329 Dialectical Behavioral Therapy
model developed for individuals with borderline personality disorder.318 The
emphasis is on reducing relapse to eating and substance behaviors. Program
participants attend weekly individual therapy and group skills sessions. Work is
currently underway to evaluate this program.
Future research is needed to address what is the most effective treatment for this
population.
69
Best Practice Recommendations
 An integrated approach to treatment/support (see Section 2.3 for
discussion of program and system integration) is recommended.
 Within this integrated approach it is recommended that interventions for
substance abuse and the eating disorder be planned and implemented
concurrently unless there are compelling clinical reasons (e.g., life
threatening factors) for focusing on one of the disorders first.
 The most promising intervention is a combination of medical
management; behavioral strategies to effect change in the eating and
substance abuse behaviour; and psychotherapy to address psychological
issues.
4.0 Implications of Best Practice Guidelines
at the System Level
4.1 Historical Perspective and Current Status
Ryglewicz and Pepper34 provide a historical perspective on the rapid increase in the number
of people in the community with concurrent disorders over the last 20-30 years. They note
the historical separation of three very distinct clinical populations – mental patients,
alcoholics and drug addicts. The former were in psychiatric institutions. Alcoholism was not
seen as a problem until well along its course and, if treated at all, it was in highly specialized
treatment facilities. Drug addiction was seen as confined to a small segment of society and
viewed largely in a criminal context. These times have vanished with the shift coming
primarily from the de-institutionalization of mental health services; the corresponding
movement towards community support for people with severe mental illness;73 and the
increasing availability of drugs in the community since the 1960’s. So rather than the three
formerly separate clinical populations there are now large groups of people in the community
with overlapping and interacting mental health and substance use problems. The difficulty
from the service delivery perspective is that community agencies, planners and policy makers
have been stuck in the single-problem mode of thinking because of the long established
barriers between the treatment systems for mental health and substance abuse. The barriers
came about as a result of separate training and development in the two fields, which became
entrenched in separate funding, administrative and policy structures. An additional barrier is
the perceived complexity, uncertainty, and level of difficulty associated with a more
integrated approach.
Taking an historical perspective on the emergence of the two systems of care and support for
people with mental health and substance use disorders helps to better understand the
problems being faced by consumers who currently need to cross over the two systems.
Placing things in an historical perspective also helps us understand the current status of
efforts to improve on the situation at both the service delivery and system levels. At both
levels, the barriers across the two systems are being eroded ever so slowly. Some provinces/
territories are now in various stages of merging their mental health and substance abuse
services.
4.1.1 Similarities across the two systems
Planners, policy makers and service providers in the fields of mental health and substance
abuse in Canada are finding themselves on common meeting ground. Examples include, but
are not limited to:
 the acceptance of a broad bio-psychosocial model for mental health and substance use
problems, and the need for a continuum of care which recognizes the value of many
different types of services;
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 the legitimate role of self-help organizations in both sectors and, in particular, the
emergence of the consumer survivor movement in the delivery of mental health services.
This shift counterbalances professional perspectives and training with lived experiences
which give high priority to more basic needs of food, shelter, clothing, work, friendship,
etc.;
 the increasing role of pharmacologic therapy in the treatment of substance use and
advances in genetic research in both fields;
 the growing recognition of family members and significant others both as a group in need of
services themselves, and as a critical support in developing and implementing an
individual’s care and support plan;
 the extent to which both mental health and substance abuse treatment services are linked
to the correctional system and other issues related to formal and informal social control;
 the significant role of stigma in both fields, not only as a factor influencing help seeking
and outcome, but also as part of the community context that calls for advocacy and public
education;
 the potential for common, or at least converging, outcome indicators and other
performance measures;
 the increasing recognition of the overlap in the population needing help and expressed
needs of consumers for better continuity of care within and across the respective systems.
Despite the many areas of common ground that have emerged in recent years between the
addiction and mental health systems, including the merging of the two systems at the
provincial, department level, in some provinces, significant challenges remain in the
development of integrated care and support for people with concurrent disorders.
4.1.2 A Less Prescriptive Approach at the System Level
In Canada and elsewhere we are just at the beginning stages of developing and trying out
various strategies to better integrate services at the systems level. There is very little
published information that goes beyond an assessment of the many challenges and barriers to
systems integration, to actual implementation and evaluation of different concrete strategies.
In general, however, the current state of knowledge and practice wisdom is not sufficiently
developed to offer best practice recommendations at the system level.
There were two complementary components to this project – focus groups with consumers
and a survey of key informants. In each component, the focus was the system-level
implications for the best practice guidelines.
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4.2 The Consumer’s Experience and Perspective
In order to keep the best practice advice grounded in the experience and expressed needs of
people with concurrent disorders, five focus groups were held with current or former
consumers of mental health and substance abuse services, to determine those aspects which
had implications for planning integrated programs and systems for screening, assessment and
treatment/support. We held two groups in Quebec, two in Ontario and one in British
Columbia. Participants were recruited through local mental health and substance abuse
programs or integrated concurrent disorders programs. Each group had between 5-8
participants who were remunerated for their time and transportation costs. They consented
to the use of their comments for the purposes of this project. The two groups that took place
in Quebec were conducted in French. Each group was facilitated by a trained mental health
or substance abuse professional and discussion was guided by a predetermined topic list (see
Appendix H). The discussion was summarized and analyzed for themes relevant to the
objectives of the project. The focus here is on the main themes that emerged and the
implications at the system level.
4.2.1 Results of Focus Groups
There was a very high level of consistency across the various groups. The strongest theme
that emerged was the additional and severe stigma associated with having both substance use
and mental health problems. The stigma expressed itself in various forms, including repeated
and chronic self-harm experiences, self-deprecation, the fear of being judged, and the hurtful
experience of judgmental attitudes.
I would really like to say the threat of being punished for being an addict and having
any sort of mental illness, there always seems to be this threat hanging over that we
are in some way responsible for this, we brought this upon ourselves, and if we don’t
do A, B or C then our children will be taken and our welfare will be cut, our housing
will be gone … there’s just such an extraordinary threat and that just absolutely add
on to already extraordinary pressure, and I mean its very demoralizing.
Feel like there is a lot of pressure not to get help, its like get on with your life, get back
to work, what are you doing, you’re not working, well why aren’t you working …
A related theme was the high need for support and continuity of care to deal with their wide
range of health and psychosocial difficulties, including for example, the need for housing,
prenatal or child care, income, employment, and money for transportation. The support of
family, friends, employer and the agency support worker were seen as critical.
I’ve had a mental health worker to stand beside me, but she’s always, always been
there for me and I think that’s what really made me better, that constant, constant
continuous care.
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That there are clearly two systems of care was another emergent theme. For some people
there were feelings of immense frustration and anger with being shunted back and forth
between mental health and substance abuse agencies, and with the lack of openness in both
types of services to talk about their dual sets of problems. Some people felt that when in the
substance abuse system they had to treat the substance abuse problem first and they were
openly discouraged from talking about their mental health issues. Others expressed
frustration with the mental health system.
What (mental health) providers do is they’ll look at me and say I’m in a real abuse
stage, they say forget about the mental health issue you’ve got a real substance abuse
problem and you’ve got to go get help for that and either they ignore the using or the
fact that I have an addiction, or else they won’t even deal with the mental health
aspect of it because I’ve been using.
For some participants there was an acceptance of the two systems of care; an
acknowledgment that “this is how things are set up”; and even expressions of surprise that
one might deal with substance use problems in a mental health program and vice versa. For
example, those holding this view accepted the fact that they would deal with substance use
problems only within a substance abuse program. Not only did service providers not ask
about the other issue, this was not always seen as a concern because clients felt it was up to
them to disclose the information. Only once they had established a relationship of trust with
the service provider would they feel comfortable discussing both issues. The need to have a
strong and supportive relationship with a family physician was also noted as he/she can “hold
the key” to navigating the larger system effectively.
A fourth emergent theme was that recognition of the problem was an important first step and
that there were often years in between recognizing and dealing with their dual problems of
substance use and mental health. Treatment for the two sets of problems would therefore
begin at different times and quite separately. This failure to recognize the concurrent
disorders was connected to several related issues including the common experience of
misdiagnosis due to the interacting and often masking effects of the substance use, and the
lack of education and training among professionals they encountered along the way. This was
compounded by a fear that if you “reveal too much” this can prevent you from receiving
treatment or be more likely to lose support, children and family connections.
One of the biggest problems that I ran into was the issue of misdiagnosis because you
know active, addictive drug use or alcohol use, or anything else will parrot particular
mental health disorders.
Other major themes were the difficulty getting into the system and, once connected, the
frustration in dealing with poorly coordinated services. Concerns about accessing the system
ranged from there being inconsistent definitions of whom they would treat, to outright
refusal to accept you if you had concurrent disorders. Others expressed frustration with the
lack of basic information about what is out there for services and supports.
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When you ask for help, that’s when you need it.*
When you do decide you do want to get help you just have to wait for so long; there
should be enough people; and getting turned down and going to different places to try
to get help. Some places you’re not bad enough for and too bad for others.
There should be one centre of information so that there is no confusion as to where to
look, even if it’s small enough just to send people in the right direction.
Yeah there isn’t just one place - its almost as if the left doesn’t know what the right is
doing.
The concerns about lack of cooperation and coordination among service providers were even
more revealing about the difficulties encountered navigating the system. In particular it was
seen as difficult to build a trusting relationship with a service provider if you do not see them
on a continuous basis.
I don’t find that there is good communication between, like even when you sign a
release form I don’t find he’s getting the information or they are relaying it. So there’s
a real emptiness there, and you end up providing the same information or lets say
getting tests done at a whole bunch of different places – it could be done once.
I’ve gotten help for each individual thing but to get help for, like at the same time, you
fall between the cracks and if one of your disorders is worse than another and then
one doctor thinks your seeing somebody else, basically nobody’s helping you, nobody
follows up, you kind of disappear in there.
Basically a coordination of services, a central place, a person, that’s what’s missing.
This admission, that admission, this specialist, that specialist but nobody’s really
doing anything, nothing’s really getting done, just a whole bunch of appointments
going nowhere.
Finally, participants voiced their concerns about the lack of resources. They commented in
particular on the poor access to counselors, especially in rural areas, as well as the need for
more treatment programs and groups specifically for individuals with concurrent disorders.
Those who were involved in a specialized concurrent disorders program were very supportive
of their program and spoke positively about their experience.
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* Translated from: “Quand on demande de l’aide, c’est là qu’on en a besoin”.
4.2.2 System Implications
The following implications are drawn from the experiences discussed during the focus
groups:
 screening for concurrent disorders, followed by comprehensive diagnostic assessment
should be viewed as critical components of local mental health and substance abuse
systems;
 there must also be an openness to deal with both the mental health and substance use
problems regardless of the doorway into the system the person has entered. There must be
an emphasis on engaging the person in a non-stigmatizing, trustworthy environment and
accepting the person where they are at in terms of the degree of program or system
integration they feel comfortable with at that point in time;
 there is a need to reduce waiting times and for better access to information about what
services and supports are available in the community. This could include better sharing of
information among the service providers in the community as well as more centralized
information services (e.g., 1-800 lines; web sites);
 there is a need for good linkages across services and, in general, improved coordination.
Continuity of the caregiver is critical to the provision of needed supports. Continuity also
helps develop the kind of trusting relationship which may be necessary for full disclosure of
the nature and severity of the substance use and mental health problems. Assessment,
therefore, must be seen as an ongoing rather than a one-off aspect of service provision;
 the psychosocial needs of people with concurrent disorders, particularly co-occurring
severe and persistent mental illness, are significant. Issues such as housing, childcare and
money for transportation can seriously disrupt the best of intentions for dealing with
substance use or other aspects of the co-morbidity. Support for these needs, particularly
through community outreach, must also be a critical component of local service delivery
systems;
 there is a critical need for better training of mental health professionals in substance abuse
and of substance abuse professionals in mental health. The family physician can also play a
key role in helping the person navigate the local network of services and needs to be well
informed and trained to do so;
 the planning of services/supports, and systems of services/supports, for people with
concurrent disorders must involve people who have experienced these problems directly as
well as their family members.
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4.3 Service Provider and Planner Perspectives
After developing a draft of the best practice recommendations at the service delivery level,
feedback was sought from a number of administrators, program managers, staff, planners and
policy makers across Canada on the implications for both the program and system levels. A
total of 39 potential respondents were identified. The survey was not intended to be
scientifically representative. A regional balance was sought across Canada as well as a
balance across mental health and substance abuse programs. A small number of participants
were working in integrated concurrent disorders programs identified through the “National
Program Inventory - Concurrent Mental Health and Substance Use Disorders” (published
separately).
The survey questionnaire was sent by e-mail or fax with the option provided to either
complete and return by e-mail, by fax or to answer the questions in a telephone interview. A
total of 19 people responded. Since some people chose to respond anonymously, there is not
a final regional distribution of those who responded. The breakdown across mental health
and addictions was as follows: seven from a mental health service; eight from a substance
abuse service; two from an integrated concurrent disorders program, and two in the “other”
category (community program consultant; funder/planner).
A copy of the survey questionnaire is available.* The general flow of the questions was to
inquire about (a) how reasonable the recommendation was (e.g., universal screening for
mental health problems in substance abuse services); (b) how far off the recommendation
was from current practice; and (c) what it would take to achieve the goal set by the
recommendation. These questions were asked first with respect to their agency, if they were
a direct service provider, and then with respect to their network or system of services.**
Questions covered the draft recommendations for screening, comprehensive assessment, and
program- and system-level integration. Other items asked for feedback on the classification
system for sub-grouping within the larger category of ‘concurrent disorders’. A final question
sought any other feedback felt to be appropriate and helpful to the goals of the project.
In this section a brief summary of the feedback on the service delivery recommendations and
their implications at the system level is provided. There was a high degree of support for the
classification system proposed in Section 2.2.6. Sixteen respondents were favourable. Two
others gave more qualified support commenting, for example, on the potential need for
something different to subgroup adolescents. The remaining respondent thought the groups
would not match well to the current program structure of their facility, and that different
groupings may be needed for different sub-populations (e.g., youth, geriatric, referrals from
corrections).
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* Dr. Brian Rush at 416-535-8501(ext. 6625) or brian_rush@camh.net.
** ‘System’ was self-defined as the level most appropriate for the respondent (i.e., local, regional, provincial/territorial).
Screening
Of the 19 respondents, 12 felt that the recommendation for universal screening for
substance use and mental health disorders was reasonable; five were supportive but cited
additional caveats, such as the need for agreed upon tools, resources and training. Two
people thought the goal was not reasonable. When asked to comment on how far off this
recommendation was in terms of current practice, the responses covered the full spectrum:
“not doing anything like this in a formal fashion” (n= 4); preliminary integration that would
eventually lead to agreed upon screening protocols (n= 6); some screening activities
currently underway (n=5). Within one jurisdiction the mental health system was said to be
further ahead than the substance abuse system in terms of screening; in another jurisdiction
the opposite was said to be true. One respondent commented on the variability across the
regions of their province, with the level of screening activity reflecting the degree of
local/regional coordination.
In terms of what it would take to implement a recommendation for system-wide screening
for substance use and mental health disorders, the most common response was training,
including cross-training and commitment of training resources (n =8). Five people
commented on the need for “top down” support and commitment, including the political
will to make it happen and monitor compliance. The need for better coordination and
communication across the dual mental health and substance abuse systems was mentioned
by three people, including the need for incentives to form partnerships. The need for more
resources to implement the recommendation was mentioned twice and one person noted the
need for more services in general.
Assessment
Of the 19 respondents, 12 felt that the recommendation for comprehensive mental health
and/or substance use assessment following positive results of a screening process was
reasonable for their network of services. Four respondents gave a supportive but qualified
response. They cited, for example, the difficulty accessing psychiatrists, if indeed the mental
health diagnosis would only be considered acceptable if performed by a psychiatrist. One
person felt that the goal may be reasonable locally but not at a larger systemic level. Two
respondents felt their local substance abuse and mental health services were not sufficiently
coordinated to make this a reasonable goal. One respondent was simply ‘unsure’ of the
recommendation.
When asked to comment on the recommendation addressing comprehensive substance use
and mental health assessment, a wide spectrum of responses was evident. Eight respondents
felt this would be a long way off for their network, citing such challenges as the need for
significant training and education in clinical assessment and the shortage of psychiatrists if
they were required for mental health diagnosis. In addition, eight respondents felt they were
partially there already and gave a variety of examples. Some felt they were closer in rural
than in large urban centres with more complex systems. The opposite was thought to be true
in other areas. One respondent noted the development of their integrated concurrent
disorders program and in one area significant cross-training had begun. Two respondents
noted the planning and coordination activities that had been initiated.
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In terms of what it would take to implement a system-wide recommendation for
comprehensive mental health and substance use assessment for those screened positive with
concurrent disorders, a variety of closely related responses were offered. The most common
response concerning the need for more staff resources (n=7) and more funding in general
(n=4). Two people specifically mentioned the need for more involvement/direction from
psychiatrists. The need for a strong commitment to the process was also cited (n=5), linked
with more top-down guidance from funding authorities (n=2). This included a
recommendation for mental health and substance abuse to be funded from the same
envelope and the same regional governance mechanism. Five respondents cited the need for
a better integrated system, such as better front-line linkage; multi-disciplinary teams;
incentive for partnerships. Linkages were seen as critical in the assessment process. The need
for training and education was mentioned by four respondents, as was the need for agreed
upon assessment tools.
System-level Integration
There was a high level of support for making the program-level and system-level integration
distinction and the specific definitions offered (14 out of 19 respondents). One person felt
that true system-level integration required merging the systems of mental health and
substance abuse at the policy, funding and government levels.
When asked how reasonable the goal was for system-level integration within their own
particular network (local, regional or provincial), there was clearly more optimism than
pessimism about the future. Thirteen of the 19 respondents felt it was reasonable but
typically with a qualification or two added. Some spoke of current efforts underway at formal
or informal coordination mechanisms; two people felt it was feasible but cautioned to start
small and build on the successes; one person felt integration at the system level was a
reasonable goal but not as preferable as integration at the program level; one person said it
was a reasonable goal for some clients but not for all at this time; one person cited the need
for considerable training and education. Only 3 of the 19 respondents felt it was not a
reasonable goal; one person citing the difference across the two systems as being too wide to
be bridged at the present time.
In answer to the question about how far off their own network of services was from a goal of
system integration, only four of the 19 respondents felt they were a long way off. Specific
comments indicated a willingness to integrate but concerns about the lack of structure to do
so, or the distance in their region between the resource for comprehensive assessment and
the resource for treatment. The more typical response reflected their current attempts at
integration but considered themselves only part way there. Some comments highlighted local
joint planning activities; efforts of front line staff; variation in integration across different
locations; and the need for some additional resources, such as a psychiatrist. Other
respondents simply said they were close, or that it was doable in a particular time frame (e.g.,
two years).
In terms of what it would take to achieve system-level integration for people with concurrent
disorders, the most frequent responses (n=5) related to having more knowledgeable staff
through training and education. This included comments about making progress towards
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more shared philosophies and the kind of experiential learning that can come through
cross-training or co-location. Four people commented on the need for more resources
including a psychiatrist and trained staff dedicated to substance abuse issues. Other
individual comments related to the need for a joint planning steering committee; finding
ways to do business differently; and needing strong corporate commitment. Two people
noted the need for regulations or other compliance incentives. Finally, two people noted the
value of these best practice guidelines themselves as an effective tool for training workshops
and planning activities.
Other comments and suggestions: Several other comments were offered by the key
informants which are relevant to this section on system-level integration. Relevant
comments included:
 a major systemic barrier is the different educational base for substance abuse and mental
health workers;
 from the client’s perspective a program integrated with mental health may not be perceived
positively given the stigma associated with mental health in general;
 guidelines need to articulate best practices without necessarily tying them to a structure.
Without new funding sources or multiple mergers across the province it is not realistic to
expect staff to be under one organizational structure even if this were the best model;
 transportation for consumers is an issue especially in rural areas;
 availability of support/self-help groups is a challenge. The group “Dual Recovery
Anonymous” is a 12 - step organization with a website and chatroom. Providing training on
the web and access to this web site is an option in rural communities;
 this client group requires multiple opportunities to be engaged in settings that match their
needs. Traditional 12-step programs are too large, too long and frequently too entrenched
in their traditions to accommodate people who need medication;
 telepsychiatry is an education and training model that can be extended to rural areas.
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4.4 Mechanisms and Models for System-level
Integration for Concurrent Disorders
In an earlier section system-level integration was defined as:
The development of enduring linkages between service providers or treatment units
within a system, or across multiple systems, to facilitate the provision of services to
individuals at the local level. Mental health treatment and substance abuse
treatment are, therefore, brought together by two or more clinicians/support workers
working for different treatment units or service providers. Various coordination and
collaborative arrangements are used to develop and implement an integrated
treatment plan (adapted from71).
As with program-level integration, this treatment plan may involve addressing the substance
use and mental health disorders either concurrently or sequentially, but always in the
context of a consistent and coordinated approach tailored to the unique needs and
capacities of the individual.
Also as noted earlier, models for system integration have been much less frequently
evaluated with respect to consumer outcomes and service delivery costs than is the case with
program-level integration. Indeed there is virtually no such research specific to concurrent
disorders. Further there is little documented experience from which to draw practice
wisdom. This section will outline alternative mechanisms and models that seek to better
integrate services and supports for people with concurrent disorders, recognizing that there
must be more description than prescription, and draws from:
 an important evaluation study that examined the effectiveness of different strategies to
develop systems of care for people with severe mental illness353,354 and recent research
investigating the effectiveness of various system integration strategies for improving
outcomes for people who are homeless;71,355
 seminal studies in the U.S. that identified systemic barriers to effective service delivery for
people with concurrent disorders;27, 356
 key summaries of system-level barriers and potential solutions 24,357 including more recently
published work that describes various integration mechanisms at the local level in the
U.S.,70,155 and which outlines a collaborative strategy to improve linkages at the
state-level;72
 the most recent work of Mueser and colleagues44 which also makes the distinction between
program- and system-level integration and which discusses some organizational strategies
for developing capacity for integrated services. Many of these strategies are also relevant at
the system level;
 reports from Canadian studies outlining key elements of best practice at the system level
for mental health reform11 or which discuss alternative strategies to better coordinate
substance abuse services;12
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 recommended practice and lessons learned in various initiatives involving organizational or
system-level change processes;
 the results of the various components of this project aimed at identifying system-level
challenges and potential solutions, i.e., the consumer focus groups, the “National Program
Inventory - Concurrent Mental Health and Substance Use Disorders” (published
separately), and the key informant survey.
4.4.1 What the Literature Tells Us About the Effectiveness of Coordination
In the Robert Woods Johnson Program on Chronic Mental Illness,353,354 nine cities
throughout the United States were funded to develop community-wide systems of care for
people with chronic mental illness.* Each city was expected to create a public mental health
authority that would improve continuity of care, move funds to needed areas, develop a
range of housing options and enhance the range of rehabilitation services available. The
evaluation found that authorities could be successfully established, increasing centralization,
coordination and continuity of care. However, consumer outcomes did not improve. This
finding may reflect methodological limitations linking system-level changes to consumer
outcomes. Or it could mean that structural changes do not obviate the need for funding high
quality programs and services.
Another large scale project in the United States sought to demonstrate the effectiveness of
different services to people who were homeless as well as outcomes associated with various
system integration strategies. Strategies included, for example, an interagency coordinating
body; co-location of services; system integration coordinator; interagency agreements and/or
service delivery teams; and interagency MIS tracking systems. In those study sites funded
specifically to implement system integration, the evaluation focused on (a) whether
implementation of these strategies leads to improvements in system integration; and (b)
whether system integration leads to better outcomes for the study population. The
investigators found that many system integration strategies were implemented and that
system integration was achieved at the project level. However, few differences were observed
at the consumer level; a notable exception being housing outcomes which increased as the
level of integration increased. The study is also important as an example of how the
implementation of system-level integration strategies can be defined and monitored over
time.355
More research is clearly needed on the effectiveness of system-level integration on consumer
outcomes. These studies are difficult to mount and the results are open to many
interpretations. Evaluation studies are needed which examine variation in system integration
across several sites. In addition smaller scale evaluation studies are also needed which focus
on process issues in planning and implementing many of the system-level integration
strategies examined in these larger studies.
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* This summary is abstracted from the best practice report for mental health reform.11
Finally it should be noted that what little literature does exist on system integration
strategies for concurrent disorders is not particularly relevant to rural and remote areas with
significant issues related to distance/travel and chronic shortages of psychiatrists,
psychologists and registered social workers to make diagnoses. Family physicians are also in
short supply in many areas. Systems research in these areas is particularly needed.
4.4.2 Barriers to Integration and Potential Solutions
With respect to people with concurrent disorders specifically, the focus here is more on
identifying potential solutions than identifying well-known systemic barriers identified in the
literature.27 However, it is worth noting that despite the considerable areas of
rapprochement across the two systems of mental health and substance abuse, many of the
commonly identified challenges to better integration were reinforced in the focus groups and
key informant survey. Examples would include:
 historical differences in alliance with the medical model and differences in the educational
and experiential requirements to work in the two fields;
 low tolerance that still exists in some substance abuse programs for any psychoactive
medication;
 lack of acceptance of harm reduction approaches in some substance abuse services and
which may be necessary for effective engagement of this population in the care and support
system;
 use of confrontational techniques that are too stress inducing or otherwise inappropriate
with people with some combinations of concurrent disorders (e.g. substance use and severe
and persistent mental illness);
 different policy, planning, funding and governance streams.
A technical assistance report from the U.S. on the coordination of substance abuse and
mental health services357 was the first comprehensive attempt to outline potential solutions
to the long standing barriers to systemic integration across substance abuse and mental
health. They summarized several working principles for those attempting to coordinate
services across these dual systems. Examples include:
 services coordination is usually a slow, evolutionary process;
 successful coordination depends on leadership and talents of responsible people;
 service providers’ perception of the benefits of services coordination is crucial;
 effective coordination of services requires shared information systems;
 a common government strategy facilitates services coordination;
 formal inter-organizational agreements facilitate the coordination process;
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 being responsible to a common super-ordinate authority facilitates coordination;
 efforts to develop the sharing of ideology that supports coordination appear worthwhile;
 relevant training and continuing education are necessary for staff as well as their
supervisors.
This report also included a description of specific coordination mechanisms and models,
including co-location; information and referral; centralized intake and referral; inter-agency
networks such as multi-disciplinary teams; case management; sharing of staff; financing
models and training and education. This list was subsequently expanded upon in the
Treatment Improvement Protocol (TIP) for concurrent disorders,24 including, for example,
shared data systems; and linkages with the wider health, social, and correctional service
system.
Mueser and colleagues44 summarize two general strategies for program-level integration,
namely adding substance abuse specialists to mental health services (or vice versa),* and
creating blended teams. These strategies, however, can also work at the system level through
the development of inter-agency service teams. Further, the organizational factors that
would facilitate or inhibit the development of program integration are also relevant at the
system level. Their list of factors includes:
 leadership, including an internal champion and a monitoring mechanism;
 defining the target population (e.g. homeless);
 infrastructure, including dedicated staff, clinical tools, processes for developing specific
competencies and quality improvement;
 training and supervision, which should be viewed as the centerpiece of a system of services
for people with concurrent disorders. Cross-training is a viable option;
 screening and assessment protocols with appropriate inter-agency linkages and verified
through some form of utilization review;
 an array of services including a foundation of mental health and substance abuse services
and specialized concurrent disorders services;
 self-help liaison, for example, Double Trouble groups;
 levels of care with appropriate linkages, for example, between inpatient services for
stabilization and outpatient services for longer term care and support;
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* They note that since most people with concurrent disorders receive their primary treatment in mental health
services that the most common strategy has been to add substance abuse specialists to these services. This is less
true for subgroups other than those with severe mental illness (Group 2).
 program monitoring, including quality review procedures, process evaluation and outcome
monitoring. This also includes the regular use of a fidelity scale for assessing the degree of
integration*; and
 the close involvement of consumers and family members in program design and
implementation.
Some of the factors noted by Mueser and colleagues44 reflect more general strategies in the
literature on organizational and system change processes. Examples would include the need
for a strong champion or opinion leader;358 developing motivation for change across the
organization/system;359 and meaningful involvement of key stakeholders, including service
recipients and their families.360 Other factors reflect comments made in the focus groups and
the key informant survey (e.g., the need for leadership and commitment).
Some of the organization/system factors noted by Mueser and colleagues44 also reflect the
best practice recommendations for implementation of mental health reform in Canada11 and
substance abuse treatment12 (e.g., the need for a service continuum). Thus, it is likely that
many of the recommendations for improved service coordination within each of the mental
health and substance abuse systems will also be worthwhile exploring to improve
coordination across the two systems. Examples may include:
 supportive and widely supported policy. This includes policy that supports both service
development and integration activities;
 a clear point of responsibility for planning integration activities and funding;
 training plan which is part of a larger human resources strategy;
 the need for evaluation and monitoring of integration activities and expected outcomes.
Measures of improved coordination can include, for example, mutual awareness, frequency
of interaction, frequency and direction of referrals and information exchange, formalization
of agreements.
4.4.3 A Shopping List of Alternatives to Support System Integration
In synthesizing the information and themes, the following list of alternative strategies may
support system-level integration:
 it is critical that people with concurrent disorders and their family members be
meaningfully involved in planning and system development activities;
 given the pace of knowledge development and the extent to which innovative solutions are
being explored there is a need for a mechanism to share information and lessons learned. A
possible vehicle to achieve this would be a Canadian-based web site and potentially a
national Concurrent Disorders Resource Centre that would support research dissemination
and knowledge transfer;
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* An integration fidelity scale that can be adapted to different situations is included in Appendix I.
 training and education must be the centrepiece of concurrent disorders program and
system development. This includes cross-training, continuing education, and formal
curricula development and credentialing;
 a healthy mix of top-down commitment from funders, senior administrators and Executive
Directors and bottom-up exploration of linkages by front-line staff based on individual
cases;
 developing a joint inter-agency planning committee is a viable option to start the local
system integration process with reasonable goals and time frames in order to maximize the
chance of success and build motivation to continue the change process. There may be
considerable value to a staged approach starting, for example, with informal coordination
activities and information sharing; to perhaps a cross-training program and then to service
agreements for assessment and treatment/support. It is important that there be a dedicated
resource person to support the planning and development process. It is also important to
recognize that, due to the complexity of integration across systems, the change process
must be seen as evolutionary, non-linear and requiring time and patience;
 there is a need for clinical case consultation, including a potential role for telepsychiatry to
program and system integration in rural and remote areas;
 shared data systems that cross mental health and substance abuse systems should be
explored and pilot tested;
 widespread adoption of blended service delivery teams such as the Assertive Community
Treatment teams which include a substance abuse counselor;
 formal inter-agency partnerships can be developed which go beyond joint planning
exercises to the level of service agreements or potentially merged organizations;
 central access models are often recommended in both mental health and substance abuse
reform processes. There is likely value in developing improved access models, including
basic information about services and supports that are available, which span substance
abuse and mental health;
 policy initiatives can be undertaken at the funding level which would support integrated
services and systems, and provide a mechanism for demonstration projects.
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5.0 Implications for Research
The following are the research recommendations:
 there is wide variation in the level and content of integrated treatment at the program
level. More research is needed on the effectiveness and cost-effectiveness of various
interventions for many of the sub-groups within the concurrent disorders population, as
well as fidelity measures to assess the nature and level of integration;
 there is wide variation in the level and content of integrated treatment at the system level.
More research is needed on the impact of these system-level interventions on access to
treatment and support; engagement and retention in the system and the effectiveness and
cost-effectiveness of various interventions for each of the sub-groups within the concurrent
disorders population. Research should also investigate the value of fidelity measures to
assess the nature and level of system integration; and urban/rural differences;
 two clusters of concurrent disorders were omitted from these of best practice guidelines due
to a lack of research evidence – concurrent substance use and sexual disorders; and
concurrent substance use, mental health disorders and pathological gambling. More
research is needed in these areas;
 more research is needed on treatment/support for specific combinations of psychoactive
substance use disorders (e.g., cocaine) and specific mental health disorders (e.g.,
depression);
 more research is needed on the link between substance use disorder and anger disorders
that are independent of antisocial personality disorder;
 more research is needed on the link among dysfunctional parenting, child abuse and
co-occurring mental health and substance use disorders;
 brief, validated measures are needed that would screen for mental health disorders among
people seeking treatment for substance use disorders.
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Appendix B*
DSM-IV Criteria for Substance Use Disorders and
Substance-Induced Disorders
*Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision. Copyright 2000 American Psychiatric Association
Substance Use Disorders
Substance Dependence
A maladaptive pattern of substance use, leading to clinically significant impairment or
distress, as manifested by three (or more) of the following, occurring at any time in the
same 12-month period:
1. tolerance, as defined by either of the following:
a) a need for markedly increased amounts of the substance to achieve
intoxication or desired effect.
b) markedly diminished effect with continued use of the same amount of the
substance.
2. withdrawal, as manifested by either of the following:
a) the characteristic withdrawal syndrome for the substance (refer to Criteria A
and B of the criteria sets for withdrawal from the specific substances)
b) the same (or a closely related) substance is taken to relieve or avoid
symptoms.
3. the substance is often taken in larger amounts or over a longer period than was
intended.
4. there is a persistent desire or unsuccessful efforts to cut down or control substance
use.
5. a great deal of time is spent in activities necessary to obtain the substance (e.g.,
visiting multiple doctors or driving long distances), use the substance, or recover
from its effects.
6. important social, occupational, or recreational activities are given up or reduced
because of substance use.
7. the substance use is continued despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been caused or
exacerbated by the substance (e.g., current cocaine use despite recognition of
cocaine-induced depression, or continued drinking despite recognition that an
ulcer was made worse by alcohol consumption).
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Specify if:
With Physiological Dependence: evidence of tolerance or withdrawal (i.e., either Item
1 or 2 is present)
Without Physiological Dependence: no evidence of tolerance or withdrawal (i.e.,
neither Item 1 nor 2 is present)
Substance Abuse
A. A maladaptive pattern of substance use leading to clinically significant impairment
or distress, as manifested by one (or more) of the following, occurring within a
12-month period:
1) recurrent substance use resulting in a failure to fulfill major role obligations at
work, school, or home (e.g., repeated absences or poor work performance
related to substance use; substance-related absences, suspensions, or
expulsions from school; neglect of children or household)
2) recurrent substance use in situations in which it is physically hazardous (e.g.,
driving an automobile or operating a machine when impaired by substance
use)
3) recurrent substance-related legal problems (e.g., arrests for substance-related
disorderly conduct)
4) continued substance use despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by the effects of the substance
(e.g., arguments with spouse about consequences of intoxication, physical
fights)
B. The symptoms have never met the criteria for Substance Dependence for this class
of substance.
Substance-Induced Disorders
Substance Intoxication
A. The development of a reversible substance-specific syndrome due to recent
ingestion of (or exposure to) a substance. Note: Different substances may produce
similar or identical syndromes.
B. Clinically significant maladaptive behavioral or psychological changes that are due
to the effect of the substance on the central nervous system (e.g., belligerence,
mood lability, cognitive impairment, impaired judgement, impaired social or
occupational functioning) and develop during or shortly after use of the substance.
C. The symptoms are not due to a general medical condition and are not better
accounted for by another mental disorder.
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Substance Withdrawal
A. The development of a substance-specific syndrome due to the cessation of (or
reduction in) substance use that has been heavy and prolonged.
B. The substance-specific syndrome causes clinically significant distress or impairment
in social, occupational, or other important areas of functioning.
C. The symptoms are not due to a general medical condition and are not better
accounted for by another mental disorder.
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Appendix C
Classification Scheme from Ryglewicz and Pepper34
Group 1:
A major mental illness and a major problem with alcohol and/or drug abuse, dependence or
addiction. An example given was a woman with diagnosed bipolar illness and alcohol
dependence.
Group 2:
A major mental illness and a special vulnerability to the effects of alcohol and other drugs. An
example given was a young man with schizophrenia who was abusing but not dependent
on alcohol and other drugs.
Group 3:
Personality disorder and/or mental/emotional problems that are complicated and aggravated by
alcohol and/or street drug use or abuse, but no major mental illness that in itself would
produce psychotic episodes or require hospitalization. An example given was a woman with
an Axis I disorder of post-traumatic stress disorder, bulimia and substance dependent
on cannabis and cocaine but in partial remission.
Group 4:
Diagnosed or identified alcohol/drug abuse, dependence or addiction, plus personality disorder
or other mental/emotional/cognitive problems that are masked by the substance use and which
may increase during withdrawal. An example given was a man in substance abuse
treatment but who finds it difficult to participate due to a personality disorder as
reflected in his intolerance for the group activities, lack of acceptance of others, and too
easily threatened by any confrontation.
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Appendix D
Brief Description of the Mental Health and
Substance Abuse Treatment Systems in Canada
Mental Health Service Delivery System*
With few exceptions,** the funding, planning, delivery and evaluation of mental health
services in Canada falls within the provincial mandate for health services generally.
Community mental health programs, provincial psychiatric hospital services (PPHs), general
hospital psychiatric unit services (GHPUS), and physician services for mental health
conditions are all publicly funded in Canada. The preferred model of mental health service
delivery advocates for a range of community services operating in conjunction with GHPUS
and a regional tertiary care centre. Approaches to achieving this systems model differ in
rural and northern areas where scarcity of resources and small populations dictate multiple
professional and program roles.
Virtually all the provinces and territories have undergone recent efforts to reform their
mental health system. Consistent with best practice at the systems level11 there is a broad
consensus on the “continuum of care” perspective. This perspective calls for a range of
community services that match the diverse needs of people with mental health problems.
The provinces and territories are also similar with respect to the target population given the
most priority; that being people with severe mental illness as opposed to those with more
moderate mental health problems. This priority reflects the needs of the more severely
disabled population, the large majority of whom are now living in the community with
marginal resources.
Within most regions of the country the system of mental health services is comprised of
various types of community mental health services for both consumers and family members;
consumer-run organizations and family support groups, individual practitioners, including
psychiatrists, physicians, psychologists, social workers, and other types of clinicians and
therapists, and acute care inpatient facilities.
Availability of the many different types of community mental health services varies from
region to region within the provinces and territories. Key elements include case
management, crisis response, housing, clubhouses, as well as vocational/educational/
employment supports.11 Case management programs are viewed as critical and, in Canada,
are either intensive, attempting to directly provide a comprehensive, continuous treatment
and rehabilitation program, or generic, being less intensive, less specialized and less
comprehensive. Several provinces have recently funded one type of intensive case
management, Assertive Community Treatment teams (ACT), as a key component of mental
health reform. These programs are targeted primarily at the group of people with severe
mental illness coming out of psychiatric institutions to live in the community.291 Crisis
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* Much of the this section has been abstracted from Goering et al.361
** Most notably mental health services for Aboriginal people, those in the federal corrections system and the military.
response systems can include many types of interventions ranging from phone lines, walk-in
clinics, mobile crisis teams, free-standing crisis centres, hospital emergency departments with
holding beds to inpatient psychiatric units.
To complement the growth of the community mental health sector generally, the last two
decades have also seen dramatic changes in perceptions about the capabilities of consumers
themselves, and related components of community support. This derives, in part, from the
emergence of the consumer and psychiatric survivor movement in Canada, the U.S. and
other parts of the world in the post-deinstitutionalization era.362 The Canadian Mental
Health Association - National (CMHA), a non-governmental, non-profit organization, has
been a leading force in altering views across Canada about consumer capacities and
necessary elements of a system of care. Its major policy document, A New Framework for
Support for People With Severe Mental Disabilities2 insists upon the inclusion of all stakeholders
and sectors in planning and providing mental health care and support. The framework
replaces the past undue emphasis upon professional services and gives greater attention to
natural supports, self-help and access to basic needs (e.g., housing, income, work). It also
explicitly recognizes the value of experiential knowledge. The framework has stimulated
considerable policy and program development across Canada. While provinces vary in their
accomplishments, there has been steady progress in developing linkages between mental
health and generic community supports; increased involvement of consumers and families in
service design and delivery; and increased support for consumer and family organizations.
Some provinces/territories are now in the process of merging their mental health and
substance abuse systems.
The largest proportion of primary mental health care in Canada is delivered by general
practitioners (GPs) working alone, in groups, or in conjunction with specialists; including
psychiatrists, psychologists, social workers and occupational therapists. All general
practitioner and psychiatrist services, including mental health services, are fully insured by
publicly funded, single payer, provincial health insurance plans. These plans do not usually
cover services provided by other mental health professionals. A recent Ontario study on the
utilization of GP and psychiatrist mental health care363 is likely indicative of practice across
the country. In 1992/93, three quarters of users of mental health services in Ontario received
care from GPs compared with about 9% of users who received care from GPs and
psychiatrists together, and only 10% who received services from psychiatrists alone. There is
increasing interest in Canada in developing models of shared care between GPs and
psychiatrists to enhance the capacity of the primary mental health care sector.364 Stronger,
more direct working relationships between these providers are expected to result in better
coordinated and more economical care.
Provincial psychiatric hospitals (PPHs) are among the services that have been funded
directly by the mental health departments/divisions of the provincial governments. Recently,
as newer administrative models such as regionalization have evolved, PPHs have either been
devolved from direct government administration to autonomous incorporation, or have been
placed under the aegis of regional health boards. The PPH’s have been the main provider of
long-stay mental health beds for people with severe and persistent mental illness. However, a
consistent part of mental health reform in all provinces has involved bed reductions in these
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large institutions. There has been a corresponding increase in the role of general hospital
psychiatric units (GHPUS) in providing acute care and crisis response. These units are
funded through general hospital global budgets. Mandated GHPU services in most provinces
include inpatient care, outpatient care, day care, emergency care and consultation.365,371 The
role of PPHs with regard to inpatient care is increasingly in the area of tertiary care; that is
they will provide specialized treatment and rehabilitation services for individuals whose
needs for care are too complex to be managed in the community.
There is a close and complex relationship between the mental health system and the
criminal justice system in Canada. Based on a major survey of over 2000 inmates, the
prevalence of mental health disorders and concurrent disorders is high in Federal Canadian
prisons.366 For example, the risk of having had at least one episode of a psychotic illness was
10.4% and the incidence of depressive disorders was 29.8%. The lifetime prevalence rate of
antisocial personality disorder was 74.9% using stringent diagnostic criteria. As many as 89%
of the total inmate population had a profile of lifetime prevalence of antisocial personality or
substance abuse/dependence. It is acknowledged in the correctional system that current
approaches generally fail to provide for the special needs of those with concurrent disorders
in jails and prisons. There are varying abilities and inclinations to develop treatment models
for this population. Some obstacles are resource based. Further impediments are based on
critical mass for programming given that the forensic population in need of intervention for
concurrent disorders is not homogenous. Nevertheless, there is clearly a need within the
correctional environment to further train mental health professionals in the assessment of
substance abuse and to incorporate mental health issues into substance abuse treatment. In
the Canadian federal correctional system one approach is to have a treatment component or
module regarding substance abuse within a mental health treatment program. However,
there is no integrated approach. Conversely, there is no component that specifically
addresses mental illness within the substance abuse treatment programs offered either in the
institutions or to offenders in the community.
The Substance Abuse Treatment System*
The emergence of the formal drug and alcohol treatment system in Canada and most parts of
the developed world was associated with a shift from a moralistic to a health-oriented
perspective.368,373 Although medical practitioners, and to a lesser extent psychiatrists, played
a major role in formal treatment programs, it was the people in recovery from a substance
use disorder who had a dominant role in both delivering services in the community, and
through self-help programs such as Alcoholics Anonymous. Since the 1960’s and 70’s there
has been a process of professionalization of the field and the widespread adoption of a broad
biopsychosocial model of addiction. Over this same time period the dominance of the
medical profession, and most definitely the psychiatric profession, has diminished in most
provinces.** In contrast, the mental health field has been more heavily dominated by a
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* Abstracted in part from Roberts and Ogborne,367 Rush and Ogborne368 and Ogsborne
et al.369
** This is not to say the medical and psychiatric profession does not continue to play a very important role. These
professionals, however, do not dominate substance abuse related planning or policy initiatives or direct service
delivery in most provinces and territories.
medical model, and while there has been general acceptance of a broader psychosocial
rehabilitation approach and community mental health services, the psychiatric profession
remains more closely tied to day-to-day care through the need for formal psychiatric
evaluation to establish diagnosis, and the prescription of medication for symptom
management.
Like mental health, most treatment for substance use disorders is now funded directly by
provincial and territorial governments, and indirectly by the federal government through
transfer payments. The federal government provides direct funding for substance abuse
treatment and rehabilitation services to some specific groups. This includes on-reserve
aboriginal people, members of the RCMP and the armed forces, and those in the federal
corrections system. The federal government also sponsors two national programs that
transfer money to the provinces/territories for substance abuse treatment mainly for women
and youth, and people with disabilities. These programs require equal contributions from
provincial and territorial governments. With the exception of Quebec, there are few
specialized private programs that require their clients to pay for treatment.
Also like mental health, substance abuse services are not provided exclusively by specialized
programs. For example management of withdrawal may take place in a general hospital ward;
a specialized medical or non-medical withdrawal management centre, or through an
outpatient or ‘home-based’ service arrangement. Counseling is provided by variously skilled
human service providers based in schools, workplaces, community-based social services,
hospitals, corrections agencies, as well as the specialized substance abuse treatment services.
Many general practitioners also provide counseling and prescribe drugs such as naltrexone or
disulfiram to treat alcohol use disorders. Increasingly general practitioners are also assuming
responsibility for the prescription of methadone to people with opiate dependence. General
practitioners are a key resource for counseling for substance use disorders in rural and
remote areas where there may be few, if any, alternatives.
In addition to the services available through the wider health, social and correctional service
systems, counseling and other treatment for substance use disorders are also provided by
specialized programs on an outpatient, day/evening or residential basis. While these
programs are sometimes freestanding, (i.e., accountable to their own Board), many are
sponsored by community agencies or hospitals. In some provinces they are operated directly
by government although this is now the exception rather than the rule. Correctional
services, both federal and provincial, also provide substance abuse counseling and treatment
to offenders on probation, those incarcerated and those released from incarceration. Across
the country there is considerable variation in the availability and accessibility of different
types of programs, and in the types of treatment provided. In some cases these variations
reflect different local needs. However, the relationships between needs and local service
arrangements are often less than optimal due to resource limitations, a lack of information
for planning, or relatively uncritical enthusiasm for particular types of programs and services.
In general, treatment provided by specialized services is non-medical except in programs
which provide general medical and psychiatric assessment and support as needed. It is more
typical for programs to refer to outside medical and psychiatric services based on information
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obtained during assessment. Some programs have medical staff who prescribe methadone to
people with opiate dependence and anti-alcohol drugs to those with alcohol problems. There
is increasing interest in the use of naltrexone in the treatment of alcohol use disorders.
Except for programs such as methadone maintenance, some treatment programs encourage
complete abstinence from alcohol and other psychoactive drugs. This is especially the case
among those programs where substance abuse is viewed as a disease. However, some
programs are based on social learning models of alcohol and drug use and have harm
reduction goals that do not require complete abstinence. Harm reduction goals typically
focus on reducing the use of alcohol and other drugs to lower the risk of severe
consequences (e.g., risk of HIV infection and hepatitis C from needle sharing), and to
establish improvements in other life areas. It is also widely acknowledged that a significant
percentage of people in treatment have been pressured to do so by sources such as family or
their employer, or by more formal requirements of the courts or welfare system.220 In a
treatment system that operates with a high degree of such formal and informal social control,
not all people in the system are highly motivated for making changes. Thus, there is
increasing use of motivational interviewing, cognitive-behaviour therapy, and tailoring
services to the client’s stage of change. These methods are well supported in the research
literature for substance use disorders12 and for the treatment of many people with concurrent
disorders.35
Many specialized treatment programs, and many substance abuse counselors in other
settings, encourage clients to attend self-help supports such as Alcoholics Anonymous,
Narcotics Anonymous or Cocaine Anonymous. These have a common ‘disease model’
perspective on substance abuse and advocate complete abstinence from alcohol and other
drugs. Self-help groups are entirely self supporting and organized by people who are
recovering from a substance use disorder. They encourage members to learn from the
experience of others and to follow a 12-step program of recovery. The groups have meetings
in all major cities and many rural communities. Given the manner in which these groups
operate (e.g., strong adherence to the principle of anonymity) their effectiveness has not
been researched as much as other types of support. While the self-help approach is not
suited to all people seeking help (nor does it pretend to be), research does indicate that it
has a clear role in conjunction with more formal services and supports in the treatment
system.226,370,371
Self-help groups are a major resource for people with substance abuse problems and far more
people attend these groups than seek help from specialized treatment programs.82 However,
the majority of people with alcohol or drug problems do not seek any kind of help for these
problems.372,373 Those who do use specialized services tend to have more serious problems,
although the treatment seeking population is very heterogeneous. Some of those who seek
treatment are heavily dependent on alcohol or other drugs, but others far less so. Some
estimates would suggest that about 50% of the client population in some settings meet the
DSM IV criteria for substance abuse but not dependence.374 Thus, there is increasing
support for harm reduction approaches and non-abstinence treatment goals tailored to the
level of severity of the person’s substance use and other circumstances.375 While the levels
and pattern of alcohol or drug use are highly variable within treatment seeking populations,
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poly-drug use (including alcohol) is very common. Local variations in the availability of
specific types of drugs and local ethno-cultural factors influence the types of problems
presented to treatment services.
Many substance abuse treatment agencies have an open door policy, but include program
components geared toward the needs of some specific subgroups (e.g., women, youth, people
with HIV/AIDS or concurrent disorders). In other instances the whole agency may be
targeted at a particular population (e.g., a women’s withdrawal management centre; youth
outpatient treatment agency). Such specialization is common but also highly variable within
and between regions.
A major focus of efforts to improve substance abuse treatment services has been on the
development of a continuum of services – withdrawal management, brief intervention,
comprehensive assessment, more intensive outpatient or day treatment, short or longer term
residential, continuing care. There is also a considerable interest in early identification and
intervention. The development of effective case management arrangements has also been a
prominent concern. There is a high interest in developing and implementing more
standardized assessment protocols and placement criteria that would aim for more optimal
use of the available resources, for example, through referral of people with the most severe
problems to the most intensive treatment settings.376 However, unlike the managed care
system in the U.S. which controls access to treatment with the placement criteria
recommended by the American Society of Addiction Medicine,22 such placement criteria
currently operate here in Canada on a more voluntary basis.
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Appendix E
Terms for Substance Abuse and Mental Health Screening
1. The sensitivity of a screening tool refers to its ability to detect the condition or health
concern that it is intended to detect.377 A highly sensitive tool for mental health or
substance abuse will, therefore, not miss too many people who have either a mental
health or substance use disorder as determined by a subsequent diagnostic assessment.
2. The specificity of a screening tool refers to its ability to avoid saying that someone may
have the problem or health concern when in fact they do not.377 A highly specific tool
for mental health or substance abuse will, therefore, not identify too many people as
possibly having either a mental health or substance use disorder only to have this ruled
out by subsequent diagnostic assessment.
3. While the goal is usually to develop screening tools that are high in both sensitivity and
specificity, one may lean toward high sensitivity and use later assessment to rule out the
false positives. If, however, subsequent assessment of many false positives is seen as
inappropriate (e.g., too expensive) one would lean toward higher specificity. Normally,
one tries to strike a balance.
4. Sensitivity and specificity, however, tell only part of the story about the operating
characteristics of a screening tool. It is also important to determine the predictive value
of a screening tool.377 Positive predictive value refers to the probability of being positive
on the criterion measure, if one is identified as at risk with the screening tool; negative
predictive value refers to the probability of being negative on the criterion measure if
one is identified as not at risk with the screening tool. This means that a tool which has
a certain level of sensitivity and specificity will actually perform better or worse when
used in settings that differ substantially in the prevalence of the condition or health
concern being detected. Thus, a substance abuse screening tool can have a higher
predictive value when used, for example, in a setting providing services to the homeless
with a very high percentage of people with substance use disorders, compared to an
early intervention program for schizophrenia where the percentage is not as high. Thus,
a screening tool that works for one setting, or sub-population, may not be the best
choice for another.
5. There is an important distinction between population screening, where everyone in the
service would be given the screening questions or procedures, and strategic screening,
whereby the questions or procedures are applied only for certain sub-groups already
thought to be at higher risk. This is getting at the issue of predictive value mentioned
above - the payoff will be higher when you use the screening tool with those subgroups
with the highest prevalence of the problem. The choice between population or strategic
screening is often a matter of the available resources, and the consequences of missing
people who really should have been screened positive for further diagnostic assessment.
The consequences of missing a substance abuse disorder can be very substantial for
some mental health disorders such as schizophrenia or bipolar disorders.
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Appendix F
Checklist of Common Consequence of Substance Abuse
Consequences Examples
Housing instability getting evicted from apartment, group home,
family
Symptom relapses apparently
unrelated to life stressors
increases in psychotic symptoms, worsening
of depression, mania
Treatment noncompliance failing to attend medication or other clinic
appointment
Violent behaviour or threats of
violence
getting into fights, throwing objects, cursing
at others
Sudden, unexplained mood shifts depression and hopelessness, anger,
euphoria, anxiety, expansiveness
Suicidal ideation or attempts thoughts or talk about hurting or killing
oneself, contemplating death, thinking of
plans to hurt oneself
Cognitive impairments increased confusion, memory problems,
difficulty planning ahead not related to a
stress-induced symptom relapse
Difficulty budgeting funds frequent attempts to borrow money, stealing
money, pawning one’s own or others’
possessions
Prostitution trading sex for money, food, clothing or
drugs/alcohol
Social isolation increased avoidance of others
Social difficulties frequent arguments with family, friends
Employment difficulties frequently tardy or absent, arguments with
employer or other employees, having pay
docked, job loss
Hygiene and health problems deterioration in personal hygiene and
grooming, medical problems, weight loss
Legal problems arrests for disorderly conduct, drunken
driving, possession of illicit drugs, shoplifting
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Appendix G
Tools and Interventions for Working with People with
Co-occurring Substance Abuse and Severe and Persistent
Mental Illness (from Mueser et al., in press)44
Common Obstacles to Assessment and Solutions for
Concurrent Substance Abuse and Severe Mental Illness
Obstacles Solution
Failure to take a proper history Ask client directly about substance use and
its consequences, beginning with past use.
Denial and minimization Expect denial and minimization and tap
additional sources of information about
clients’ substance abuse.
Confusion about effects of substance
use
Explore associations between substance use
and course of psychiatric illness; if client uses
substances, assume problems in functioning
are at least partly related to substance use.
The primary-secondary mental
illness substance use disorder
distinction
View both substance abuse and mental
illness as primary disorders.
Cognitive, psychotic, and mood
related distortions
Be aware of possible distortions without
ruling out all client self-reports; seek out
other sources of information about client’s
substance abuse.
History of sanctions Openly discuss the clinician’s legal
responsibilities, the client’s concerns about
legal issues, and control over the client’s
finances.
Pre-motivational state Recognize that low motivation is common
early in dual diagnosis treatment and seek to
actively engage client.
Different norms for substance use
disorder
Remember that client may experience
adverse consequences to much lower
amounts of alcohol and drug use than people
with no psychiatric illness; the quality of
substance use is less important than the
consequences of use.
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Potential Interventions at Different Stages of Treatment
(continued from Mueser et al.44)
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Stage of Treatment
Engagement Persuasion
Active
Treatment
Relapse
Prevention
Case Management X X X X
Family Work X X X X
Pharmacologic Treatment X X X X
Assertive Outreach X X X
Coerced or Involuntary Interventions X X X
Residential Programs X X
Motivational Interviewing X X X
Persuasion Groups X X
Cognitive-Behavioural Counseling X X X
Social Skills Training X X X
Vocational Rehabilitation X X X
Active Treatment Groups X X
Self-help Groups X X
Appendix H
Topic List for Focus Groups
Focus Group Questions
1. I would like to start by asking each of you to tell us your name and what brought you
here today.
2. Thinking about your experiences in either the addiction or mental health systems, once
a person recognizes that they need help with a drug, alcohol or mental health problem,
what types of problems do people usually face when they are getting the help they need?
Probe:
waiting list;
no program for concurrent disorders;
being bounced back and forth between the two systems;
transportation issues;
duplication of assessments.
3. How do you think people feel about (ask about problems mentioned above i.e. waiting
list, etc.):
Probe:
frustrated;
scared;
angry;
disappointed.
4. When receiving treatment for a mental health problem, how well do the service
providers deal with substance use problems?
Probe:
Are questions asked about drinking habits or drug use?
Why do you think questions about these issues are not asked?
How are these questions asked?
How up front are people about alcohol or drug use?
What would stop people from revealing this information?
What would help people to reveal this type of information?
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5. When receiving treatment for an alcohol or drug problem, how well do the service
providers deal with mental health problems such as depression, anxiety or stress?
Probe:
Are questions asked about mental health problems and diagnoses?
Why do you think questions about these issues are not asked?
How are these questions asked?
How up front are people about mental health problems?
What would stop people from revealing this information?
What would help people to reveal this type of information?
6. When someone is dealing with a mental health, alcohol or drug problem, do you think
that people in their support system know about both problems? By support system we
mean, people such as family, friends, counselors or other important people.
Probe:
Do you think people in the support system understand both problems? (Why not?)
Do people get the kind of support they need for both problems? (Why not?)
What would stop someone from revealing both problems?
What would help someone to reveal both problems?
7. Thinking about your experiences getting treatment and ongoing support, what has been
the most helpful? What has been the least helpful and could have been done better?
8. We are trying to improve the treatment and support for people with both mental health
and alcohol or drug use problems, what advice do you have for us?
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Appendix I
Program Integration Fidelity Scale*
(from Mueser et al., in press44)
Dual Disorders Integrated Treatment Fidelity Scale
Instructions
This scale identifies 16 critical components of integrated dual disorder treatment. It is
designed to identify the strengths and weaknesses of existing programs or systems of care.
The scale can be completed based on a single treatment center or program, or across an
array of programs and services within an entire system. The data used to complete the scale
include interviews with clinicians and program managers, and reviews of clinical records.
The forms are divided into three parts: 1) anchored 5-point scales for each of the 16
treatment components; 2) definitions, sources of information, and probe questions for each
component; and 3) a score sheet for summarizing the ratings.
High scores indicate better fidelity to the principles of integrated treatment. Total scores
above 73 indicate high levels of fidelity, scores between 56 and 72 indicate moderate levels
of fidelity, and scores 55 and below indicate low levels of fidelity.
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* Definition and instructions for completion available from Mueser et al.44
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Dual Disorders Integrated Treatment Fidelity Scale
SCORE SHEET
Center: _________________________
Informants – Name: ___________________________ Position: _____________________
Dates ___________________________
Number of records reviewed: _________________
Rater: __________________________
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Ratings
I Organizational Factors
1. Integration of services 1 2 3 4 5
2. Comprehensiveness of services 1 2 3 4 5
3. Time unlimited services 1 2 3 4 5
4. Outreach 1 2 3 4 5
5. Client to clinician ratio 1 2 3 4 5
II Assessment and Treatment Planning
6. Comprehensive assessment 1 2 3 4 5
7 Treatment plan 1 2 3 4 5
8. Crisis plan 1 2 3 4 5
9. Stage-wise interventions 1 2 3 4 5
III Therapeutic Treatment Modalities
10. Integrated group treatment 1 2 3 4 5
11. Type of integrated group treatment 1 2 3 4 5
12. Individual counseling 1 2 3 4 5
13. Family intervention 1 2 3 4 5
14. Pharmacologic interventions 1 2 3 4 5
IV Other Interventions
15. Involuntary interventions 1 2 3 4 5
16. Self-help groups 1 2 3 4 5
Total Score
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